



Enviromental Risk Factors for Dry Eye Disease

PROGRAMA DE DOCTORADO

EN OPTOMETRÍA Y CIENCIAS DE LA VISIÓN

Doctorando:

María Vidal Rohr

Directores:

James S. Wolffsohn Leon N. Davies Alejandro Cerviño Expósito

Birmingham, Septiembre 2019

This project has received funding from the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No. 642760 EDEN ITN-EJD Project Horizon 2020.





ENVIRONMENTAL RISK FACTORS FOR DRY EYE DISEASE*

MARIA VIDAL ROHR

Doctor of Philosophy

UNIVERSITY OF VALENCIA

September 2019

© Maria Vidal-Rohr. 2019

Maria Vidal-Rohr asserts her moral right to be identified as the author of this thesis

This copy of the thesis has been supplied on condition that anyone who consults it

is understood to recognise that its copyright rests with its author and that no

quotation from the thesis and no information derived from it may be published

without appropriate permission or acknowledgement.

* The project received funding by EU Horizon 2020 research & innovation programme under Marie Skłodowska-Curie grant agreement No 642760. **Prof. James S. Wolffsohn** and **Prof. Leon N. Davies**, both from Aston University, and **Dr. Alejandro Cerviño Expósito** from University of Valencia, **CERTIFY** that the present report entitled: "Environmental risk factors for dry eye disease", summarizes the research work carried out under their supervision, by Maria Vidal Rohr, Msc and constitutes her thesis to apply for the double interdisciplinary degree of Doctor of Philosophy in Optometry and Vision Sciences at the University of Valencia and Aston University.

And to make it be on record, and complying with current legislation, they sign the present certificate in _____, on the ____ day of ____ of the year ____.

Prof. James S. Wolffsohn Prof. Leon N. Davies

Dr. Alejandro Cerviño Expósito

UNIVERSITY OF VALENCIA

ENVIRONMENTAL RISK FACTORS FOR DRY EYE DISEASE

Maria Vidal Rohr

Doctor of Philosophy

September 2019

SUMMARY

Dry eye disease (DED) is one of the most frequently encountered ocular conditions, which is clinically under-recognized mainly due to a poor consensus on its diagnosis. It is considered as a multifactorial disease of the ocular surface, where the homeostasis of the tear film is disrupted. In 2017, the Tear Film Ocular Surface Dry Eye Workshop II (TFOS DEWS II) proposed a global consensus in the diagnosis of DED. For the present thesis, three different studies were performed, in which the recommended diagnostic criteria was used, to provide a wider insight into DED epidemiology. Prevalence rates and potential risk factors for DED and DED subtypes were estimated among a single population in the UK. DED subtypes included aqueous deficient (ADDE) and evaporative (EDE) forms of the disease, described by measurements of tear meniscus height, tear evaporation, tear lipid layer thickness and meibomian gland dysfunction. Moreover, a self-administered DED diagnostic method based on the TFOS DEWS II recommendations was examined. To summarise, this thesis has determined:

- A prevalence of 19.7-56.4%, 9.0%, 62.8% and 10.9% for DED, ADDE, EDE and both DED subtypes, respectively.
- Sex, age, education, smoking habits, contact lens wear, health conditions/problems, computer use, sleep quality and outdoor activity as significant risk factors for DED.
- Age as potential risk factor for ADDE.
- Both computer use and contact lens wear as potential risk factors for EDE.
- A diagnostic sensitivity of 100% and specificity of 54% of the proposed DED diagnostic method. This method would serve as a rapid and cost-effective DED diagnosis to be used for future epidemiological research.

Keywords: diagnosis, epidemiology, prevalence, logistic regression, blink test

UNIVERSITY OF VALENCIA

ENVIRONMENTAL RISK FACTORS FOR DRY EYE DISEASE

Maria Vidal Rohr

Doctor of Philosophy

September 2019

RESUMEN

La enfermedad del ojo seco (EOS) es una de las afecciones oculares más frecuentes, que está clínicamente poco reconocida debido principalmente a un escaso consenso en su diagnóstico. Se considera como una enfermedad multifactorial de la superficie ocular, en la cual la homeostasis de la película lagrimal esta interrumpida. En 2017, el Tear Film Ocular Surface Dry Eye Workshop II (TFOS DEWS II) propuso un consenso global en el diagnóstico de EOS. Para la presente tesis, se realizaron tres estudios diferentes, en los cuales se usó el criterio de diagnóstico recomendado, para proporcionar un mayor conocimiento de la epidemiología de EOS. Así pues, se estimaron la prevalencia y los posibles factores de riesgo de EOS y sus subtipos dentro de una determinada población de Inglaterra. Como subtipos de EOS se incluyeron las formas por déficit acuoso (OSDA) y evaporativa (OSE) de la enfermedad, descritas por medidas de la altura del menisco lagrimal, la evaporación lagrimal, el grosor de la capa lipídica lagrimal y el grado de disfunción de las glándulas de meibomio. Además, se examinó un método de diagnóstico de EOS autoadministrado conforme a las recomendaciones del TFOS DEWS II.

Para resumir, esta tesis determinó:

- Una prevalencia de 19.7-56.4%, 9.0%, 62.8% y 10.9% para EOS, OSDA, OSE y ambos subtipos de EOS, respectivamente.
- El sexo, la edad, el nivel de educación, los hábitos de fumar, el uso de lentes de contacto, los problemas o las condiciones de salud, el uso de ordenador, la calidad del sueño y la exposición exterior como significantes factores de riesgo de EOS.
- La edad como posible factor de riesgo para OSDA.
- El uso lentes de contacto y ordenador como posibles factores de riesgo para OSE.
- Una sensibilidad diagnóstica de 100% y una especificidad de 54% del método de diagnóstico propuesto. El método serviría como un diagnóstico de EOS que es rápido y rentable para ser usado en futuros estudios epidemiológicos.

Keywords: diagnóstico, epidemiología, prevalencia, regresión logística, blink test

Meinen Eltern

ACKNOWLEDGMENTS

I would like to express my gratitude to my supervisors Prof. James S. Wolffsohn, Prof. Leon N. Davies and Dr. Alejandro Cerviño Expósito for their guidance throughout my PhD.

A special thanks goes to Prof. James S. Wolffsohn for his immense knowledge and encouragement. To the European Dry Eye Network (EDEN) group, particularly, to Dr. Francesco Menduni and Tugce Ipek. With their friendship, strength, faith and perseverance, they have made me complete my writing up.

A sincere thanks goes to the study participants – without them, none of this would have been possible. To Lisa-Marie Baker for pushing me forward in the last participant recruitment, to Dr. Richard Amstrong and Prof. Christof Backhaus for sharing their statistical expertise, and to Dr. Susie Jones for her remarkable support during my first PhD year.

Also, a big thanks goes to Dr. Tecla Bonci, Dr. Fiona Cruickshrank, Dr. Grupreet Bhogal-Bhamra, Dr. Paramdeep Singh Bilkhu and Isotta Rigoni for their help and the fun times in and out of work environment.

Lastly, I would like to thank my parents for their unconditional love and support, regardless of everything that came in their way. And my brother and grandparents, for believing in me and inspiring me to achieve greatness. Without them, I would not be where I am today.

5

CONTENTS

SUMMARY		3
ACKNOWLEDGMEN	۲S	5
LIST OF FIGURES		9
LIST OF TABLES		11
LIST OF ABBREVIAT	IONS	13
1. CHAPTER 1: LIT	ERATURE REVIEW	15
1.1 Overview		15
1.2 The lacrim	al functional unit	15
1.3 The tear fil	m	16
1.4 Definition of	of dry eye disease	17
1.5 Classificat	on of dry eye disease	18
1.6 Epidemiolo	ogy of dry eye disease	20
1.6.1 Dry eye	prevalence by the Women's Health Study criteria	20
1.6.2 Dry eye	prevalence by symptoms	21
1.6.3 Dry eye	prevalence by signs	24
1.6.4 Dry eye	prevalence by symptoms and signs	26
1.6.5 Environr	nental risk factors for dry eye disease	26
1.6.5.1 Asses	sing dry eye risk factors	27
1.6.5.2 Repor	ting dry eye risk factors	
1.6.5.2.1 Th	e precision of dry eye risk factors	
1.6.5.2.2 Th	e significance of dry eye risk factors	
1.6.5.3 Classi	fying dry eye risk factors	40
1.6.5.3.1 No	n-modifiable dry eye risk factors	40
1.6.5.3.1.1	Sex	40
1.6.5.3.1.2	Ethnicity	41
1.6.5.3.1.3	Age	41
1.6.5.3.1.4	Health conditions	42
1.6.5.3.1.5	Ocular surgery	42
1.6.5.3.1.6	Ambient conditions	43
1.6.5.3.2 Mo	odifiable dry eye risk factors	44
1.6.5.3.2.1	Visual display terminals	44
1.6.5.3.2.2	Contact lens wear	45
1.6.5.3.2.3	Poor sleep quality	46
1.6.5.3.4 Nu	trition	46
1.7 Thesis rati	onale	47

2.	CHAF	TER 2: STUDY METHODOLOGY	49
	2.1	Overview	49
	2.2	Study design	49
	2.2.1	Power calculation	49
	2.2.2	Study population	51
	2.2.3	Recruitment	51
	2.2.4	Inclusion and exclusion criteria	53
	2.2.5	Clinical assessment	53
	2.2.	5.1 Diagnostic considerations	54
	2.2.	5.2 Dry eye risk factor survey	56
	2.2.	5.3 Dry eye questionnaires	60
	2.2.	5.4 Tear film evaporation	62
	2.2.	5.5 Tear film osmolarity	64
	2.2.	5.6 Tear film volume	65
	2.2.	5.7 Lipid layer thickness	67
	2.2.	5.8 Tear film stability	69
	2.2.	5.9 Ocular staining	71
	2.2.	5.10 Lid wiper epitheliopathy	76
	2.2.	5.11 Meibomian gland dysfunction	78
3.	CHAF	TER 3: THE PREVALENCE OF DRY EYE DISEASE IN THE UK	80
	3.1	Overview	80
	3.2	Introduction	80
	3.3	Methodology	81
	3.3.1	Data processing	82
	3.3.2	Statistical analysis	82
÷	3.4	Results	82
	3.4.1	Dry eye prevalence by the TFOS DEWS II criteria	83
	3.4.2	Dry eye prevalence by the WHS criteria	87
	3.4.3	Correlations between DED signs and symptoms	87
;	3.5	Discussion	88
4.	CHAF	TER 4: THE RISK FACTORS OF DRY EYE DISEASE IN THE UK	01
			91
4	+.I 1 0		91
4	+.∠ 1 2	Methodology	91
4	+.J 121	Data processing	ອາ ດາ
	4.3.1 120	Statistical analysis	92
	4.J.Z	Statistical allarysis	93

4	.4	Results	93
	4.4.1	Dry eye risk factors	95
	4.4.2	Correlations among dry eye risk factors	98
4	.5	Discussion	99
5.	CHAF	TER 5: SUBCLASSIFICATION OF DRY EYE DISEASE IN THE	
UK			102
5	.1	Overview	102
5	.2	Introduction	102
5	.3	Methodology	104
	5.3.1	Data processing	106
	5.3.2	Statistical analysis	106
5	.4	Results	107
	5.4.1	Sub-classification signs of non-dry eye participants	107
	5.4.2	Cut-off values of dry eye subclassification tests	108
	5.4.3	Presumed differential dry eye diagnosis	108
	5.4.4	Prevalence of dry eye subtypes	110
	5.4.5	Frequency of evaporative dry eye signs in evaporative dry eye participants	111
	5.4.6	Relationship between subclassification signs in dry eye participants	112
	5.4.7	Relationship between subclassification signs and symptoms of dry eye disease	112
	5.4.8	Potential risk factors of dry eye subtypes	113
5	.5	Discussion	113
6.	CHAF	TER 6: IMPROVING DRY EYE EPIDEMIOLOGICAL RESEARCH	
			119
6	.1	Overview	119
6	.2	Introduction	119
6	.3	Methodology	120
	6.3.1	Power calculation	123
	6.3.2	Data processing	123
	6.3.3	Statistical analysis	124
6	.4	Results	125
6	.5	Discussion	127
7.	CHAF	TER 7: DISCUSSION AND CONCLUSIONS	130
8.	REFE	RENCES	136

LIST OF FIGURES

Figure 1.1	The lacrimal functional unit (LFU)	15
Figure 1.2	Subclassification of DED	19
Figure 2.1	Relationship between sample size and expected prevalence	50
Figure 2.2	Study advertisement	52
Figure 2.3	Aston University Health Clinics	53
Figure 2.4	The Keratograph 5M	55
Figure 2.5	The dry eye risk factor survey (DERFS)	59
Figure 2.6	DED questionnaires used	61
Figure 2.7	Tear evaporation measured with the Delfin VapoMeter	63
Figure 2.8	Tear osmolarity measured with the TearLab	65
Figure 2.9	Lower TMH measured with the Keratograph 5M	67
Figure 2.10	Colour fringe LLT observed with the Keratograph 5M	69
Figure 2.11	First NIKBUT observed with the Keratograph 5M	71
Figure 2.12	Lissamine green instillation via wetted filter paper strip	73
Figure 2.13	Fluorescein staining image analysis with ImageJ	74
Figure 2.14	Lissamine green staining image analysis with ImageJ	75
Figure 2.15	LWE staining image analysis with ImageJ	77
Figure 2.16	MGD analysis with ImageJ	79
Figure 3.1	Study population distribution	83
Figure 3.2	Birmingham's (United Kingdom) population census (2016)	83
Figure 3.3	DED prevalence by the TFOS DEWS II criteria	84
Figure 3.4	DED prevalence by the TFOS DEWS II criteria (stratified by sex)85
Figure 3.5	DED prevalence by the TFOS DEWS II criteria (stratified by age)86
Figure 3.6	DED prevalence by the WHS criteria (stratified by sex and age).	87

Figure 5.1	Distribution of ADDE and EDE signs among healthy non-DED participants
Figure 5.2	Prevalence of DED subtypes110
Figure 5.3	Frequency of evaporative DED signs in EDE participants111
Figure 6.1	The Optrex [™] dry eye blink test (reproduced with permission of Reckitt Benckiser)
Figure 6.2	ROC curve assessing the diagnostic ability of the Optrex [™] dry eye blink test

LIST OF TABLES

Table 1.1	DED prevalence by the WHS criteria21
Table 1.2	DED prevalence by symptoms22
Table 1.3	DED prevalence by signs25
Table 1.4	DED prevalence by symptoms and signs26
Table 1.5	DED risk factor assessment
Table 2.1	Required study population (stratified by age and sex)51
Table 2.2	The Guillon-Keeler grading scale68
Table 3.1	Correlations between DED signs and symptoms
Table 4.1	Recording of DED risk factors92
Table 4.2	Study population characteristics94
Table 4.3	Distribution of risk factors among non-DED and DED participants96
Table 4.4	Risk factors for DED97
Table 4.5	Correlations among DED risk factors
Table 5.1	Previous large-scale clinical-population-based studies on DED subtypes
Table 5.2	Subclassification DED signs of non-DED participants (stratified by sex and the absence/presence of health conditions/problems)
Table 5.3	Correlations of subclassification signs in DED participants112
Table 5.4	Correlations of subclassification DED signs and symptoms in DED participants
Table 5.5	Correlations between pure DED subtypes† and potential risk factors of DED113
Table 6.1	Ocular surface grading scales used121
Table 6.2	Tear film and ocular surface characteristics of the study participants
Table 6.3	Correlations of DED symptoms and signs with the Optrex [™] dry eye blink test

LIST OF ABBREVIATIONS

Abbreviation	Full name
ADDE	Aqueous deficient dry eye
ARCHA	Aston Research Centre for Healthy Ageing
CI	Confidence Interval
CL	Contact lens
CLD	Contact lens discomfort
DED	Dry eye disease
DEQ-5	5-item Dry Eye Questionnaire
DERFS	Dry Eye Risk Factor Survey
EDE	Evaporative dry eye
EDEN	European Dry Eye Network
FBUT	Fluorescein tear break-up time
FTMH	Fluorescein tear meniscus height
IDEEL	Impact of Dry Eye on Everyday Life
K5M	Keratograph 5M
LFU	Lacrimal functional unit
LLT	Lipid layer thickness
LWE	Lid wiper epitheliopathy
MGD	Meibomian gland dysfunction
MQ	McMonnie's Questionnaire
N/A	Not applicable
NEI	National Eye Institute
NIBUT	Non-invasive tear break-up time
NIKBUT	Non-invasive Keratograph tear break-up time

OR	Odds Ratio
OSDI	Ocular Surface Disease Index
PRT	Phenol red thread
ROC	Receiver operative characteristics
TFOS DEWS I	Tear Film Ocular Surface Dry Eye Workshop I
TFOS DEWS II	Tear Film Ocular Surface Dry Eye Workshop II
ТМН	Tear meniscus height
VDT	Visual display terminal
WHS	Women's Health Study

1. CHAPTER 1: LITERATURE REVIEW

1.1 Overview

The chapter compiles available literature on dry eye disease. Its purpose is to summarize current knowledge in the disease definition, classification and epidemiology; and to identify research problems in the literature that justify the rationale of the present thesis.

1.2 The lacrimal functional unit

Dry eye disease can result from any alteration occurring in the anatomy and physiology of the lacrimal functional unit (LFU) (Figure 1.1) (Lemp *et al.*, 2007).



Figure 1.1 The lacrimal functional unit (LFU)

The LFU is an integrated system that compromises the cornea, conjunctiva, lacrimal glands, meibomian glands, eyelids, nasolacrimal draining system and the involved afferent and efferent nerves (cranial nerves V and VI) (Lemp *et al.*, 2007). Its overall function is to maintain the integrity of the tear film (Lemp *et al.*, 2007).

1.3 The tear film

The tear film is a transparent fluid that covers the eye. As such, it preserves the health of the ocular surface. It is traditionally described at the cornea as a tri-laminar structure (Wolff, 1946; Holly and Lemp, 1977), consisting of:

- The <u>lipid layer</u>, which is the outermost layer of the tear film (Wolff. 1946; Holly and Lemp, 1977). It is composed of polar and non-polar lipids that are secreted primarily by the meibomian glands and, with a lesser amount, by the eyelid glands of Moll and Zeiss (Wolff. 1946; Holly and Lemp. 1977). The lipids are believed to retard tear evaporation from the ocular surface and hence to avoid ocular desiccation (Willcox *et al.*, 2017).
- The <u>aqueous layer</u>, which constitutes the bulk of the tear film (Wolff. 1946; Holly and Lemp. 1977). It contains mainly water and specific proteins and electrolytes that are protective and nutritive to the ocular surface (Willcox et al.. 2017). The substances are secreted by the main lacrimal gland and the accessory lacrimal glands of Krause and Wolffring, with additional contributions arising from the conjunctival epithelial cells (Wolff. 1946; Holly and Lemp. 1977).
- The <u>mucin layer</u>, which is the innermost layer of the tear film (Wolff. 1946; Holly and Lemp. 1977). It consists of mucins that are secreted by the conjunctival goblet cells and distributed in decreasing gradient from the ocular surface towards the lipid layer (Wolff. 1946; Holly and Lemp. 1977). The mucins are

thought to prevent tear overspill by adhering the aqueous layer onto the ocular surface (Willcox et al.. 2017).

A new consensus defines the tear film as a mixture of the aqueous and mucin layer with an overlying lipid phase (Doane, 1994). However, there is a continual return to the traditional model due to its explanatory simplicity (Willcox *et al.*, 2017).

1.4 Definition of dry eye disease

Efforts to define dry eye disease (DED) include the publication of three substantial reports (Lemp, 1995; Lemp *et al.*, 2007; Craig *et al.*, 2017). The National Eye Institute (NEI)/Industry Workshop on Clinical Trials in Dry Eyes was the first in defining DED (Lemp, 1995). Their definition was published in 1995 as follows:

"Dry Eye is a disorder of the tear film due to tear deficiency or excessive tear evaporation, which causes damage to the interpalpebral ocular surface and is associated with symptoms of discomfort (Lemp, 1995)."

At this stage, DED was termed as a disorder of the tear film, where tear deficiency or excessive tear evaporation played causative roles (Lemp, 1995). The disorder was described as the presence of ocular signs that relate to symptoms of discomfort (Lemp, 1995).

In 2007, a better understanding of the pathogenesis of DED allowed the Tear Film Ocular Surface Dry Eye Workshop I (TFOS DEWS I) (Lemp *et al.*, 2007) to restructure the 1995 definition as follows:

"Dry eye is a multifactorial disease of the tears and ocular surface that results in symptoms of discomfort, visual disturbance, and tear film instability with potential damage of the ocular surface. It is accompanied by increased osmolarity of the tear film and inflammation of the ocular surface (Lemp et al., 2007)."

For the first time, DED was defined as a disease with a multifactorial nature, where an alteration of the tear film and ocular surface was characterized by several underlying causes (Lemp *et al.*, 2007). Ocular discomfort, visual disturbance and tear film instability were considered as hallmarks of the disease (Lemp *et al.*, 2007). In addition, hyperosmolarity and both ocular surface damage and inflammation were recognized as further DED markers (Lemp *et al.*, 2007).

Finally, in 2017, a last definition by the Tear Film Ocular Surface Dry Eye Workshop II (TFOS DEWS II) (Craig *et al.*, 2017) described DED as follows:

"Dry eye is a multifactorial disease of the ocular surface characterized by a loss of homeostasis of the tear film, and accompanied by ocular symptoms, in which tear film instability and hyperosmolarity, ocular surface inflammation and damage, and neurosensory abnormalities play etiological roles (Craig et al., 2017)."

Again, DED was characterized by the presence of ocular symptoms and signs. The concept of "loss of homeostasis of the tear film" was included to be considered as the pathophysiological core feature of the disease (Craig *et al.*, 2017). This would serve to acknowledge any changes occurring in the ocular surface and tear film, irrespective to which aetiological factor or combination of aetiological factors had initiated the disease process (Craig *et al.*, 2017).

1.5 Classification of dry eye disease

DED is classified into two main etiological entities (Figure 1.2), evaporative or aqueous deficient dry eye (Lemp *et al.*, 2007). Both forms may co-exist with

increasing disease severity, which can be easily assessed by scoring patients' symptomatology (Craig *et al.*. 2017; Wolffsohn *et al.*. 2017).





Aqueous deficient dry eye (ADDE) is characterized by a reduced secretion and volume of the aqueous component that arises from any damage, dysfunction or reduced innervation of the lacrimal gland and is divided into two major groupings, Sjögren syndrome and non-Sjögren syndrome (Lemp *et al.*, 2007; Craig *et al.*, 2017).

Evaporative dry eye (EDE) is described as an excessive tear film loss via evaporation from the ocular surface in the presence of normal lacrimal function (Lemp *et al.*, 2007; Craig *et al.*, 2017). This alteration is explained by an unstable lipid layer due to blink and eyelid abnormalities, which are classified as either intrinsic (i.e. meibomian gland dysfunction) or extrinsic (i.e. contact lens wear) (Lemp *et al.*, 2007; Craig *et al.*, 2017).

1.6 Epidemiology of dry eye disease

One major challenge in the epidemiology of DED has been the lack of a standardized worldwide definition (Stapleton *et al.*, 2017). This has led to the use of diverse diagnostic criteria, which, in turn, complicates the comparison and interpretation of epidemiologic study results about the prevalence and risk factors of the disease (Stapleton *et al.*, 2017).

The most consistent diagnostic criteria in the literature appears to be that first adopted by the Women's Health Study (Stapleton *et al.*, 2017). Other epidemiological studies have diagnosed DED either by the presence of its symptoms, signs or both symptoms and signs (Stapleton *et al.*, 2017).

1.6.1 Dry eye prevalence by the Women's Health Study criteria

The diagnosis of DED by the Women's Health Study (WHS) criteria is based on the presence of self-reported symptoms of ocular dryness and irritation either often or constantly, or a previous disease diagnosis by a physician (Uchino *et al.*, 2008, 2011; Schaumberg *et al.*, 2009; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014; Um *et al.*, 2014; Na *et al.*, 2015).

The WHS criteria has mostly been conducted in Asian populations and has shown a DED prevalence of 12.5% to 23.7%, with females more affected than males (Uchino *et al.*, 2011; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014) (Table 1.1). The lowest prevalence rate of 4.3% has been reported in American males (Schaumberg *et al.*, 2009).

Studies describing DED by symptom self-report and clinical diagnosis separately have estimated a respective prevalence of 2.2-24.41% and 3-12.7% (Uchino et al...

2008. 2011; Schaumberg et al.. 2009; Zhang. Chen and Wu. 2012; Ahn et al.. 2014; Um et al.. 2014; Na et al.. 2015).

Study	Population	Prevalence (%[95%	Prevalence (%[95%Cl])			
Authors, Year	Country Age (years) Sex (n)	By clinical diagnosis or symptom self- report	By clinical diagnosis	By symptom self-report		
Schaum- berg et al., 2009	USA ≥ 50 25444 ♂	4.3 [n/a]	3.0 [n/a]	2.2 [n/a]		
Zhang et al., 2012	China n/a 927 ♀ 958 ♂	23.7 [n/a]	1.3 [n/a]	23.1 [n/a]		
Uchino et al., 2011	Japan ≥ 40 1423 ♀ 1221 ♂	♀ 21.6 [19.5-23.9] ♂ 12.5 [10.7-14.5]	♀ 7.9 [6.6-9.5] ♂ 2.0 [1.3-3.0]	♀ 18.7 [16.7-20.8] ♂ 11.5 [9.7-13.4]		
Ahn et al., 2015	South Korea ≥ 19 6676 ♀ 4990 ♂	16.0 [14.6-17.3]	8.0 [7.3-8.7]	14.4 [13.1-15.7]		
Uchino et al., 2008	China 15-18 585 ♀ 2848 ♂	n/a	♀ 8.0 [7.4-8.4] ♂ 4.3 [3.9-4.6]	♀ 24.4 [23.9-25.0] ♂ 21.0 [20.1-21.8]		
Um et al., 2014	South Korea ≥ 30 9398 ♀ 7033 ♂	n/a	All 10.4 [9.9-10.9] ♀ 12.7 [12.6-12.7] ♂ 4.6 [4.6-4.6]	All 17.7 [17.1-18.3] ♀ 19.4 [19.4-19.5] ♂ 9.8 [9.8-9.9]		
Na et al., 2015	Korea ≥19 6655 ♀	n/a	12.3 [n/a]	n/a		
DED = dry eye disease. WHS = Women's Health Study. N/a = not applicable. ♀ = female. ♂ = male. Cl =						

 Table 1.1
 DED prevalence by the WHS criteria

confidence interval.

1.6.2 Dry eye prevalence by symptoms

The prevalence rates of DED diagnosed by symptoms (Table 1.2) are not as comparable as those diagnosed with the WHS criteria since they rely upon different definitions of symptomatic DED (Stapleton *et al.*, 2017). Nevertheless, it can be generally ascertained that symptomatic DED is more prevalent in females than in males (Lu *et al.*, 2008; Tongg *et al.*, 2009; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Paulsen *et al.*, 2014; Tan *et al.*, 2015).

Symptomatic DED has been described as either agreeing with a statement that defines the disease as having several symptoms (Vehof *et al.*, 2014; Na *et al.*, 2015), self-reporting to have at least one of several DED symptoms either often, sometimes, constantly or all of the time (Lu *et al.*, 2008; Jie *et al.*, 2009; Tongg *et al.*, 2009; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Paulsen *et al.*, 2014; Tan *et al.*, 2015), or showing a positive result to the Ocular Surface Disease Index (OSDI) questionnaire (Hashemi *et al.*, 2014; Malet *et al.*, 2014).

Studies defining symptomatic DED by symptom self-report were mostly conducted on Asian populations and showed different prevalence rates, ranging from 6.5% to 52.4% (Lu *et al.*, 2008; Jie *et al.*, 2009; Tongg *et al.*, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Tan *et al.*, 2015). In the USA (Paulsen *et al.*, 2014) and Spain (Viso, Rodriguez-Ares and Gude, 2009), the same method was used, reporting prevalence rates of 14.5% and 18.4%. respectively.

DED symptoms, which have been agreed to be either normally present or present for the past three months, were found similarly prevalent among Korean (20.0%) (Na *et al.*, 2015) and British females (20.8%) (Vehof *et al.*, 2014). On the other hand. an OSDI score of \geq 23 estimated a disease prevalence of 18.3% in Iran (Hashemi *et al.*, 2014) and of 39.2% in France (Malet *et al.*, 2014).

Study	Population	Prevalence (%[95%CI])		
Authors, Year	Country; Age (years); Sex (n)	By agreeing to a statement	By symptom self- report	By OSDI score ≥ 23
Na et al., 2015	Korea ≥19 6655 ♀	20.0 [n/a] ^A	n/a	n/a
Vehof et al., 2015	United Kingdom 20-83 1635 ♀	20.8 [19.5-22.1] [₿]	n/a	n/a

 Table 1.2
 DED prevalence by symptoms

Table 1.2	(continued)
-----------	-------------

Paulsen et al., 2014	USA 21-81 1789 ♀ 2271 ♂	n/a	All 14.5 [n/a] ^c ♀ 17.9 [n/a] ^c ♂ 10.5 [n/a] ^c	n/a
Han et al., 2011	Korea ≥ 65 340 ♀ 317 ♂	n/a	All 30.3 [n/a] ^D ♀ 34.7 [n/a] ^D ♂ 25.6 [n/a] ^D	n/a
Tan et al., 2015	Singapore 15-83 561 ♀ 443 ♂	n/a	All 12.3 [10.3- 14.4] ^E ♀ 14.8 [12.0-18.0] ^E ♂ 9.0 [6.5-12.] ^E	n/a
Jie et al., 2009	China 40-84 1112 ♀ 3327 ♂	n/a	21.0 [n/a] ^F	n/a
Viso et al., 2009	Spain 40-96 411 ♀ 243 ♂	n/a	All 18.4 [15.4- 21.3] ^F ♀ 21.8 [17.9-25.8] ^F ♂ 12.5 [8.3-16.6] ^F	n/a
Guo et al., 2010	China 40-91 837 ♀ 979 ♂	n/a	All 50.1 [47.8- 52.4] ^F ♀ 50.2 [46.8-53.6] ^F ♂ 49.9 [46.8-53.1] ^F	n/a
Tong et al., 2009	Singapore 40-80 1704 ♀ 1576 ♂	n/a	All 6.5 [5.7-7.4] ^F ♀ 4.9 [3.9-6.0] ^F ♂ 8.2 [6.9-9.7] ^F	n/a
Lu et al., 2008	China ≥ 40 809 ♀ 1031 ♂	n/a	All 52.4 [50.2- 54.7] ^F ♀ 52.9 [49.5-56.3] ^F ♂ 52.1 [49.1-55.2] ^F	n/a
Hashemi et al., 2013	Iran 40-64 595 ♀ 413 ♂	n/a	n/a	All 18.3 [15.9-20.6] ♀ 20.0 [16.9- 23.1] ♂ 15.7 [12.2- 19.3]
Malet et al., 2014	France 73-94 561 ♀ 354 ♂	n/a	n/a	All 39.2 [n/a] ♀ 44.7 [n/a] ♂ 30.5 [n/a]

DED = dry eye disease. N/a = not applicable. OSDI = Ocular Surface Disease Index. \bigcirc = female. \bigcirc = male. CI = confidence interval.

A. Symptoms of dryness, foreign body sensation, itching burning or sandiness.

B. Symptoms of foreign body sensation, itching, burning or sandiness not related to allergy and for the past three months.

C. Use of artificial tears at least once per day or symptoms of dryness, grittiness or burning either moderately bothersome/greater or often/sometimes.

D. At least one of six symptoms (dryness, grittiness/sandiness, burning, stickiness of eyelids, watery eyes/tearing and redness) either often or all of the time and for the past two weeks.

E. At least one of five primary symptoms of the McMonnies questionnaire (soreness, scratchiness, dryness, grittiness and burning) either often or constantly.

F. At least one of six symptoms (dryness, grittiness/sandiness, burning, redness, crusting of eyelashes and morning stickiness of eyelids) either often or all of the time.

1.6.3 Dry eye prevalence by signs

The prevalence of DED by signs (Table 1.3) vary considerably. Following clinical tests were used to describe DED by signs:

- The fluorescein tear break-up time (FBUT) (Lu *et al.*, 2008; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Hashemi *et al.*, 2014; Malet *et al.*, 2014), which determines the stability of the tear film. It measures the number of seconds that elapse between a blink and the appearance of the first tear film disruption, which is easily seen following instillation of sodium fluorescein into the eye.
- The Schirmer test II (Lu et al., 2008; Viso, Rodriguez-Ares and Gude, 2009; Guo et al., 2010; Hashemi et al., 2014), which measures the aqueous production of the tear film. The test involves the insertion of a filter paper strip, after using ocular anesthesia, over the one-third temporal lower eyelid margin. The length of the wet area (in millimeters) is read off after 5 minutes of application and gives an indication of the aqueous tear film volume.
- Fluorescein and rose bengal staining (Viso, Rodriguez-Ares and Gude, 2009; Hashemi *et al.*, 2014). Both sodium fluorescein and rose bengal are ophthalmic dyes used to visualize eventual ocular surface damage in DED. In DED epidemiology, sodium fluorescein has been exclusively used to evaluate corneal damage (Viso. Rodriguez-Ares and Gude. 2009; Hashemi et al.. 2014). In contrast, rose bengal has been used to stain both cornea and conjunctiva (Viso. Rodriguez-Ares and Gude. 2009; Hashemi et al.. 2014).

Study	Population	Dry eye prevalence	e (%[95%Cl])		
	Country	By	By Schirmer test II	By fluorescein	By rose bengal
	Age (years)	FBUT ≤10s	<5mm	staining ≥1 [†]	staining ≥3 [‡]
	Sex (n)			Ū	0
Malet	France	All 44.9 [n/a] ^A	n/a	n/a	n/a
et al.	73-94	♀ 43.7 [n/a] ^Ā			
2014	561 ♀	∂ 46.6 [n/a] ^A			
	354 👌				
Guo et	China	All 37.7[35.5-39.9]	All 19.9[18.4-22.1]	All 6.0[4.9-7.1]	n/a
al.	40-91	♀ 35.1[31.9-38.4]	♀ 17.5[¹ 4.8-19.9]	♀ 6.1[4.5-7.7] [¯]	
2010	837 ♀	ð 39.9 [[] 36.9-43.0]	ð 22.2[19.6-24.8]	॑ 5.9[4.4-7.4]	
	979 👌				
Lu et	China	All 35.3[33.1-37.5]	All 35.3[33.1-37.5]	All 5.8[4.7-6.9]	n/a
al.	≥ 40	♀ 38.1[34.7-41.4]	♀ 38.1[34.7-41.4]	♀ 5.7[4.1-7.3]	
2008	809 Q	33.1[30.2-36.0]	₫ 33.1[30.2-36.0]	₫ 5.9[4.5-7.4]	
	1031 ්	0[]	0[]	0	
Viso et	Spain	All 15.6[12.7-18.5]	All 37.0[33.2-40.7]	All 7.0[4.9-8.9]	All 13.0[10.3-15.6]
al.	40-96	♀ 17.0[13.2-20.9]	♀ 37.1[32.4-41.9]	♀ 7.2[4.7-8.9]	♀ 11.8[8.5-15.0]
2009	411 ♀	a 12.8[8.5-17.2]	36.630.4.3-	8 6.4 3.3-9.6	a 15.0 10.4-19.7
	243 న	°	42.8]	° ' '	·
	-				
Hashe-	Iran	All 34 2[29 5-38 8]	All 17 8 [15 5-	All 11 3[8 5-	All 4 9[3 4-6 5]
mi et	40-64	○ 37 6 [32 3-42 9]	20.01	14 11	○ 6 0[3 9 - 8 1]
al	595 C	⁺ 29 1[23 7-34 5]	0 17 1 [14 2-20 1]	0 12 319 0 -	⁺ 3 5[1 5-5 5]
2014	413 Å	0 20.1[20.1 04.0]	⁺ 18.6 [14.8-22.4]	15 51	oxford
2014	- 10 ()		0 10.0 [14.0-22.4]	₹ 9 9 [6 5-13 3]	ONIOIG
				oxford	

Table 1.3	DED prevalence	by	signs
-----------	----------------	----	-------

DED = dry eye disease. N/a = not applicable. FBUT= fluorescein tear break-up time. \bigcirc = female. \bigcirc = male. CI = confidence interval.

A. FBUT ≤ 5s.

†. Fluorescein staining was graded as 0 (no staining), 1 (mild staining with a few disseminated stains and limited to less than one third of the cornea), 2 (moderate staining with severity between grades 1 and 3) and 3 (severe staining with confluence stains and occupying half or more of the cornea). **‡.** Rose bengal staining was graded using the van Bijsterveld staining score system.

An FBUT of ≤10s (Lu *et al.*, 2008; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Hashemi *et al.*, 2014), Schirmer test II of <5mm (Lu *et al.*, 2008; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Hashemi *et al.*, 2014), fluorescein score of ≥ 1 (Lu *et al.*, 2008; Viso, Rodriguez-Ares and Gude, 2009; Guo *et al.*, 2010; Hashemi *et al.*, 2014) and rose bengal score of ≥ 3 (Viso, Rodriguez-Ares and Gude, 2009; Hashemi *et al.*, 2014) have estimated a disease prevalence of 15.6-37.7%, 17.8-37.0%, 5.8-11.3% and 4.9-13.0%, respectively. However, when an FBUT value of ≤ 5 seconds was used (Malet *et al.*, 2014), the prevalence of DED was reported to be up to 44.9%. The discrepancy in the disease prevalence may be explained by poor standardization and invasiveness of the tests (Stapleton *et al.*, 2017).

1.6.4 Dry eye prevalence by symptoms and signs

Four different population-based studies exist (Viso, Rodriguez-Ares and Gude, 2009; Hashemi et al., 2014; Malet et al., 2014; Vehof et al., 2014), whereby the prevalence of DED has been estimated by a combination of symptoms and signs (Table 1.4). Unfortunately. due to the heterogeneity of used disease diagnoses, direct comparisons of the prevalence rates are not possible (Stapleton *et al.*, 2017).

Table 1.4	DED prevalence by symptoms and sign
-----------	-------------------------------------

Study	Population	Dry eye prevalen	ce (%[95%Cl])		
	Country Age (years) Sex (n)	By clinical diagnosis and daily use of artificial tears	By showing an OSDI ≥ 23 or using daily artificial tears	By showing an OSDI ≥ 23 and at least one sign (FBUT ≤ 10s. Schirmer test II <5mm. fluorescein staining ≥1 [†] or rose bengal staining ≥3 [‡])	By symptom self-report and at least one sign (FBUT ≤ 10s. Schirmer test II <5mm. fluorescein staining ≥1 [†] or rose bengal staining ≥3 [‡])
Vehof et al. 2015	United Kingdom 20-83 1635 ♀	9.6[8.7-10.6]	n/a	n/a	n/a
Malet et al. 2014	France 73-94 561 ♀ 354 ♂	n/a	All 21.9[n/a] ♀ 27.1[n/a] ♂ 13.6[n/a]	n/a	n/a
Hashemi et al. 2014	Iran 40-64 595 ♀ 413 ♂	n/a	n/a	All 8.7[6.9-10.6] ♀ 10.6[8.0-13.2] ♂ 6.1[3.8-8.3]	n/a
Viso et al. 2009	Spain 40-96 411 ♀ 243 ♂	n/a	n/a	n/a	All 11.0[8.6-13.3] ♀ 11.9[8.8-15.1] ♂ 9.0[5.3-12.6]

DED = dry eye disease. N/a = not applicable. OSDI = Ocular Surface Disease Index. FBUT= fluorescein tear break-up time. \mathcal{Q} = female. \mathcal{J} = male. Cl = confidence interval.

†. Fluorescein staining was graded as 0 (no staining), 1 (mild staining with a few disseminated stains and limited to less than one-third of the cornea), 2 (moderate staining with severity between grades 1 and 3) and 3 (severe staining with confluence stains and occupying half or more of the cornea).

‡. Rose bengal staining was graded using the van Bijsterveld staining score system.

1.6.5 Environmental risk factors for dry eye disease

Logistic regression analyses have been performed in epidemiological studies concerned with quantifying associations between environmental conditions and DED (Uchino et al., 2008, 2011; Lu et al., 2008; Tongg et al., 2009; Jie et al., 2009; Schaumberg *et al.*, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014; Um *et al.*, 2014; Vehof *et al.*, 2014; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Paulsen *et al.*, 2014; Tan *et al.*, 2015; Na *et al.*, 2015). The term environment is broadly used to refer to any external and internal bodily states habitually experienced by an individual, such as demographic factors (i.e age), lifestyle factors (i.e. contact lens wear), ambient factors (i.e humidity) and physiological or genetic factors (i.e health conditions) (Lemp *et al.*, 2007).

1.6.5.1 Assessing dry eye risk factors

In logistic regression, the odds ratio (OR) is widely used to quantify how much likely an environmental condition contributes to DED (Uchino *et al.*, 2008, 2011; Lu *et al.*, 2008; Tongg *et al.*, 2009; Jie *et al.*, 2009; Schaumberg *et al.*, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014; Um *et al.*, 2014; Vehof *et al.*, 2014; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Paulsen *et al.*, 2014; Tan *et al.*, 2015; Na *et al.*, 2015) (Table 1.5).

Mathematically, the OR is calculated as follows: OR = the logarithm of the odds of DED among individuals with the condition/ the logarithm of odds of DED among individuals without the condition, where the odds of DED is defined as the probability of having the disease divided the probability of not having the disease (Szumilas, 2010).

An OR of 1 is indicative of no effect relationship between the condition and the disease (Szumilas, 2010). Ratios of < 1 and > 1 suggest that being exposed to the condition decreases and increases the odds of DED, respectively (Szumilas, 2010). In other words, an OR of > 1 means that the condition is a risk factor of DED (Szumilas, 2010).

Study	DED diagnosis	Risk factor	Risk categories	OR [95%CI]	p-value
Schaum	WHS	∄ Age (vears)	50-54	1.00	
-bera et	criteria	000	55-59	0.81 [0.64-1.04]	n/a
al			60-64	0.72 [0.55-0.93]	n/a
2009			65-69	0.92 [0.71-1.20]	n/a
			70-74	1.18 [0.92-1.53]	n/a
			74-79	1.51 [1.15-1.97]	n/a
			≥80	1 76 [1 34-2 32]	n/a
		A Race/Ethnicity	White	1 00	n/a
			African American	1 13 [0 76-1 68]	n/a
			Asian/Pacific Islander	1.10 [0.70-1.00]	n/a
			Hispanic	1.00 [0.7 9-2.00]	n/a
			Inspanic Unknown/Othor	0.02 [0.53-1.07]	n/a
		1 Decise of		0.93 [0.55-1.65]	II/d
			South		-
		residence	vvest	0.93 [0.53-1.63]	n/a
			Midwest	1.01 [0.85-1.18]	n/a
			Northeast	0.96 [0.81-1.14]	n/a
			Other	1.61 [0.85-3.04]	n/a
		d Hypertension	No	1.00	
			Yes	1.28 [1.12-1.45]	n/a
		🕈 Benign prostatic	No	1.00	
		hyperplasia	Yes	1.26 [1.09-1.44]	n/a
		♂ Diabetes mellitus	No	1.00	
			Yes	0.97 [0.74-1.24]	n/a
Zhang	WHS	Myopia	No	1.00	
et al	criteria	5	Yes	1.49 [0.99-2.23]	n/a
2012		Contact lens wear	No	1.00	
		-	Yes	1 22 [0 81-1 81]	n/a
		Inadequate	No	1 00	
		refractive	Yes	1 98 [1 58-2 49]	n/a
		correction	100	1.00[1.00 2.40]	n/a
		Erequent self-	No	1 00	
		administered	Yes	1 84 [1 40_2 41]	n/a
		topical ophthalmic	103	1.0-21]	n/a
		medication			
		Poor sleep quality	No	1 00	
		Foor sleep quality	Voc	1 24 [1 05 1 71]	nla
Llabina	MUC		10.40	1.34 [1.05-1.71]	11/d
	VVHS	o Age (years)	40-49		- 1-
et al.,	criteria		50-59	1.22 [0.67-2.20]	n/a
2011			60-69	1.03 [0.55-1.94]	n/a
			70-79	1.03 [0.54-1.99]	n/a
			≥80	0.95 [0.43-2.09]	n/a
		d Body mass index	18.5-24.9	1.00	
		(kg/m²)	<18.5	2.07 [0.98-4.39]	n/a
			> 25.0	1.11 [0.72-1.70]	n/a
		🕉 Visual terminal	No	1.00	
		display use (hours)	0-2	0.71 [0.40-1.27]	n/a
			2-4	0.52 [0.21-1.26]	n/a
			≥ 4	1.10 [0.54-2.24]	n/a
		♂ Contact lens use	No	1.00	
			Yes	3.84 [1.46-10.10]	n/a
		♂ Stroke	No	1.00	
		-	Yes	1.33 [0.69-2.55]	n/a
		3 Hypertension	No	1.00	
		J JI	Yes	1.39 [0.94-2.06]	n/a
			40-49	1.00	
		+ , , , , , , , , , , , , , , , , , , ,	50-59	1 08 [0 68-1 72]	n/a
			60-69	1 16 [0 71_1 80]	n/a
			70_79	1 52 [0 02_2 51]	n/a
			>80	1 36 [0 79_2 34]	n/a

Table 1.5 DED risk factor assessment

		${ig Q}$ Body mass index	18.5-24.9	1.00	
		(kg/m^2)	<18.5	1.17 [0.69-1.97]	n/a
			> 25.0	0.69 0.48-1.01	n/a
		$^{\circ}$ Visual terminal	No	1.00	
		display use (hours)	0-2	1 03 [0 62-1 7]	n/a
			2-4	2 33 [1 12-4 85]	n/a
			> 1	1 88 [0 05 3 73]	n/a
		O Contract lana was	2 4 No	1.00 [0.90-0.70]	n/a
		\downarrow Contact lens use			1
			Yes	3.61 [2.13-6.10]	n/a
		$\stackrel{\circ}{_{\sim}}$ Stroke	No	1.00	
			Yes	1.26 [0.70-2.28]	n/a
		${\mathbb Q}$ Myocardial	No	1.00	
		infarction or angina	Yes	2.64 [1.51-4.62]	n/a
Clir	nical	♂ Age (years)	40-49	1.00	
dia	gnosis		50-59	1.92 [0.56-6.63]	n/a
			60-69	1.33 [0.33-5.43]	n/a
			70-79	0.96 0.20-4.65	n/a
			≥80	Omitted	n/a
		A Body mass index	18 5-24 9	1	n, a
		(kq/m^2)	<18.5	2 28 [0 49-10 59]	n/a
		(kg/m)	> 25.0	0.52 [0.15 1.70]	n/a
		1 Vieual terminal	> 20.0	1.00	n/a
					1
		display use (nours)	0-2	0.90 [0.28-2.90]	n/a
			2-4	0.51 [0.06-4.14]	n/a
			≥ 4	1.24 [0.31-4.98]	n/a
		Contact lens use	No	1.00	
			Yes	4.38 [0.87-22.04]	n/a
		∛ Stroke	No	1.00	
			Yes	0.94 [0.12-7.49]	n/a
		♂ Hypertension	No	1.00	
			Yes	0.68 [0.24-1.96]	n/a
		୍ Age (vears)	40-49	1	
		+ • • • • • • • • • • • • • • • • • • •	50-59	1.78 [0.95-3.35]	n/a
			60-69	1 70 [0 86-3 37]	n/a
			70-79	0.45 [0.17-1.17]	n/a
			>80	1 00 [0 47 2 50]	n/a
			19 5 24 0	1.09 [0.47-2.00]	n/a
		\neq Body mass muck (kg/m ²)	10.5-24.9		-
		(Kg/III ⁻)	< 10.5	0.96 [0.44-2.21]	n/a
			> 25.0	0.72 [0.39-1.31]	n/a
		$\stackrel{\circ}{\downarrow}$ Visual terminal	No	1.00	
		display use (hours	0-2	0.97 [0.49-1.93]	n/a
			2-4	2.52 [1.04-6.13]	n/a
			≥ 4	1.40 [0.56-3.46]	n/a
		${\mathbb Q}$ Contact lens use	No	1.00	
			Yes	4.36 [2.33-8.17]	n/a
		♀ Stroke	No	1.00	
			Yes	1.24 [0.45-3.37]	n/a
		♀ Myocardial	No	1.00	
		infarction or angina	Yes	0.97 [0.32-2.95]	n/a
Svr	nntoms	Age (vears)	40-49	1.00	
(///	HS	(jears)	50-59	1 13 [0 61_2 11]	n/a
crit	aria)		60 69	1.00 [0.51 1.03]	n/a
Chi	cha)		70 70	1.00 [0.01-1.00]	n/a
			70-79 >90	1.03 [0.52-2.03]	n/a
			200	1.02 [0.45-2.27]	n/a
			10.0-24.9		
		(ĸg/m²)	<18.5	2.04 [0.93-4.48]	n/a
		A.u	> 25.0	1.22 [0.78-1.88]	n/a
		් Visual terminal	No	1.00	
		display use (hours)	0-2	0.76 [0.42-1.37]	n/a
			2-4	0.48 [0.18-1.25]	n/a
			≥ 4	1.00 [0.46-2.16]	n/a

Table 1.5(continued)

		A Contact lens use	No	1.00	
			Yes	4 48 [1 69-11 90]	n/a
		∛ Stroke	No	1.00	n/a
		0 etrette	Yes	1 42 [0 74-2 75]	n/a
		A Hypertension	No	1.00	n/a
			Yes	1.56 [1.04-2.35]	n/a
		⊖ Age (vears)	40-49	1.00 [1.04 2.00]	n/a
			50-59	1 00 [0 60-1 65]	n/a
			60-69	1 27 [0 75-2 14]	n/a n/a
			70-79	1 90 [1 11-3 23]	n/a n/a
			>80	1 46 [0 82-2 60]	n/a n/a
		^O Body mass index	18 5-24 9	1.00	n/a
		(kq/m^2)	<18.5	1.34 [0.78-2.29]	n/a
		(((g,))))	> 25.0	0 74 [0 50-1 09]	n/a n/a
		◯ Visual terminal	No	1 00	n/a
		display use (hours	0-2	1 10 [0 64-1 88]	n/a
			2-4	2 28 [1 05-4 96]	n/a
			> 4	2 44 [1 22-4 90]	n/a
		Contact lens use	 No	1 00	1
			Yes	2 67 [1 54-4 65]	n/a
		○ Stroke	No	1 00	n/a
			Yes	1 12 [0 60-2 00]	n/a
		O Myocardial	No	1 00	n/a
			Ves	2 71 [1 53_/ 70]	n/a
Δhn et	Clinical		19-29	1.00	Ti/a
al	diagnosis	/ige (years)	30-39	1.00	0.84
2014	alagnoolo		40-49	1 20 [0 90-1 70]	0.23
2014			50-59	1 80 [1 20-2 70]	<0.01
			60-69	1 70 [1 10-2 70]	0.02
			≥70	1.00 [0.60-1.70]	0.93
		Sex	Male	1.00	0.00
		COA	Female	2 80 [2 10-3 70]	<0.01
		Monthly household	Lowest quintile	1.00	0.01
		income	2nd-4th quintile	1.10 [0.80-1.60]	0.53
			Highest quintile	1.20 [0.80-1.80]	0.39
		Education	Elementary school	1.00	
			Middle school	1.30 [0.80-2.00]	0.24
			High school	1.50 [1.00-2.2]	0.06
			University/higher	1.60 [1.00-2.40]	0.05
		Residential area	Urban	1.00	
			Rural	1.00 [0.70-1.30]	0.90
		Occupation	Occupation Farming,	1.00	
		-	fishing and forestry		
			Administrator,	1.50 [0.80-2.90]	<0.17
			management,		
			professional		
			business and		
			financial operations		
			occupations		
			Sales and related	1.30 [0.70-2.60]	<0.37
			occupations		
			Business and	0.90 [0.50-1.70]	0.86
			financial operations		
			occupations		
			Installation,	1.30 [0.70-2.50]	0.45
			maintenance and		
			repair occupations or		
			technicians		
			Laborer	1.30 [0.70-2.40]	0.48
			Unemployed	1.50 [0.90-2.70]	0.14

Table 1.5 (continued)

Hypertension No 1.00 Prehypertension 0.90 [0.70-1.10] 0.30 Obesity (kg/m ²) Underweight (<18.5) 1.00 Normal (18.5-24.9) 0.90 [0.60-1.40] 0.75 Obesity (> 25.0) 0.80 [0.60-1.30] 0.40 Hypercholesterole- mia Yes 1.20 [0.90-1.60] 0.13 Hypertriglycemia No 1.00 0.66 Rheumatoid No 1.00 0.66 Rheumatoid No 1.00 0.29 Thyroid disease No 1.00 0.29 Yes 1.30 [0.80-2.20] 0.29 Thyroid disease No 1.00 0.99 Yes 1.30 [0.60-1.00] 0.99 0.34 Stress Least stressful 1.00 0.01 Stress Least stressful 1.30 [1.00-1.70] 0.07 Extremely stressful 1.70 [1.10-2.60] 0.01 0.82 were Yes 2.60 [2.0-3.30] <0.01 Symptoms Age (years) 19-29					
Prehypertension 0.90 [0.70-1.10] 0.30 Hypertension 0.8 [0.60-1.00] 0.07 Underweight (<18.5)		Hypertension	No	1.00	
$ \begin{array}{c c c c c c c c c c c c c c c c c c c $			Prehypertension	0.90 [0.70-1.10]	0.30
Obesity (kg/m²) Underweight (<18.5) Normal (18.5-24.9) 0.09 [0.60-1.40] 0.75 Hypercholesterole- mia No 1.00 0.40 Hypertriglycemia No 1.00 0.40 Hypertriglycemia No 1.00 0.40 Hypertriglycemia No 1.00 0.40 Hypertriglycemia No 1.00 0.40 Yes 0.39 [0.70-1.30] 0.66 Rheumatoid No 1.00 Yes Thyroid disease No 1.00 0.99 Yes 0.70 [0.60-1.00] 0.09 Sleep duration 6-8 hours 1.00 0.40 Yes 0.7 [0.50-1.10] 0.10 0.40 Stress 1.00 Moderately stressful 1.70 [1.00-1.70] 0.71 Extremely stressful 1.00 1.00 Moderately stressful 1.30 [1.00-1.20] 0.82 Users 0.70 [1.00-1.30] 0.89 No 1.00 1.00 Stress 1.929 1.00 0.01 0.62<			Hypertension	0.8 [0.60-1.00]	0.07
$\begin{array}{c c c c c c c c c c c c c c c c c c c $		Obesity (kg/m ²)	Underweight (<18.5)	1.00	
Hypercholesterole- mia Obesity (> 25.0) 0.80 [0.60-1.30] 0.40 No 1.00 0.13 Hypertriglycemia No 1.00 0.13 Hypertriglycemia No 1.00 0.66 Rheumatoid No 1.00 0.61 Thyroid disease No 1.00 0.29 Thyroid disease No 1.00 229 Thyroid disease No 1.00 229 Sleep duration 6-8 hours 1.00 0.09 Sleep duration 6-8 hours 1.00 0.09 Stress 1.00 0.00 0.00 Stress 1.00 0.00 0.01 Moderately stressful 1.00 0.01 0.70 Extremely stressful 1.00 0.01 0.82 user Yes 0.70 [1.00-1.20] 0.82 Users 2.60 [2.00-3.30] <0.01			Normal (18.5-24.9)	0.90 [0.60-1.40]	0.75
Hypercholesterole- mia No 1.00 1.00 0.13 Hypertriglycemia No 1.00 0.13 0.66 Rheumatoid No 1.00 Yes 0.90 [0.70-1.30] 0.66 Rheumatoid No 1.00 Yes 1.30 [0.80-2.20] 0.29 Thyroid disease No 1.00 Yes 1.70 [1.20-2.40] <0.01			Obesity (> 25.0)	0.80 0.60-1.30	0.40
mia Yes 1.20 [0.90-1.60] 0.13 Hypertriglycemia No 1.00 0.00 0.66 Rheumatoid No 1.00 Yes 0.90 [0.70-1.30] 0.66 Rheumatoid No 1.00 Yes 1.30 [0.80-2.20] 0.29 Thyroid disease No 1.00 Yes 1.70 [1.20-2.40] <0.01		Hypercholesterole-	No	1.00	
Hypertriglycemia No 1.00 1.00 No Rheumatoid No 1.00 0.66 Rheumatoid No 1.00 0.66 Yes 0.90 [0.70-1.30] 0.66 Thyroid disease No 1.00 Yes 1.70 [1.20-2.40] <0.01		mia	Yes	1.20 [0.90-1.60]	0.13
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Hypertriglycemia	No	1.00	
Rheumatoid No 1.00 1.00 Yes 1.30 [0.80-2.20] 0.29 Thyroid disease No 1.00 Yes 1.70 [1.20-2.40] <0.01			Yes	0.90 [0.70-1.30]	0.66
Yes 1.30 [0.80-2.20] 0.29 Thyroid disease No 1.00 Yes 1.70 [1.20-2.40] <0.01		Rheumatoid	No	1.00	
Thyroid disease No 1.00 1.00 Yes 1.70 [1.20-2.40] <0.01			Yes	1.30 [0.80-2.20]	0.29
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$		Thyroid disease	No	1.00	
Lifetime smoker No 1.00 Yes 0.70 [0.60-1.00] 0.09 Sleep duration 6-8 hours 1.00 <6 hours 1.10 [0.90-1.50] 0.34 >8 hours 0.7 [0.50-1.10] 0.10 Stress Least stressful 1.00 Moderately stressful 1.00 Moderately stressful 1.70 [1.10-2.60] 0.01 Extremely stressful 1.70 [1.10-2.60] 0.01 Never drink an 1.00 Not a binge alcohol user Yes 0.70 [1.00-1.20] 0.82 user Yes 0.70 [1.00-1.20] 0.82 user Yes 0.70 [1.00-1.20] 0.82 User Yes 0.70 [1.00-1.20] 0.89 History of eye No 1.00 Symptoms Age (years) 19-29 1.00 (WHS criteria) 40-49 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01 ≥70 1.20 [0.80-1.90] 0.34 Sex Male 1.00 Female 1.90 [1.50-2.40] <0.01 Monthly household income 2nd-4th quintile 1.20 [0.90-1.60] 0.14 Highest quintile 1.20 [0.90-1.60] 0.14 Highest quintile 1.20 [0.90-1.60] 0.28 Education Elementary school 1.00 Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.65 High s			Yes	1 70 [1 20-2 40]	<0.01
Ves 0.70 [0.60-1.00] 0.09 Sleep duration 6-8 hours 1.00 0.34 ~6 hours 1.10 [0.90-1.50] 0.34 ~8 hours 0.7 [0.50-1.10] 0.10 Stress Least stressful 1.00 Moderately stressful 1.30 [1.00-1.70] 0.07 Extremely stressful 1.70 [1.10-2.60] 0.01 Binge alcohol user Never drink an 1.00 Not a binge alcohol 0.80 [1.00-1.20] 0.82 user Yes 0.70 [1.00-1.30] 0.89 History of eye No 1.00 0.01 Symptoms Age (years) 19-29 1.00 0.01 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.80-1.40] 0.61 Sex Male 1.00 0.01 Education Eemale 1.90 [1.50-2.40] <0.01		l ifetime smoker	No	1.00	-0.01
Sleep duration 6-8 hours 1.00 0.100 0.34 <6 hours			Yes	0 70 [0 60-1 00]	0.09
Stress 1.10 [0.90-1.50] 0.34 >8 hours 0.7 [0.50-1.10] 0.10 Stress Least stressful 1.00 Moderately stressful 1.30 [1.00-1.70] 0.07 Extremely stressful 1.70 [1.10-2.60] 0.01 Binge alcohol user Never drink an 1.00 Never drink an 1.00 0.80 [1.00-1.20] 0.82 user Yes 0.70 [1.00-1.30] 0.89 History of eye No 1.00 0.01 Symptoms Age (years) 19-29 1.00 0.62 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01		Sleep duration	6-8 hours	1 00	0.00
Stress 0.7 [0.50-1.10] 0.04 Stress Least stressful 1.00 0.10 Binge alcohol user Never drink an alcohol 1.70 [1.10-2.60] 0.01 Binge alcohol user Never drink an alcohol 1.70 [1.00-1.20] 0.82 History of eye No 1.00 0.01 Symptoms Age (years) 19-29 1.00 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.80-1.40] 0.62 Sex Male 1.00 0.01 60-69 1.60 [1.10-2.10] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01				1 10 [0 90-1 50]	0 34
Stress Least stressful Moderately stressful Extremely stressful 1.00 0.10 Binge alcohol user Never drink an alcohol 1.00 0.07 Not a binge alcohol user Never drink an alcohol 1.00 0.01 History of eye surgery No 0.80 [1.00-1.20] 0.82 Yes 0.70 [1.00-1.30] 0.89 (WHS criteria) Age (years) 19-29 1.00 Symptoms Age (years) 19-29 1.00 (WHS criteria) Sex Male 1.00 0.62 Age (years) 19-29 1.00 0.34 So-59 1.50 [1.10-2.10] 0.31 0.34 Sex Male 1.00 0.34 Sex Male 1.00 0.34 Group 270 1.20 [0.80-1.90] 0.34 Sex Male 1.00 0.01 Monthly household Lowest quintile 1.20 [0.90-1.60] 0.14 Highest quintile 1.20 [0.90-1.60] 0.28 Elementary school 1.00			>8 hours	0 7 [0 50-1 10]	0.04
Binge alcohol user Moderately stressful Extremely stressful Never drink an alcohol Not a binge alcohol user 1.30 [1.00-1.70] 1.70 [1.10-2.60] 0.07 History of eye surgery Yes 0.80 [1.00-1.20] 0.82 Yes 0.70 [1.00-1.30] 0.89 History of eye surgery Yes 2.60 [2.00-3.30] <0.01		Stress	l east stressful	1.00	0.10
Binge alcohol user Extremely stressful 1.70 [1.10-2.60] 0.01 Binge alcohol user Never drink an alcohol 1.00 0.82 Never drink an alcohol 0.80 [1.00-1.20] 0.82 History of eye No 1.00 0.01 Symptoms Age (years) 19-29 1.00 0.01 (WHS criteria) 40-49 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.80-1.40] 0.62 Symptoms Age (years) 19-29 1.00 (WHS criteria) 30-39 1.10 [0.80-1.40] 0.62 Sex Male 1.00 0.01 60-69 1.60 [1.10-2.30] <0.01		olless	Moderately stressful	1 30 [1 00 1 70]	0.07
Binge alcohol user Extremely sitessitul 1.70 [1.10-2.00] 0.01 Binge alcohol user Never drink an alcohol 1.00 0.82 Not a binge alcohol 0.80 [1.00-1.20] 0.82 User Yes 0.70 [1.00-1.30] 0.89 History of eye No 1.00 0.62 Symptoms Age (years) 19-29 1.00 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01			Extremely stressful	1.30 [1.00-1.70]	0.07
Binge alcohol user Never unit an alcohol 1.00 Not a binge alcohol 0.80 [1.00-1.20] 0.82 User Yes 0.70 [1.00-1.30] 0.89 History of eye No 1.00 0.00 Symptoms Age (years) 19-29 1.00 0.62 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01		Pingo alaahal usor	Nover drink on	1.70 [1.10-2.00]	0.01
Not a binge alcohol user Not a binge alcohol yes 0.80 [1.00-1.20] 0.82 History of eye surgery Yes 0.70 [1.00-1.30] 0.89 Mot a binge alcohol user No 1.00 0.89 Yes 2.60 [2.00-3.30] <0.01		Billige alcollol user		1.00	
History of eye surgery No 1.00 0.89 Symptoms Age (years) 19-29 1.00 0.62 (WHS criteria) Age (years) 19-29 1.00 0.62 Symptoms Age (years) 19-29 1.00 0.62 (WHS criteria) 40-49 1.10 [0.80-1.40] 0.62 Sex Male 1.00 0.34 So-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01			Not a bingo alcohol	0 90 [1 00 1 20]	0.92
Yes 0.70 [1.00-1.30] 0.89 History of eye surgery No 1.00 Symptoms Age (years) 19-29 1.00 (WHS criteria) 30-39 1.10 [0.80-1.40] 0.62 Symptoms Age (years) 19-29 1.00 WHS criteria) 40-49 1.10 [0.90-1.50] 0.34 So-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01			Not a binge alconor	0.00[1.00-1.20]	0.62
History of eye surgery No 1.00 0.70 [1.00-1.30] 0.89 History of eye surgery No 1.00 0.01 0.01 Symptoms (WHS criteria) Age (years) 19-29 1.00 0.62 (WHS criteria) 30-39 1.10 [0.80-1.40] 0.62 Sex 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01			Vee	0 70 [1 00 1 20]	0.90
Instituty of eye No 1.00 surgery Yes 2.60 [2.00-3.30] <0.01		Lister of aug	res	0.70[1.00-1.30]	0.09
Surgery Yes 2.00 [2.00-3.30] <0.01 Symptoms (WHS criteria) Age (years) 19-29 1.00 0.62 Surgery 40-49 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01		HISTORY OF EYE	NO		-0.01
Symptoms (WHS Age (years) 19-29 1.00 (WHS 30-39 1.10 [0.80-1.40] 0.62 criteria) 40-49 1.10 [0.90-1.50] 0.34 50-59 1.50 [1.10-2.10] 0.01 60-69 1.60 [1.10-2.30] <0.01	0	surgery	res	2.00 [2.00-3.30]	<0.01
$\begin{array}{cccc} (WHS & 30-39 & 1.10 \ [0.80-1.40] & 0.62 \\ criteria) & 40-49 & 1.10 \ [0.90-1.50] & 0.34 \\ 50-59 & 1.50 \ [1.10-2.10] & 0.01 \\ 60-69 & 1.60 \ [1.10-2.30] & <0.01 \\ \geq 70 & 1.20 \ [0.80-1.90] & 0.34 \\ \end{array}$	Symptoms	Age (years)	19-29	1.00	0.00
criteria)40-491.10 [0.90-1.50]0.3450-591.50 [1.10-2.10]0.01 $60-69$ 1.60 [1.10-2.30]<0.01	(WHS		30-39	1.10 [0.80-1.40]	0.62
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$	criteria)		40-49	1.10 [0.90-1.50]	0.34
$ \begin{array}{cccccccccccccccccccccccccccccccccccc$			50-59	1.50 [1.10-2.10]	0.01
$\begin{array}{c ccccccccccccccccccccccccccccccccccc$			60-69	1.60 [1.10-2.30]	<0.01
Sex Male 1.00 Female 1.90 [1.50-2.40] <0.01			≥70	1.20 [0.80-1.90]	0.34
Monthly household income Female 1.90 [1.50-2.40] <0.01		Sex	Male	1.00	
Monthly household income Lowest quintile 1.00 2nd-4th quintile 1.20 [0.90-1.60] 0.14 Highest quintile 1.20 [0.90-1.60] 0.28 Education Elementary school 1.00 Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63			Female	1.90 [1.50-2.40]	<0.01
income 2nd-4th quintile 1.20 [0.90-1.60] 0.14 Highest quintile 1.20 [0.90-1.60] 0.28 Education Elementary school 1.00 Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63		Monthly household	Lowest quintile	1.00	
Highest quintile 1.20 [0.90-1.60] 0.28 Education Elementary school 1.00 Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63		income	2nd-4th quintile	1.20 [0.90-1.60]	0.14
Education Elementary school 1.00 Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63			Highest quintile	1.20 [0.90-1.60]	0.28
Middle school 1.10 [0.80-1.40] 0.65 High school 1.00 [0.80-1.40] 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63		Education	Elementary school	1.00	
High school 1.00 0.80-1.40 0.93 University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63			Middle school	1.10 [0.80-1.40]	0.65
University/higher 1.50 [1.10-2.00] 0.02 Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63			High school	1.00 0.80-1.40	0.93
Residential area Urban 1.00 Rural 1.10 [0.80-1.50] 0.63			University/higher	1.50 [1.10-2.00]	0.02
Rural 1.10 [0.80-1.50] 0.63		Residential area	Urban	1.00	
			Rural	1.10 [0.80-1.50]	0.63

Table 1.5(continued)

		Occupation	Farming, fishing and forestry	1.00	
			Administrator,	1.40 [0.80-2.30]	0.20
			management,	- •	
			professional		
			business and		
			Sales and related	1.60 [0.90-2.60]	0.09
			occupations		0.00
			Business and	1.20 [0.70-1.90]	0.54
			financial operations		
			occupations		
			Installation,	1.30 [0.80-2.20]	0.35
			maintenance and		
			technicians		
			Laborer	1.40 [0 80-2 20]	0.22
			Unemployed	1.50 [0.90-2.30]	0.09
		Hypertension	No	1.00	
			Prehypertension	1.00 [0.80-1.20]	0.92
			Hypertension	0.90 [0.70-1.10]	0.23
		Obesity (kg/m ²)	Underweight (<18.5)	1.00	0.04
			Normal $(18.5-24.9)$		0.31
		Hypercholesterole-	No	1.00 [0.70-1.40]	0.99
		mia	Yes	1.40 [1.10-1.70]	<0.01
		Hypertriglycemia	No	1.00	
		··· •·	Yes	0.90 [0.70-1.20]	0.50
		Rheumatoid	No	1.00	
			Yes	0.90 [0.50-1.50]	0.66
		Thyroid disease	No	1.00	
			Yes	1.50 [1.10-2.00]	0.01
		Lifetime smoker	No	1.00	0.00
		Pingo plackal user	Yes Never drink an	0.90 [0.70-1.10]	0.30
		binge aiconol user	ivever arink an	1 00	
			Not a binde alcohol	1.20 [1.0-1 40]	0.09
			user		0.00
			Yes	1.10 [0.90-1.40]	0.30
		Sleep duration	6-8	1.00	
		(hours)	<6	1.30 [1.00-1.60]	0.03
		Otraca	>8	0.90 [0.60-1.20]	0.48
		Stress	Least stressful Moderately stressful		0.03
			Extremely stressful	1 60 [1 10-2 30]	0.03
		History of eve	No	1.00	0.02
		surgery	Yes	2.20 [1.80-2.70]	<0.01
Uchino	Clinical	♂ Contact lens use	No	1.00	
et al.,	diagnosis		Soft contact lenses	4.20 [2.80-6.20]	0.19
2008			Hard contact lenses	4.40 [1.30-15.40]	<0.001
		$\begin{array}{c} \searrow \end{array}$ Contact lens use	NO Soft contact langes		<0.001
			Soli contact lenses	4.90 [2.30-10.30] 2 50 [0 50-12 20]	<0.001
	Symptoms	A Contact lens use	No	1 00	SU.UU I
	(WHS		Soft contact lenses	4.60 [3.80-5.70]	<0.001
	criteria)		Hard contact lenses	2.60 [1.10-5.90]	0.029
	,				

		~ ^		4.00	
		$\stackrel{\circ}{\downarrow}$ Contact lens use	No	1.00	-0.004
			Soft contact lenses	5.80 [3.60-9.30]	< 0.001
		_	Hard contact lenses	5.50 [2.20-13.70]	0.003
Um et	Clinical	Sex	Male .	1.00	
al.,	diagnosis		Female	3.02 [2.61-3.50]	n/a
2014		Age (years)	30-30	1.00	
			40-49	0.91 [0.73-1.13]	n/a
			50-59	1.06 [0.85-1.31]	n/a
			60-69	1.37 [1.11-1.68]	n/a
			≥70	0.90 [0.71-1.14]	n/a
		City size	Rural	1.00	
			Metropolitan cities	1.68 [1.30-2.17]	n/a
			Other cities	1.58 [1.22-2.06]	n/a
	Symptoms	Sex	Male	1.00	
	(WHS		Female	2.21 [1.96-2.48]	n/a
	criteria)	Age (years)	30-30	1.00	
			40-49	0.97 [0.80-1.16]	n/a
			50-59	1.11 [0.93-1.33]	n/a
			60-69	1.26 [1.06-1.51]	n/a
			≥70	1.06 [0.87-1.29]	n/a
		City size	Rural	1	
		-	Metropolitan cities	1.39 [1.09-1.77]	n/a
			Other cities	1.27 [1.00-1.62]	n/a
Na et	Clinical	♀ Psychological	Low	1.00	
al.,	diagnosis	stress perception	Moderate	1.70 [1.20-2.40]	n/a
2015	0		Severe	2.00 1.40-2.80	n/a
			Very severe	2.70 1.60-4.60	n/a
		O Depressed mood	No	1.00	
		τ μ	Yes	1.50 [1.10-2.00]	n/a
		♀ Suicidal thoughts	No	1.00	
			Yes	1 20 [0 90-1 50]	n/a
		Psychological	No	1.00	n/a
		counseling	Yes	1 80 [1 00-3 10]	n/a
			No	1.00 [1.00 0.10]	n/a
			Ves	1 40 [0 90-2 20]	n/a
		0 Anviety/Denres-	None	1.40 [0.30-2.20]	Π/α
		sion	Ves	1.50 [1.10-2.00]	n/a
	Symptoms			1.00 [1.10-2.00]	Π/α
	/by	\pm 1 Sychological stress perception	Moderate	1.00	n/a
	(by ograping to	siless perception	Sovere	2 00 [1 40 2 70]	n/a
				2.00 [1.40-2.70]	n/a
	a statement)		No	2.00 [1.00-4.00] 1.00	11/d
	statement)	\pm Dehressed mood	NU		n/o
		O Suioidal thoughta	No.	1.30 [1.00-1.70]	n/a
		\mp Suicidal thoughts			n/o
			TCS No	1.30 [0.90-1.70]	n/a
					n/o
			T CS	∠.00 [1.10-3.00] 1.00	n/a
					nla
			Tes	1.10[0.70-1.60]	n/a
			NO		<i>n</i> / <i>n</i>
		sion	res	1.50 [1.10-1.90]	n/a
Vehof et	Symptoms	$\stackrel{\vee}{_{\sim}}$ Age (years)		1.01 [1.01-1.02]	<0.0005
al.,	(by	$\stackrel{\circ}{\downarrow}$ Use of contact	No	1.00	0.045
2014	agreeing to	lenses	Yes	1.78 [1.10-2.87]	0.018
	а	$\mathop{{\cup}}\limits_{\to}$ Cataract surgery	No	1.00	
	statement)		Yes	1.70 [1.24-2.32]	0.001
		$\mathop{{\scriptscriptstyle \bigcirc}}_{\scriptstyle \leftarrow}$ Glaucoma	No	1.00	
			Yes	1.34 [0.89-2.02]	0.16
		$ \mathcal{Q} $ Age-related	No	1.00	
		macular	Yes	1.52 [0.99-2.33]	0.054
		degeneration			
Table 1.5

(continued)

	\bigcirc Osteoporosis	No	1.00	
		Yes	1.2 [0.90-1.60]	0.23
	♀ Asthma	No	1.00	
	I	Yes	1 40 [1 14-1 71]	0.001
		No	1.40[1.14 1.71]	0.001
	¥ Eczema	INU Mala		-0.000
	- ··· / ·	Yes	1.70[1.41-2.05]	<0.0005
	$\stackrel{\circ}{_{ m }}$ Allergy (any)	No	1.00	
		Yes	1.42 [1.20-1.68]	<0.0005
	♀ Any thyroid	No	1.00	
	problems	Yes	1 38 [1 12-1 71]	0.003
		Ne	1.00 [1.12 1.1 1]	0.000
	¥ Hypotitytoluisiii	NO	1.00	0.40
		Yes	1.30 [0.93-1.82]	0.12
	$\stackrel{\circ}{_{ m P}}$ Hyperthyroidism	No	1.00	
		Yes	1.41 [0.80-2.49]	0.24
	${\mathbb Q}$ Rheumatoid	No	1.00	
	arthritis	Yes	1 34 [1 02-1 75]	0.034
		Ne	1.04 [1.02 1.10]	0.004
		NO		0.04
	_	Yes	1.15 [0.88-1.52]	0.31
	Ŷ	No	1.00	
	Hypercholesterole-	Yes	1.31 [1.10-1.56]	0.002
	mia			
		No	1 00	
	[∓] Typertension	NO Xee		0.0
		res	1.12 [0.94-1.35]	0.2
	$\stackrel{\circ}{_{ m P}}$ Diabetes	No	1.00	
		Yes	1.22 [0.85-1.77]	0.28
	\bigcirc Osteoarthritis	No	1.00	
	1	Yes	1 33 [1 11-1 59]	0.002
		No	1 00	0.002
		No		0.01
		res	1.17 [0.92-1.49]	0.21
	\mathcal{P} Stroke	No	1.00	
		Yes	2.50 [1.55-4.02]	<0.0005
	♀ Migraine	No	1.00	
		Yes	1.24 [1.04-1.49]	0.018
	O Irritable bowel	No	1 00	
		No.	1.00	<0.000E
	syndrome	res	1.92 [1.00-2.30]	<0.0005
		NO	1.00	
	widespread pain	Yes	2.61 [1.92-3.56]	<0.0005
	syndrome			
	Pelvic pain	No	1.00	
	+ · · · · · · · ·	Yes	1 64 [1 33-2 02]	<0.0005
		No	1.04[1.00-2.02]	-0.0000
		NO		-0.0005
		res	1.67 [1.35-2.07]	<0.0005
Clinical	${\mathbb Q}$ Age (years)		1.05 [1.03-1.06]	<0.0005
diagnosis	otcolorightarrow Use of contact	No	1.00	
and dailv	lenses	Yes	1.01 [0.43-2.37]	0.99
use of	Octata Surgery	No	1 00	
artificial	+ eataraot sargery	Ves	1 60 [1 16 2 47]	0.006
		Tes	1.09[1.10-2.47]	0.000
lears	eq Glaucoma	INO	1.00	
		Yes	1.56 [0.95-2.57]	0.077
	otag Age-related	No	1.00	
	macular	Yes	1.56 [0.91-2.66]	0.11
	degeneration			
		No	1 00	
		No	1.00	0.00
	○ A . II.		1.22 [U.97-1.53]	0.08
	arphi Asthma	NO	1.00	
		Yes	1.54 [1.17-2.04]	0.002
	♀ Eczema	No	1.00	
		Yes	1.48 [1.14-1.93]	0.004
	○ Alleray (any)	No	1 00	0.001
		Voc	1 40 [1 11 1 00]	0.005
	○ A		1.42 [1.11-1.80]	0.005
	arphi Any thyroid	NO	1.00	
	problems	Yes	1.61 [1.22-2.12]	0.001

Table 1.5

(continued)

♀ Hypothyroidism No 1.00 Yes 1.48 [0.95-2.29] 0. ♀ Hyperthyroidism No 1.00 Yes 1.68 [0.83-3.40] 0. ♀ Rheumatoid No 1.00 arthritis Yes 1.38 [1.02-1.87] 0. ♀ Fertility problems No 1.00 ♀ No 1.00	0.08 0.15 0.039 0.04 0.28
Yes 1.48 [0.95-2.29] 0. ♀ Hyperthyroidism No 1.00 Yes 1.68 [0.83-3.40] 0. ♀ Rheumatoid No 1.00 arthritis Yes 1.38 [1.02-1.87] 0. ♀ Fertility problems No 1.00 1.00 ♀ No 1.00 1.00	0.08 0.15 0.039 0.04 0.28
♀ Hyperthyroidism No 1.00 Yes 1.68 [0.83-3.40] 0. ♀ Rheumatoid No 1.00 arthritis Yes 1.38 [1.02-1.87] 0. ♀ Fertility problems No 1.00 ♀ No 1.00 ♀ No 1.00	0.15 0.039 0.04 0.28
Yes 1.68 [0.83-3.40] 0. ♀ Rheumatoid No 1.00 arthritis Yes 1.38 [1.02-1.87] 0. ♀ Fertility problems No 1.00 1.00 ♀ S 1.45 [1.01-2.09] 0. ♀ No 1.00	0.15 0.039 0.04 0.28
♀ Rheumatoid No 1.00 arthritis Yes 1.38 [1.02-1.87] 0. ♀ Fertility problems No 1.00 Yes 1.45 [1.01-2.09] 0. ♀ No 1.00	.039 .04 .28
φ No 1.00 1.00 arthritis Yes 1.38 [1.02-1.87] 0. φ Fertility problems No 1.00 Yes 1.45 [1.01-2.09] 0. φ No 1.00	0.039 0.04 0.28
a fullitis res 1.36 [1.02-1.67] 0. ♀ Fertility problems No 1.00 Yes 1.45 [1.01-2.09] 0. ♀ No 1.00	0.04 0.28
Pertility problems No 1.00 Yes 1.45 [1.01-2.09] 0. Q No 1.00	0.04 0.28
Yes 1.45 [1.01-2.09] 0. ♀ No 1.00	0.04 0.28
♀ No 1.00	.28
	.28
Hypercholesterole- Yes 1.14 [0.90-1.43] 0.	
All Hypertension No. 100	
	01
	.04
Yes 1.53 [0.99-2.37] 0.	.06
\bigcirc Osteoarthritis No 1.00	
Yes 1.35 [1.08-1.68] 0.	.0007
\bigcirc Cancer No 1.00	
Yes 1.11 [0.80-1.53] 0	.54
⊖ Stroke No 1.00	
Yes 1 64 [0 88-3 05] 0	12
	. 12
\div inigranie No 1.00 1.00	002
	.002
syndrome Yes 2.24 [1.76-2.85] <	0.0005
\bigcirc Chronic No 1.00	
widespread pain Yes 2.13 [1.42-3.18] <0	0.0005
Pelvic pain No 1 00	
+ · · · · · · · · · · · · · · · · · · ·	0 0005
	0.0000
	0 0005
	0.0005
Paulsen Symptoms Age (years)	/a
et al., (by self- Sex Male 1.00	
2014 report) Female 1.45 [1.14-1.85] n/	/a
Contact lens use Never 1.00	
Past 1.09 [0.83-1.43] n/	/a
Current 2.09 [1.56-2.79] n/	/a
Arthritis No 1.00 n/	/a
Yes 1.41 [1.09-1.82]	
Allergies No 1.00	
Yes 154 [1 18-2 01] n/	/a
Thyroid disease No 100	, a
	/a
	1-
Yes 1.44 [1.10-1.90] n/	/a
Antihistamines No 1.00	
Yes 1.41 [1.07-1.86] n/	/a
Steroids No 1.00 n/	/a
Yes 1.47 [1.10-1.97]	
Han et Symptoms Sex Male 1.00	
al. (by self- Female 1 64 [1 15-2 33] 0	006
2011 report) Region Rural 100	
	0 001
	0.001
	70
70-74 0.94 [0.61-1.44] 0.	./b
75-79 1.32 [0.80-2.16] 0.	.28
80-84 1.14 [0.58-2.25] 0.	.70
≥ 85 1.93 [0.83-4.47] 0.	.12

Tan et	Symptoms	Gender	Female	1.00	
al.,	(by self-		Male	0.82 [0.52-1.28]	0.38
2015	report)	Age (years)	Young (<25)	1.00	
	1 7	5 (7 -7	Mid (25-45)	1 27 [0 72-2 24]	0 41
			Old (>4E)	1.27 [0.72-2.24]	0.41
		O and a still	Ulu (240)	1.30 [U./ 1-2.50]	0.30
		Contact lens wear	NO	1.00	
			Yes	2.96 [1.81-4.83]	<0.0005
		Alcohol use	No	1.00	
			Yes	1 49 [0 55-4 04]	0.43
			Sometimes	0.31 [0.04-2.37]	0.26
		Madiaation aida	Ne	1.00	0.20
		Medication side	NO	1.00	0.05
		effect	Yes	1.84 [0.99-3.44]	0.05
Jie et	Symptoms	Age (years)		1.00	
al.,	(by self-			1.03 [1.02-1.05]	<0.001
2008	report)	Gender	Male	1.00	
	[7		Female	1 56 [1 23_1 08]	<0.001
		Bagian	Purel	1.00 [1.20-1.80]	NO.001
		Region	Rurai	1.00	
			Urban	1.89 [1.46-2.45]	<0.001
		Undercorrection of	No	1.00	
		refractive error	Yes	1.42 [1.11-1.82]	0.005
		l ow degree of	Νο	1.00	-
		nuclear cataract	Ves	0 81 [0 60-0 07]	0.02
Cue et	Sumptome		No	1.00	0.02
Guo et	Symptoms	Age-related			.0.001
al.,	(by self-	cataract	Yes	4.05 [3.03-5.42]	<0.001
2010	report)	Pterygium	No	1.00	
	• •		Yes	3.35 [2.58-4.35]	<0.001
		Age (vears)		1 00	
		rige (years)		2 42 [2 42 4 92]	<0.001
			N4.1	3.42 [2.42-4.03]	\0.001
		Gender		1.00	
			Female	1.01 [0.84-1.21]	>0.05
		Low education	No	1.00	
		level (<3 vears)	Yes	1.00 [0.76-1.33]	>0.05
			No	1 00	
		etetue	Vee		>0.0E
		Status	tes	1.10 [0.92-1.33]	20.05
		Smoking	NO	1.00	
			Yes	1.06 [0.81-1.39]	>0.05
		Alcohol	No	1.00	
		consumption	Yes	1.01 [0.75-1.36]	>0.05
		High altitude	No	1 00	
		. iigii ailitado	Voc	1 26 [0 82 4 02]	>0.05
T		Ormalan		1.20 [0.02-1.93]	-0.05
longg		Gender	remale	1.00	
et al.,			Male	1.16 [0.72-1.85]	n/a
2009		Age (years)	40-49	1.00	
		/	50-59	1.21 [0.83-1.75]	n/a
			60-69	0.88 [0.54-1.43]	n/a
			70-80		n/a
		Cigaratta amalvin-	No.	1.00	i i/ d
			Yes	1.//[1.1/ - 2.66]	n/a
		Thyroid disease	No	1.00	
			Yes	2.58 [1.29-5.18]	n/a
		Income (S\$)	< 500	1.00	
		(-+)	500-1000	1 00 [0 65-1 54]	n/a
			1000 2000	1 /0 [0.00-1.04]	n/a
			2000-2000	1.49 [0.03-2.01]	ii/a
			2000-3000	1.88 [0.93-3.83]	n/a
			>3000	1.74 [1.13-2.68]	n/a
		Highest education	No formal education	1.00	
		attained	Less than elementarv	0.83 [0.42-1.66]	n/a
			Flementary school	1 14 [0 70-1 84]	n/a
			High school	1 26 [0 71 2 22]	n/a
					11/d
			College/university	1.20 [0.59-2.44]	n/a

Table 1.5(continued)

		Type of housing	1-2 room public flat	1.00	
			3-4 room public flat	0.95 [0.61-1.48]	n/a
			5 room public flat	1.48 [0.86-2.53]	n/a
			Private housing	1.07 [0.29-3.88]	n/a
		Outdoor work	No	1.00	
			Yes	1.23 [0.74-2.05]	n/a
		Currently driving	No	1.00	
		vehicle	Yes	0.99 [0.67-1.46]	n/a
Lu et		Pterygium	No	1.00	
al.,			Yes	1.3 [1.0-1.7]	0.031
2008					
		Age (years)		3.29 [2.48-4.37]	<0.001
		Sex	No	1 00	
		CON	Yes	1 03 [1 0-1 7]	>0.05
		Low education	No	1.00[1.0-1.7]	- 0.00
		level (<3 years)	Ves	1 61 [1 22-2 12]	0.001
			No	1.01[1.22-2.12]	0.001
		ctatus	Voc	1.00	<0.001
		Status	No	2.39[1.40-3.00]	<0.001
		SHIOKING	NO	1.00	0.001
		Alashal	Ne	1.27 [0.97-1.00]	0.001
		Alconol	NO		> 0.0F
			res	1.27 [0.97-1.00]	>0.05
			NO		<0.001
		(≥4000 to 3300-	res	1.85 [1.45-2.37]	<0.001
Useba	0		NI-		
Hasne-	Symptoms	Pterygium	NO Xa a	4 70 [-/-]	0.000
miet	(USDI 2 23)		res	1.70 [n/a]	0.020
al.,					
2014					
Molet et	Sumptomo	Education	No advaction or	1.00	
Malet et	Symptoms	Education	No education or	1.00	
Malet et al.,	Symptoms (OSDI ≥ 23)	Education	No education or primary school	1.00	0.40
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary	1.00 0.75 [0.50-1.12]	0.16
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary school	1.00 0.75 [0.50-1.12]	0.16
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary school Long secondary	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77]	0.16 0.002
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary school Long secondary school	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77]	0.16 0.002
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary school Long secondary school High school or	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00]	0.16 0.002 0.05
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education	No education or primary school Short secondary school Long secondary school High school or University	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00]	0.16 0.002 0.05
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2)	No education or primary school Short secondary school Long secondary school High school or University	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02]	0.16 0.002 0.05 0.41
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking babits	No education or primary school Short secondary school Long secondary school High school or University	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00	0.16 0.002 0.05 0.41
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits	No education or primary school Short secondary school Long secondary school High school or University Never Former	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24]	0.16 0.002 0.05 0.41 0.35
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits	No education or primary school Short secondary school Long secondary school High school or University Never Former Current	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79]	0.16 0.002 0.05 0.41 0.35 0.59
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00	0.16 0.002 0.05 0.41 0.35 0.59
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on	No education or primary school Short secondary school Long secondary school or High school or University Never Former Current 0-2 3-4	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74]	0.16 0.002 0.05 0.41 0.35 0.59
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day)	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2 3-4 5-10	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day)	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2 3-4 5-10 No	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2 3-4 5-10 No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61 2.28]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75 3 33]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of <	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87, 1,72]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.57
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Patinopathy	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.57
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Retinopathy	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00 0.68 [0.26 4 20]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.57 0.25
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Retinopathy	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes No Yes No	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00 0.68 [0.36-1.30] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.24 0.57 0.25
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Retinopathy Glaucoma	No education or primary school Short secondary school Long secondary school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes No Yes No Yes No	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00 0.68 [0.36-1.30] 1.00 0.75 [0.26 4 72]	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.57 0.25
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Retinopathy Glaucoma	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes No Yes No Yes No Yes	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00 0.68 [0.36-1.30] 1.00 0.78 [0.36-1.73] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.23 0.24 0.57 0.25 0.55
Malet et al., 2014	Symptoms (OSDI ≥ 23)	Education Body mass index (kg/m2) Smoking habits Daily time spent on screen (hours/day) Hypothyroidism Best-corrected visual acuity of < 20/40 Cataract extraction Late AMD Retinopathy Glaucoma Ocular	No education or primary school Short secondary school Long secondary school High school or University Never Former Current 0-2 3-4 5-10 No Yes No Yes No Yes No Yes No Yes No Yes No Yes No	1.00 0.75 [0.50-1.12] 0.49 [0.31-0.77] 0.62 [0.39-1.00] 0.98 [0.94-1.02] 1.00 0.82 [0.54-1.24] 0.80 [0.36-1.79] 1.00 1.02 [0.60-1.74] 1.16 [0.66-2.04] 1.00 1.18 [0.61-2.28] 1.00 1.58 [0.75-3.33] 1.00 1.22 [0.87-1.72] 1.00 1.22 [0.61-2.47] 1.00 0.68 [0.36-1.30] 1.00 0.78 [0.36-1.73] 1.00	0.16 0.002 0.05 0.41 0.35 0.59 0.93 0.60 0.62 0.23 0.24 0.23 0.24 0.57 0.25 0.55

Table 1.5(continued)

Beta-blockers	No	1.00	
	Yes	0.90 [0.63-1.30]	0.58
Diuretics	No	1.00	
	Yes	1.27 [0.86-1.87]	0.33
Anxiolytics	No	1.00	
	Yes	1.53 [1.03-2.28]	0.04
Antidepressant	No	1.00	
	Yes	1.33 [0.83-2.11]	0.23
Antihistamines	No	1.00	
	Yes	1.48 [0.71-3.10]	0.25
DED = dry eye disease. OR = odds ratio. Q =	female. 👌 = male.	CI = confidence interval.	

It is worth noting that, similarly to DED prevalence rates, DED risk factors have been confounded by the disease diagnoses used and the population characteristics studied. A deeper description of the identified DED risk factors is included further on (section 1.6.5.3.1 and 1.6.5.3.2).

1.6.5.2 Reporting dry eye risk factors

(continued)

Table 1.5

The precision and statistical significance of ORs are often reported (Uchino *et al.*, 2008, 2011; Lu *et al.*, 2008; Tongg *et al.*, 2009; Jie *et al.*, 2009; Schaumberg *et al.*, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014; Um *et al.*, 2014; Vehof *et al.*, 2014; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Paulsen *et al.*, 2014; Tan *et al.*, 2015; Na *et al.*, 2015). Both characteristics become important to understand how confident a researcher can be when generalizing the observed DED risk factors to the wider population.

1.6.5.2.1 The precision of dry eye risk factors

Generally, the 95% confidence interval (CI) is used to determine the precision of ORs (Browner and Newman, 1986). A large 95% CI refers to less precise ORs, whereas a small 95% CI refers to more precise ORs (Szumilas, 2010).

The upper and lower 95% CIs are calculated using the following formulas: Upper 95% CI = e ^ $[ln(OR) + 1.96 \sqrt{(1/a + 1/b + 1/c + 1/d)}]$ and Lower 95% CI = e ^ $[ln(OR) + 1.96 \sqrt{(1/a + 1/b + 1/c + 1/d)}]$, where "a" is the number of exposed individuals with DED, "b" the number of exposed individuals without DED, "c" number of unexposed individuals with DED and "d" the number of unexposed individuals without DED (Szumilas, 2010).

Importantly, the 95% confidence interval depends on the sample size and the standard deviation of the study groups (Szumilas, 2010). A large sample size gives narrower 95% CIs and hence more precise ORs. On the other hand, where the dispersity is high, the 95% CIs are wider and the ORs are consequently less certain (Szumilas, 2010).

1.6.5.2.2 The significance of dry eye risk factors

Often, an OR with a 95% CI that does not include the value of zero effect (OR = 1) is interpreted as statistically significant (Szumilas, 2010). However, interpretation alone is not enough and hence the p-value is used (Szumilas, 2010).

The p-value is usually expressed as a proportion which can also easily interpreted as a percentage. Conventionally, an OR with a p-value less than 0.05 is considered statistically significant. A level of 0.05 means that only 5% of an association of this size may arise in the sample by chance, so is likely to represent a "real" association in the wider population (Szumilas, 2010).

Note that the statistical significance of an OR can never be absolutely certain as the p-value is a measure of probability. There is always the possibility of committing errors, including false positives (to conclude there is a relationship, but in fact there

is not) and false negatives (to conclude there is no relationship, when in fact there is) (Szumilas, 2010).

1.6.5.3 Classifying dry eye risk factors

Environmental risk factors for DED can be classified into modifiable and nonmodifiable (Stapleton *et al.*, 2017). Modifiable risk factors for DED are those that can be controlled in order to decrease the chance of developing or worsening the disease (Jones *et al.*, 2017). In contrast, non-modifiable cannot be changed, however, determining their presence may help in understanding a positive DED diagnosis (Wolffsohn *et al.*, 2017).

1.6.5.3.1 Non-modifiable dry eye risk factors

1.6.5.3.1.1 Sex

Females are often on major risk of DED symptoms and signs than males, suggesting that sex hormones may play an important role in the etiology of the disease (Sullivan *et al.*, 2017).

Sex hormones are synthesized by the gonads, by the adrenal glands or by conversion of steroid precursors in peripheral intracrine tissues (i.e skin or fat) to be then released into the blood circulation and regulate physiological functions of different structures of the LFU (Truong *et al.*, 2014).

Main classes of sex hormones include androgens, estrogens and progesterones. The three steroids are present in each sex at different levels, considering androgens the "male sex hormones" and both estrogens and progesterones the "female sex hormones" (Truong *et al.*, 2014; Sullivan *et al.*, 2017).

Androgens are believed to enhance the function of the meibomian glands by modulating the transport and synthesis of lipids, to regulate the secretion of the lacrimal gland and to stimulate the proliferation and immune response of corneal and conjunctival cells (Sullivan *et al.*, 2017). On the other hand, estrogens and progesterones are thought to antagonize the actions of androgens; however, further studies are needed to clarify the precise mechanism of these sex hormones (Sullivan *et al.*, 2017).

1.6.5.3.1.2 Ethnicity

The term ethnicity is used to classify any population study by their physical characteristics, such as skin colour, facial shape and hair type. In DED, Asians appear to be more affected by the disease, however, there are discrepancies in the literature (Stapleton *et al.*, 2017).

1.6.5.3.1.3 Age

Although DED can develop at any age, aging is recognized as a significant risk factor of the disease (Stapleton *et al.*, 2017). It encompasses inevitable structural and functional changes of the LFU, such as corneal irregularities accompanied with visual function degradation, atrophy of both lacrimal gland and meibomian glands, lid laxity or conjunctivochalasis (De Paiva, 2017).

The underlying mechanism of aging on the eye is often explained by increasing predisposition of older adults of systemic and topical medication use, hormonal changes (menopause), inflammatory systemic conditions and oxidative stress (Sharma and Hindman, 2014). Nevertheless, the cause of aging itself remains largely elusive.

1.6.5.3.1.4 Health conditions

Whether health conditions precede from DED or not remains uncertain (Stapleton *et al.*, 2017).

Health conditions that have been significantly associated with DED are hypertension (Ahn *et al.*, 2014), thyroid disease (Ahn *et al.*, 2014), hypercholesterolemia (Ahn *et al.*, 2014), stress (Ahn *et al.*, 2014), age-related macular degeneration (Vehof *et al.*, 2014), asthma (Vehof *et al.*, 2014), eczema (Vehof *et al.*, 2014), any type of allergy (Vehof *et al.*, 2014), rheumatoid arthritis (Vehof *et al.*, 2014), stroke (Vehof *et al.*, 2014), chronic wide pain syndrome (Vehof *et al.*, 2014), pelvic pain (Vehof *et al.*, 2014), depression (Vehof *et al.*, 2014), fertility problems (Vehof *et al.*, 2014). osteoarthritis (Vehof *et al.*, 2014), migraine (Vehof *et al.*, 2014), irritable bowel syndrome (Vehof *et al.*, 2014), cataract (Jie *et al.*, 2009; Guo *et al.*, 2010), pterygium (Lu *et al.*, 2008; Guo *et al.*, 2010; Hashemi *et al.*, 2014), anxiolytics (Malet *et al.*, 2014) and general intake of medication (Tan *et al.*, 2015).

Further research is needed to clearly understand the nature of the association between these health conditions and DED (Stapleton *et al.*, 2017).

1.6.5.3.1.5 Ocular surgery

Ocular surgery has been recognized as a probable risk factor of DED (Stapleton *et al.*, 2017). The relationship between ocular surgery and the disease is explained by different surgical contributing factors.

The main hypothesized cause of DED due to ocular surgery relates to a neural-based mechanism (Belmonte, Acosta and Gallar, 2004). Most ocular surgeries, such as cataract and refractive surgery, involve the disruption of corneal nerves by incisions that may potentially interrupt the neural feedback loop between the ocular surface

and lacrimal gland (Belmonte, Acosta and Gallar, 2004). Consequently, the aqueous tear film secretion is impaired, inducing eventual ocular surface desiccation and inflammation (Labetoulle *et al.*, 2019).

Surgical changes in the ocular surface and/or palpebral fissure may also disturb the blinking pattern, which, in turn, alter the tear film flow and stability (Chen *et al.*, 2017). In refractive surgery, the correction of higher refractive errors implies deeper ablations depths and hence increases the risk of DED (Tuisku *et al.*, 2007; Nettune and Pflugfelder, 2010).

On the other hand, the use of a light microscope during surgery may be harmful to the ocular surface (Hwang and Kim, 2014). The continuous exposure to the strong light of the microscope on the ocular surface has shown to retard the incision closure (Ipek *et al.*, 2018). Similarly, ocular tissue wounding may be delayed by the use of surgical antiseptics drops (Thomas *et al.*, 2009) and post-surgical medications containing preservatives (Baudouin *et al.*, 2010).

1.6.5.3.1.6 Ambient conditions

The eye is directly exposed to the outside and therefore is endangered by a multitude of factors occurring in an individual's surrounding (Stapleton *et al.*, 2017).

At present, controlled adverse environment chambers have served to study closely the effect of the environment on DED (Calonge *et al.*, 2018). For instance, variations in temperature, airflow velocity and relative humidity, and passive cigarette smoking have demonstrated to alter the tear film homeostasis and exacerbate DED symptoms (González-García *et al.*, 2007; Ward *et al.*, 2010; Tesón *et al.*, 2013; López-Miguel *et al.*, 2014; Martín-Montañez *et al.*, 2016). Other studies have significantly associated high altitude (Lu *et al.*, 2008; Guo *et al.*, 2010), and higher ozone levels and lower humidity levels with DED symptoms (Hwang *et al.*, 2016). In addition, the chronic exposure to traffic derived air pollution can contribute to DED characterized by symptoms and signs of tear film instability (Novaes *et al.*, 2010).

1.6.5.3.2 Modifiable dry eye risk factors

1.6.5.3.2.1 Visual display terminals

DED symptoms may impact adversely an individual's ability to perform tasks requiring sustained visual concentration (Miljanović *et al.*, 2007) and may contribute to a lower quality of life (Tong *et al.*, 2010). Long-term use of visual display terminals (VDT), especially for more than four hours daily, has been associated with DED (Kojima *et al.*, 2011; Uchino and Schaumberg, 2013).

Vision problems related to VDT use have been designated as "computer vision syndrome (Gowrisankaran and Sheedy, 2015). The term computer vision syndrome includes symptoms of eyestrain, ocular fatigue, burning sensation, irritation, redness, blurred vision and dryness (Gowrisankaran and Sheedy, 2015).

DED symptoms due to VDT use has been suggested to occur due to both reduced blink rate and incomplete blinking (Wolkoff *et al.*, 2005; Portello, Rosenfield and Chu, 2013; Chu, Rosenfield and Portello, 2014; Argilés *et al.*, 2015). Changes in blinking pattern can further contribute to tear evaporation that leads to tear film instability and mild epithelial damage (Wolkoff *et al.*, 2005; Portello, Rosenfield and Chu, 2013; Chu, Rosenfield and Portello, 2014; Argilés *et al.*, 2015). Interestingly, the blink rate has been shown to decrease as font size and contrast are reduced (Gowrisankaran, Sheedy and Hayes, 2007) or cognitive demand of the task increased (Himebaugh, 2009; Jansen *et al.*, 2010).

1.6.5.3.2.2 Contact lens wear

Contact lenses are optical devices made from biocompatible polymers that are designed to be applied onto the eye to correct vision.

DED signs and symptoms that are exclusive to contact lens wear have extensively been studied in the literature as contact lens discomfort (Nichols *et al.*, 2013). CLD is described as having either intermittent or persistent adverse ocular sensations during lens wear that are often interpreted as ocular dryness (Nichols *et al.*, 2013). Importantly, CLD has not clearly been distinguished from DED prior to contact lens wear and hence further research is needed in this area (Nichols *et al.*, 2013).

During lens wear, the tear film needs to lubricate and hydrate the contact lens for preserving the health of the ocular surface (Efron *et al.*, 2013). However, the physical presence of the contact lens in situ disrupts normal tear film function and stability dividing the tears into two compartments, the post-lens and pre-lens tear film (Holly 1981).

Both integrity and replenishment of the post-lens and pre-lens tear film are critical for cushioning the effect of blinking (Muntz). In the event of DED, contact lens wearers have reported low tear break-up times and ocular surface staining, characterized by the continuous friction between the eye and the contact lens (Efron *et al.*, 2013). Low tear film volume has also been associated with DED during contact lens wear (Efron *et al.*, 2013).

1.6.5.3.2.3 Poor sleep quality

The relationship between poor sleep quality and DED (Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014) has been scarcely studied. Poor sleep quality has been described either by short sleep duration (Ahn *et al.*, 2014) or having inadequate sleep (Zhang, Chen and Wu, 2012).

Sleep deprivation is thought to increase sympathetic and decrease parasympathetic tone (Tobaldini *et al.*, 2017). Whereas the lacrimal gland is innervated by both sympathetic and parasympathetic nervous systems, the latter is most extensive (Belmonte *et al.*, 2017) and hence any kind of sleep disturbance may considerably lessen tear secretion.

Accordingly, a small case-control study among healthy male sleepers has shown that staying awake for twenty-four hours reduces tear film volume and stability, as well as increases tear film osmolarity, leading to ocular discomfort (Lee et al., 2014).

Insomnia has also been related to DED by symptoms (Galor *et al.*, 2018) and both symptoms and signs (Ayaki *et al.*, 2016). The association is explained by the coexistence of mood disorders (Galor *et al.*, 2018) and ocular pain (Ayaki *et al.*, 2016) that possibly induces distress and exacerbates difficulties in falling asleep.

1.6.5.3.4 Nutrition

The association between certain conditions, such as vitamin A deficiency, anorexia, bulimia and malabsorption syndromes (Stapleton *et al.*, 2017), and DED allows nutrition to be identified as an important factor for the homeostasis of the tear film. Hence, the involvement of nutritional components on tear composition and physiology has been studied.

46

Supplementary vitamins are believed to protect the ocular surface from oxidative stress (Seen and Tong, 2018). For example, vitamin C has been reported to play an important role in corneal wound healing after refractive surgery (Kasctsuwan *et al.*, 1999). Multivitamin-trace supplementations, including vitamin A, vitamin B1, vitamin B2, vitamin B6, vitamin B9, vitamin E, vitamin C, calcium, iron, magnesium and/or zinc, have also shown to increase both tear film stability and volume of DED participants (Patel, Plaskow and Ferrier, 1993; Drouault-Holowacz *et al.*, 2009).

Moreover, DED participants have been benefited by a balanced intake of omega-3 and omega-6 (Roncone, Bartlett and Eperjesi, 2010; Rosenberg and Asbell, 2010; Oleñik, 2014; Bhargava *et al.*, 2015; Gatell-Tortajada, 2016). Both essential fatty acids are recommended as they display anti-inflammatory properties systematically and have shown to retard tear film evaporation and to enhance tear film secretion (Roncone, Bartlett and Eperjesi, 2010; Rosenberg and Asbell, 2010; Oleñik, 2014; Bhargava *et al.*, 2015; Gatell-Tortajada, 2016).

Importantly, more research is needed to understand which dose, composition and length of nutritional supplementation, either of vitamins or essential fatty acids, are required to effectively treat DED (Stapleton *et al.*, 2017).

1.7 Thesis rationale

The prevalence and risk factors of DED are difficult to establish. Indeed, both have differed depending on the characteristics of the population studied and the definition used for the diagnosis of the disease. Moreover, the knowledge about DED subtypes is limited. The goal of the present thesis is to perform research on DED; more specifically, to examine in isolation the impact of different diagnostic criteria on the disease prevalence (Chapter 3) and to evaluate the associated risk factors (Chapter

4), to understand if DED outcomes and risk factors may be more related to aqueousdeficient or evaporative components of the disease (Chapter 5), as well as to explore a cheap and feasible diagnostic method to improve population-based studies about DED (Chapter 6). To do so, data were collected from a single population in the UK and great care was taken in following a well-standardized study methodology (Chapter 2).

2. CHAPTER 2: STUDY METHODOLOGY

2.1 Overview

The chapter discusses the study methodology of the present thesis. It explains the rationale behind the chosen tests and the strengths and limitations of each method used.

2.2 Study design

A cross-sectional study was conducted at Aston University Eye Clinic. This research is observational in nature as it attempts to simultaneously explore the prevalence and risk factors of DED. The study was approved by the ethical committee of Aston University and conformed to the tenets of the Declaration of Helsinki.

2.2.1 Power calculation

Two hundred sixty-five participants were estimated to be an appropriate sample size for the present study. The sample size was calculated by considering a CI of 95% and using the following formula: $n = ((1.96^2)P(1-P)/d^2)$ (Arya, Antonisamy and Kumar, 2012), where "*n*" is the sample size, "*P*" the expected disease prevalence and "*d*" the allowable error. As "*P*", the prevalence rate for DED of 22.1% from a British female cohort (Prevalence: 20.8% [95% CI 19.5% to 22.1%]) (Vehof *et al.*, 2014) was used. The rationale to set "*P*" at 22.1% is based on the fact that any value nearer to 50% leads to the largest "*n*" (Figure 2.1) and hence to more confident results (Arya, Antonisamy and Kumar, 2012). Moreover, because an allowable error of 0.05 has been generally recommended when "*P*" takes values between 10% and 90% (Arya, Antonisamy and Kumar, 2012), a "d" of 5% was applied.



Figure 2.1 Relationship between sample size and expected prevalence

2.2.2 Study population

The population about conclusions were drawn were female and male adult residents in Birmingham (UK). regardless of nationality. Estimates about Birmingham resident population for 2016 were obtained from the Birmingham City Council (www.birmingham.gov.uk/census) and considered together with the above power calculation to determine the required study participants (Table 2.1).

 Table 2.1
 Required study population (stratified by age and sex)

Age	(years)	18-19	20-29	30-39	40-49	50-59	60-69	70-79	80-89
Sex	Males (n)	6	31	25	22	19	14	9	5
	Females (n)	6	31	25	22	20	14	10	7

2.2.3 Recruitment

Great efforts were made to recruit as many eligible participants as possible. Recruitment mainly occurred through Aston University staff email advertising, via advertisement within the Aston Eye Clinic and Aston Research Centre for Healthy Ageing (ARCHA), and through posters pinned around the campus (Figure 2.2). Further recruitment methods included leaflet advertising in the Birmingham City Centre and posting an advert in the weekly news bulletin of the Birmingham City Council.

How good is the 'Tear Film' of your eyes?

We are currently looking for people aged ≥ 18 years-old to participate in our 'Tear Film Evaluation' study.

At our central Birmingham Eye Clinic, we will assess how healthy your tears are. No discomfort to your eyes will be caused during the eye exam.



Phone: 0121 204 4400 Email: dryeye@aston.ac.uk Times and dates can be arranged at your convenience *Free parking provided on request*

<u>Researchers</u> M Vidal-Rohr (middle) Prof. J S Wolffsohn (left) Prof. L N Davies (right)





Received funding by EU Horizon 2020 research & innovation programme under Marie Sklodowska-Curie grant agreement No 642760.

Figure 2.2

Study advertisement



2.2.4 Inclusion and exclusion criteria

To participate in the study, participants were required to be \geq 18 years-old. They needed to be Birmingham residents who did not leave the country one month before the study to ensure that ambient differences between participants were minimized. The highest age limit was set at 90 years as the tests required considerable cooperation. Eligible participants were invited via email and advised to not wear contact lenses or use artificial tears twenty-four hours previous to the study.

2.2.5 Clinical assessment

In a single clinical session lasting approximately one hour, participants were first asked to complete a dry eye risk factor survey and two dry eye questionnaires, followed by a full ocular surface and tear film examination on their preferred eye.





Aston University Health Clinics

All participants were examined in an adjacent room of the Aston University Health Clinics (Figure 2.3) from September 2016 to March 2018. Throughout the study, the room temperature and humidity were kept by 22.4 ± 2.0 °C and 49.3 ± 8.2 %, respectively. Eye examinations only occurred after a minimum of 15 minutes of adaptation to the room conditions.

2.2.5.1 Diagnostic considerations

Minimal manipulation to the ocular surface may alter tear film physiology by inducing reflex tearing or adding foreign bodies into the tears. Invasive methods, such as the use of ophthalmic dyes to improve tear film visibility, are criticised due to disrupting the normal tear film state (Mooi *et al.*, 2017) and hence providing less reliable results (Nichols, Mitchell and Zadnik, 2004). In addition, automated methods are strongly recommended since they are less dependent on examiners' clinical expertise (Nichols *et al.*, 2002).

The main instrument used for the present study was the Keratograph 5M (K5M; Oculus Optikgeräte GmbH, Wetzlar, Germany) (Figure 2.4), a topographer using a video analysis software to overcome inaccuracies made by invasive and subjective testing of important dry eye parameters (Szczesna *et al.*, 2011). However, where non-invasive and objective methods were not possible, traditional methods were carefully adopted following substantial training. Finally, to minimise the impact of subsequent testing on tear film physiology, the involved diagnostic methods were performed in increasing order of invasiveness (Wolffsohn *et al.*, 2017), as listed below.



Figure 2.4 The Keratograph 5M

2.2.5.2 Dry eye risk factor survey

Information about the exposure of DED risk factors was obtained through a selfadministrated Dry Eye Risk Factor Survey (DERFS) (Figure 2.5). The survey was developed aiming to assess all significant DED risk factors identified in Chapter 1. It included questions about participants' demographics and life factors, including:

- <u>Ethnicity</u>. The term ethnicity has been used to classify populations into subgroups based on physical characteristics. However, there is no consensus to this purpose. Because Asians have been associated with DED (Stapleton *et al.*, 2017), an ethnicity classification including this ethnic group was considered.
- <u>Age</u>. DED is known to increase with age (Stapleton *et al.*, 2017). Participants' age decade was recorded, as this is less intrusive than assessing their precise age. The approach has largely been used in DED epidemiological research (Schaumberg *et al.*, 2009; Tongg *et al.*, 2009; Uchino *et al.*, 2011; Ahn *et al.*, 2014; Um *et al.*, 2014).
- <u>Sex</u>. Sex hormones may play an important role in DED (Truong *et al.*, 2014;
 Sullivan *et al.*, 2017) and hence participants' sex was recorded.
- Living zone and outdoor activity. DED has been significantly related with urban areas (Jie *et al.*, 2009; Han *et al.*, 2011; Ahn *et al.*, 2014) and outdoor ozone air pollution (Hwang *et al.*, 2016). Therefore, both factors were assessed. The living zone was classified into rural and urban areas (Jie *et al.*, 2009; Han *et al.*, 2011; Ahn *et al.*, 2009; Han *et al.*, 2011; Ahn *et al.*, 2014). Because data collection on air pollution as in (Hwang *et al.*, 2016) was not possible, the exposure to outdoor air pollution was graded by participants' regular hours spending outside.
- <u>Education and work</u>. DED has been significantly associated with higher educational level (Ahn *et al.*, 2014; Malet *et al.*, 2014), as well as office-based

work (Ahn *et al.*, 2014). Education was categorized as elementary/primary school, middle/secondary school, high school/6th form, and university/higher (Ahn *et al.*, 2014). Work was described by participants' daily working hours. Importantly, classifying work as non-office-based and office-based might have been intercorrelated with computer use (Ahn *et al.*, 2014) and hence was not considered.

- <u>Smoking</u>. Smoking has been significantly associated with DED (Lu *et al.*, 2008; Ward *et al.*, 2010). Although smoking habits have been described as generally smoking (Lu *et al.*, 2008), the number of cigarettes smoked per day was asked to provide a more detailed analysis.
- Contact lens wear. Both rigid and soft contact lenses interrupt normal tear film function and physiology (Efron *et al.*, 2013; Nichols *et al.*, 2013), contributing most likely to DED (Uchino *et al.*, 2008, 2011; Zhang, Chen and Wu, 2012; Paulsen *et al.*, 2014; Vehof *et al.*, 2014; Tan *et al.*, 2015). The risk factor was assessed by recording participants' contact lens type (Uchino *et al.*, 2008) and wear frequency in days per week. The contact lens wear frequency was asked to provide a more detailed analysis.
- <u>Computer use</u>. Changes in blinking patterns due to computer use can lead to DED (Wolkoff *et al.*, 2005; Portello, Rosenfield and Chu, 2013; Chu, Rosenfield and Portello, 2014; Argilés *et al.*, 2015). As in (Uchino *et al.*, 2011; Malet *et al.*, 2014), computer use was determined by regular hours per day.
- <u>Current/past health conditions/problems, medication use and stress</u>. DED has been significantly related to several systemic and mental health conditions/problems, as well as to the use of medication and stress. Hence these factors were asked (Lu *et al.*, 2008; Jie *et al.*, 2009; Guo *et al.*, 2010; Ahn *et al.*, 2014; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Vehof *et al.*, 2014; Tan *et al.*,

2015). Moreover, participants' stress status was classified into least, moderate and extreme (Ahn *et al.*, 2014).

- <u>Nutritional supplements intake</u>. Recording of nutritional supplementation was considered since these are suggested as DED treatments (Jones *et al.*, 2017) and may undercover a possible DED diagnosis and/or risk factor.
- <u>Sleep quality</u>. Sleep deprivation has been significantly associated with DED (Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014). Participants' regular sleeping hours were recorded to assess their sleep quality (Ahn *et al.*, 2014).

THE DRY EYE RISK FACTOR SURVEY To which group do you belong? Underline if applicable

Ethnicity	\rightarrow	White/ Asian/ Black/ Others
Sex	\rightarrow	Female/Male
Age	\rightarrow	10s/ 20s/ 30s/ 40s/ 50s/ 60s/ 70s/ 80s
Living zone	\rightarrow	Rural/Urban
Education	\rightarrow	Elementary or primary school/ Middle or secondary school/ High school or 6^{th} form/ University or higher

Do you Underline and/or complete if application	able						
Work?	No ↓	Yes	$ \rightarrow$	Hours/day			
Smoke?	No ↓	Yes	\rightarrow	Cigarettes/day			
Wear contact lenses?	No ↓	Yes	\rightarrow	Туре	Days/week		
Use computer?	No ↓	Yes	\rightarrow	Hours/day			
Have/had any health condition/ problem?	No ↓	Yes	\rightarrow	Describe			
Had any eye surgery?	No ↓	Yes	\rightarrow	Describe			
Take any medication?	No	Yes	\rightarrow	Describe			
Take any nutritional supplements?	↓ No	Yes	\rightarrow	Describe			
How Underline and complete if applicable							
Much do you get to sleep?	→			Hours/day			
Much do you spend outdoors on a regular day?	\rightarrow	Hours/day					
Stressful are your days?	\rightarrow	Least st	ressf	ul/ Moderately stress	sful/ Extremely stressful		

Figure 2.5

_

The dry eye risk factor survey (DERFS)

2.2.5.3 Dry eye questionnaires

DED symptoms can be gathered either through non-scripted verbal interviews or selfadministered questionnaires (Wolffsohn *et al.*, 2017). However, self-administered questionnaires are preferred given their enhanced standardization in recording the disease symptomatology (Wolffsohn *et al.*, 2017).

Currently validated symptom questionnaires with discriminative ability in DED include the Impact of Dry Eye on Everyday Life (IDEEL) (Guillemin *et al.*, 2012), the McMonnie's Questionnaire (MQ) (Gothwal *et al.*, 2010), the 5-item Dry Eye Questionnaire (DEQ-5) (Chalmers, Begley and Caffery, 2010) and the Ocular Surface Disease Index (OSDI) (Schiffman *et al.*, 2000).

The two questionnaires chosen for the present study were the DEQ-5 and OSDI. The questionnaires have been found to be concurrent with each other (Galor *et al.*, 2015) and are currently recommended to be used for the diagnosis of DED (Wolffsohn *et al.*, 2017). Whereas the DEQ-5 is found attractive due to its short length, the OSDI is recommended because of its strong establishment in the field of DED clinical trials (Wolffsohn *et al.*, 2017).

Symptomatic DED was determined using a DEQ-5 cut-off score of \geq 6 (Chalmers, Begley and Caffery, 2010) and ODSI score of \geq 13 (Schiffman *et al.*, 2000). The questionnaires were presented together on a single document page (Figure 2.6). Participants were also asked if they have had eye irritation, either rarely, sometimes, frequently or constantly, for the past month and a previous diagnosis of DED by a physician. The questions were added to further diagnose DED by the WHS criteria, which accounts as the most widely used previous diagnostic criteria in the epidemiology of DED (Stapleton *et al.*, 2017).

DRY EYE QUESTIONNAIRES

Instructions: Circle the number in the box that best represents each answer.

Have you experienced any of the following <i>during the last week</i> :							
	All of the	Most of	Half of	Some of	None of		
	time	the time	the time	the time	the time		
1. Eyes that are sensitive to	4	3	2	1	0		
light?							
Eyes that feel gritty?	4	3	2	1	0		
Painful or sore eyes?	4	3	2	1	0		
4. Blurred vision?	4	3	2	1	0		
5. Poor vision?	4	3	2	1	0		

Have problems with your eyes limited you in performing any of the following during the last

		week:				
6. Reading?	4	3	2	1	0	N/A
Driving at night?	4	3	2	1	0	N/A
8. Working with a computer or a	4	3	2	1	0	N/A
bank machine (ATM)?						
9. Watching TV?	4	3	2	1	0	N/A

Have your eyes felt uncomfortable in any of the following situations *during the last week*:

			-	-		
10. Windy conditions?	4	3	2	1	0	N/A
11. Places or areas with low	4	3	2	1	0	N/A
humidity (very dry)?						
12. Areas that are air-	4	3	2	1	0	N/A
conditioned?						

1 Questions about EYE DISCOMFORT:								
a. During a typical day in the past month, how often did your eves feel discomfort?	0 Never	1 Rarely	1 Rarely 2 Sometimes		3 Frequently	4 Constantly		
b. When your eyes feel	Never	Not at all int	ense		Ve	ery intense		
discomfort, how intense was this feeling of discomfort at the end of the day, within two hours of going to bed?	have it 0	1	2	3	4	5		
2 Questions about EYE DRYNESS:								
a. During a typical day in the past month, how often did your eyes feel dry?	0 Never	1 Rarely	2 Somet	imes	3 Frequently	4 Constantly		
b. When your eyes feel discomfort how intense was	Never	Not at all int	ense		Very intense			
this feeling of dryness at the end of the day, within two hours of going to bed?	0	1	2	3	4	5		
	3 Questi	ons about W	ATERY EY	ES:				
a. During a typical day in the past month. how often did your eyes feel watery?	0 Never	1 Rarely	2 Somet	imes	3 Frequently	4 Constantly		
	4 Questio	ons about IRF	RITATED E	YES:				
a. During a typical day in the past month. how often did your eyes feel irritated?	0 Never	1 Rarely	2 Somet	imes	3 Frequently	4 Constantly		

Have you had a previous clinical diagnosis of dry eye?

No 🗆

Figure 2.6

DED questionnaires used

Yes 🗆

2.2.5.4 Tear film evaporation

Increased tear film evaporation is thought to result from tear film instability caused by an impaired lipid layer (Craig and Tomlinson, 1997). In the present study, tear film evaporation was evaluated, although its discriminative ability in DED has not been determined yet (Wolffsohn *et al.*, 2017).

Non-DED and DED individuals have shown tear film evaporation rates of $48.85 \pm 23.47 \text{ g/m}^2/\text{h}$ and $75.78 \pm 50.26 \text{ g/m}^2/\text{h}$, respectively (Tomlinson, Doane and McFadyen, 2009). The tear film evaporation rates have been assessed using evaporimeters with open and closed chambers (Tomlinson, Doane and McFadyen, 2009). The evaporimeters contain sensors that detect changes occurring at the ocular surface, either of vapour pressure or relative humidity, from which the tear film evaporation is inferred (Tomlinson, Doane and McFadyen, 2009).

Measuring tear film evaporation is challenging. The tear film evaporation rate has shown to fluctuate highly with day time (Wojtowicz and McCulley, 2009), room humidity (Abusharha and Pearce, 2013) and temperature (Abusharha, Pearce and Fagehi, 2016). Moreover, tear film evaporation readings may be confounded by additional evaporation coming from the eyes' surrounding skin (Wolffsohn *et al.*, 2017).

The Delfin VapoMeter (Delfin Technologies Ltd, Kuopoi, Finland) (Figure 2.7) was used to assess the tear film evaporation rate. The core of the VapoMeter has a hygrometer sensor that monitors the increase of relative humidity, from which the tear film evaporation rate is deducted in units of g/m²/h. The humidity is measured within a swimming google piece that is enclosed by the eye during measurement. Participants were asked to remain their eyes open during measurement, as specified

by the manufacturer. Three consecutive tear film evaporation readings were taken, and the mean was recorded.



Figure 2.7 Tear evaporation measured with the Delfin VapoMeter

2.2.5.5 Tear film osmolarity

Higher than normal physiological solute concentration in the tear film is known as tear hyperosmolarity. Tear hyperosmolarity results either from excessive evaporation in the presence and/or absence of normal tear flow and constitutes the major trigger of other events leading to ocular surface damage and inflammation (Lemp *et al.*, 2007).

Among other clinical tests, tear film osmolarity has been demonstrated to be the best single monitoring marker for DED (Lemp *et al.*, 2011), as it has the strongest correlation to the disease severity (Tomlinson *et al.*, 2006) and the lowest variability over time scales that are clinically relevant (Sullivan *et al.*, 2012).

Unlike non-DED individuals, DED individuals show unstable osmolarity values with greater intra- and interocular variability with increasing disease severity (Tomlinson *et al.*, 2006; Keech, Senchyna and Jones, 2013). Several cut-off scores have been suggested to distinguish both groups (Bron *et al.*, 2014). To date, a threshold of \geq 308 mOsm/L of either eye or a difference of \geq 8mOsm/L between eyes is globally recommended for the diagnosis of DED (Bron *et al.*, 2014).

Past measurements of tear film osmolarity are based on determining one of two colligative properties of the tear film: the freezing point or vapour pressure (Tomlinson, McCann and Pearce, 2010; Gokhale, Stahl and Jalbert, 2013). Both freezing point and vapour pressure techniques have been criticised for requiring considerable expertise as well as for being invasive (causing reflex tearing during tear collection) and time-consuming (allowing tear evaporation during tear analysis) (Tomlinson, McCann and Pearce, 2010; Gokhale, Stahl and Jalbert, 2013).

In the present study, the tear film osmolarity was measured temporally from the inferior tear meniscus with an impedance-based osmometer: the TearLab (TearLab

Corporation, California, USA) (Figure 2.8). During measurement, the participants were asked to look up and away from the instrument. Readings were collected from each eye, and both osmolarity values and the interocular difference were recorded.



Figure 2.8 Tear osmolarity measured with the TearLab

The TearLab is considered minimally invasive, as it samples low tear film volume (less than 20nl) without direct contact with the ocular surface (Tomlinson, McCann and Pearce, 2010). However. it may be limited due to the fact that it measures the osmolarity of the tear film within the lower tear meniscus. which is hypothesised to be slightly more dilute than other parts of the tear film (Bron *et al.*, 2002).

2.2.5.6 Tear film volume

Evaluating tear film volume is essential for detecting aqueous-deficient components of DED (Wolffsohn *et al.*, 2017). In clinical settings. following diagnostic methods have been used to assess tear film volume:

- <u>The Schirmer test</u>. The Schirmer test involves the insertion of a filter paper strip, after using (Schirmer test II) or not using (Schirmer test I) ocular anesthesia, over the one-third temporal lower eyelid margin (Schirmer, 1903). The length of the wet area (in millimeters) is read off after 5 minutes of application and gives an indication of the aqueous tear film volume (Schirmer. 1903). A Schirmer score of ≤ 5 mm/5 min has been proposed to be abnormal, meaning the presence of aqueous tear deficiency (Bron *et al.*, 2007). Nevertheless, the clinical application of the Schirmer test is disputed, as it is highly variable, unreliable and poorly correlated to other DED signs and symptoms (Senchyna and Wax, 2008).
- <u>The phenol red thread test</u>. The phenol red thread (PRT) test consists of a phenol-red-impregnated cotton thread that is applied onto the eye, in a similar manner to the Schirmer test, but without needing topical anesthesia (Patel *et al.*, 1998). It has been developed to overcome the disadvantages of the Schirmer test, however, with no success (Senchyna and Wax, 2008). The PRT test has found to be poorly reliable as the Schirmer test (Moore *et al.*, 2009), falling in disuse for more than ten years ago (Wolffsohn *et al.*, 2017).
- <u>The tear meniscus height</u>. The tear meniscus is the collection of tears at the intersection of the bulbar conjunctiva and the eyelid margins. Its height represents 75-90% of the tear film volume (Holly, 1985) and is evaluated central inferior (in millimeters) with en-face slit lamp observation either using a reflective graticule (TMH) or sodium fluorescein (FTMH).

Among all tests, the TMH accounts the minimally invasive method to assess tear film volume (Wolffsohn *et al.*, 2017). A TMH of ≤ 0.2 is currently interpreted as a lack of 66

tear film homeostasis and has demonstrated good repeatability with low individual variability (Uchida *et al.*, 2007).

In the present study, TMH was assessed with the "Tear Meniscus Height" setting of the K5M and at magnification of 1.4x (Figure 2.9). Digital infrared-images were taken at the centre of the lower eyelid, with no eyelid manipulation. The TMH was centrally measured once, using the vertical alignment of the K5M reflective graticule as a reference.



Figure 2.9Lower TMH measured with the Keratograph 5M

TMH = tear meniscus height.

2.2.5.7 Lipid layer thickness

Interferometry is a valuable technique for measuring the lipid layer thickness (LLT) of the tear film (Wolffsohn *et al.*, 2017). The LLT is inferred from interferometric colour fringes observed by specular reflection at the tear lipid-aqueous interface (Guillon, 1982; Korb *et al.*, 1994).

Thickening of the lipid layer has shown to cause an interferometric colour change from grey to red, which is typically observed when the interpalpebral aperture is narrowed (McDonald, 1969) and may occur by forced blinking (Korb *et al.*, 1994).

Recently, an automated interferometer has been introduced (Goto *et al.*, 2003; Blackie *et al.*, 2009). Because we did not have access to the automated interferometer, the Guillon-Keeler grading scale (Craig and Tomlinson, 1997) was adopted for evaluating interferometric lipid videos of the K5M.

Table 2.2
 The Guillon-Keeler grading scale

Grade	Description	LLT
1. Open meshwork	Indistinct, gray, marble-like pattern, frequently visible only by the post-blin movement	≈ 15nm
2. Closed meshwork	Well defined, gray, marble-like pattern with a tight meshwork.	≈ 30nm
3. Wave pattern	Constantly changing, wave-like pattern.	≈ 30-80nm
4. Amorphous	Blue-whitish appearance with no discernible features.	≈ 80nm
5. Colour fringes	Appearance of coloured interference fringes.	≈ 80-300nm
LLT = lipid laver thickne	ess.	

The Guillon-Keeler grading scale is a validated grading scale with moderate interand intra-examiner agreement (Guillon, 1998; Nichols *et al.*, 2002). It classifies the lipid layer into five grades (by texture and colour of the observed lipid layer) (Table 2.2). where grade 1 (open meshwork) represents the lowest LLT and grade 5 (colour fringes) the highest (Craig and Tomlinson, 1997).

Videos of the lipid layer were recorded using the "Lipid Layer" software of the K5M at a modified magnification of 1.4x and for the duration of three non-forceful blinks (Figure 2.10). To ensure that the blinks were not forced, the participant was previously instructed to gaze forward comfortably while the instrument was set up for the next measure. In case of observing a lipid layer with overlapping patterns, the most predominant pattern was considered for the analysis of LLT.



Figure 2.10 Colour fringe LLT observed with the Keratograph 5M

LLT = lipid layer thickness.

2.2.5.8 Tear film stability

The number of seconds that elapse between the last blink and the appearance of the first tear film disruption is the so-called tear film break-up time (BUT) (Norn, 1969; Lemp *et al.*, 1970), which constitutes the most commonly employed clinical test to evaluate tear film stability (Wolffsohn *et al.*, 2017).

The BUT has been performed either invasively (FBUT) or noninvasively (NIBUT). Invasive methods involve instilling sodium fluorescein onto the eye and observing tear film disruptions as areas of dye discontinuity. In contrast, non-invasive methods are based on the detection of any distortions of a reflected image from the tear film. Depending on the method used, BUT values of < 5s (for FBUT) and < 10s (for NIBUT) are associated with unstable tear films (Wolffsohn *et al.*, 2017).
By nature, the BUT is a highly variable measure (Sullivan *et al.*, 2012) and hence consistency in its procedure is important. NIBUT is preferred over FBUT (Wolffsohn *et al.*, 2017), as the use of sodium fluorescein alters tear dynamics and induces earlier tear disruptions than at a natural state (Mengher *et al.*, 1985; Mooi *et al.*, 2017). Moreover, the volume of instilled fluorescein is difficult to standardise (Nichols, Mitchell and Zadnik, 2004).

For the current study, the "NIKBUT" software of the K5M was used to evaluate the NIBUT (Figure 2.11). Infrared illuminated ring patterns were focused on the participant's cornea. Recording of the reflected tear image occurred straight after having instructed the participant to deliver two natural blinks and keep their eyes open as long as possible. When the tear film was significantly broken or the participant had to blink again, the recording was automatically stopped and saved to be analysed.

The K5M software showed the analysis in an outcoming window, in which the quality of the reflections was mapped and two measures for NIBUT were given: the time at the first tear break-up occurred (NIKBUT-first) and the average of all tear break-up incidents (NIKBUT-average). Three consecutive NIKBUT-first readings were taken (separated by at least 60 seconds) and the mean was recorded.



 Figure 2.11
 First NIKBUT observed with the Keratograph 5M

 NIKBUT = non-invasive Keratograph tear break-up time.

2.2.5.9 Ocular staining

Ocular surface damage can be visualised following instillation of ophthalmic dyes. either in solution or via wetted filter paper strip. Ophthalmic dyes in current and past use are sodium fluorescein, rose bengal and lissamine green. Sodium fluorescein emits best fluorescence upon illumination through a blue excitation filter (peak wavelength of 495nm) with a yellow barrier filter (bandpass at 500nm) (Peterson, Wolffsohn and Fowler, 2006), staining epithelial cells with disrupted intercellular junctions (Feenstra and Tseng, 1992). Conversely, both rose bengal and lissamine green are believed to stain any epithelial cells, whose membrane is already compromised/damaged or exposed due to lack of mucus cover (Kim and Foulks, 1999). In DED, ocular surface damage is considered a relatively late stage of the disease (Wolffsohn *et al.*, 2017). At present, sodium fluorescein and lissamine green are recommended to be used simultaneously as part of the diagnosis of DED to assess corneal and conjunctival damage, respectively (Wolffsohn *et al.*, 2017). Lissamine green has largely replaced rose bengal, as it has similar staining patterns, but is far less toxic and irritating to the eye (Manning, Wehrly and Foulks, 1995; Machado, Castro and Fontes, 2009). Furthermore, the addition of 1% lissamine green to 1% sodium fluorescein does not significantly alter the fluorescence of the latter and provides optimal corneal and conjunctival staining with only slightly less efficacy than a non-well-tolerated mixture of 1% rose bengal and 1% sodium fluorescein (Korb *et al.*, 2008).

In the present study, 1mg sodium fluorescein (Bio Fluoro, Bio-Tech Vision Care Pvt Ltd, Gujarat, India) and 1.5 mg lissamine green (Green Glo, Hub Pharmaceuticals Llc, California, USA) were instilled via filter paper strips. The strips were wetted with saline (Sensitive Eyes[™] Plus Saline Solution, Baush & Lomb Incorporated, New York, USA) and applied near to the temporal canthus of the lower eyelid margin whilst the participant looked up and away (Wolffsohn et al.. 2017). The strips were held in place few seconds until the dyes dropped (through surface tension) onto the eyelid margin (Figure 2.12).

72



Figure 2.12 Lissamine green instillation via wetted filter paper strip

Corneal and conjunctival staining were assessed using the "Fluo imaging" and "New Picture/Video" settings of the K5M. and within two (Peterson, Wolffsohn and Fowler, 2006) and four minutes (Hamrah *et al.*, 2011) of sodium fluorescein and lissamine green instillation, respectively. Excess of fluorescein on the strip was flicked off, whereas lissamine green was fully instilled.

Overall, ocular surface damage is clinically graded with subjective scoring systems, such as the Van Bijsterveld system, Oxford scheme, NEI/ Industry-recommended guidelines, Efron scale and Brien Hold Vision Institute Grading scale (Sook Chun and Park, 2014). However, for research purposes, corneal and conjunctival staining spots were objectively analysed with ImageJ version 1.51j8 (National Institutes of Health, USA), following image processing (Figure 2.13. Figure 2.14). The approach was based on a more continuous version of the Oxford grading scheme.



Figure 2.13 Fluorescein staining image analysis with ImageJ

(A) Raw image. (B) Processing the blue colour channel of the raw image. (C) Zooming out the processed image by 75% and counting the observed staining spots. (D) Finalized fluorescein staining image analysis.

Fifty-nine corneal staining spots were observed.



Figure 2.14 Lissamine green staining image analysis with ImageJ

(A) Raw image. (B) Processing the red colour channel of the raw image. (C) Zooming out the processed image by 75%. (D) Counting the observed staining spots.

Twenty-eight conjunctival staining spots were observed.

2.2.5.10 Lid wiper epitheliopathy

Lid wiper epitheliopathy (LWE) was first described in the upper eyelid and subsequently in the lower eyelid. It is defined as an alteration of the marginal palpebral conjunctiva that comes in contact with the ocular surface (Korb *et al.*, 2002). It is diagnosed by vital staining and has been correlated to dry eye symptoms in contact lens wearers as well as non-contact lens wearer (Korb *et al.*, 2002, 2005, 2010).

LWE occurs because of tear film deficiency between the ocular surface and the eyelid wipers, contributing to continuous friction between the structures (Korb *et al.*, 2005) that may result in morphologically distinct staining patterns (Varikooty *et al.*, 2015). This friction effect is thought to be limited to just start of each blink cycle due to aquaplanning (Pult *et al.*, 2015).

LWE has recently been considered as a valuable diagnostic sign of DED (Efron *et al.*, 2016; Wolffsohn *et al.*, 2017). For the present study, LWE was evaluated by everting both eyelids and measuring the extent of lissamine green staining. Sufficient dye was instilled to ensure the visualization of the Marx line along the eyelid margin (Doughty *et al.*, 2004), and the "New Image/Video" setting of the K5M was selected.

The width and the length of the LWE staining were objectively analysed with ImageJ and classified according to the Korb four-point grading scale (For LWE width: score 0: 25% wide LWE staining; score 1: 25 – 49% wide LWE staining; score 2: 50 – 74 % wide LWE staining: score 3: \geq 75% wide LWE staining) (For LWE length: score 0: <2mm long LWE staining; score 1: 2 – 4 mm long LWE staining; score 2: 5 – 9 mm long LWE staining: score 3: \geq 10 mm long LWE staining) (Korb *et al.*, 2005) (Figure 2.15). In non-contact lens wearers, an upper LWE cut-off value of 1 (based on this scale) has shown a specificity of 96% and sensitivity of 48% of symptomatic DED (Shiraishi, Yamaguchi and Ohashi, 2014).



Figure 2.15 LWE staining image analysis with ImageJ

LWE = lid wiper epitheliopathy.

(A) Raw image. (B) Measuring the length of the observed lid wiper epitheliopathy. (C) Measuring the width of the observed lid wiper epitheliopathy. (D) Measuring the width of the lid wiper.

A LWE length of 18.53mm and LWE width of 18.51% were observed. A scale convertor of 1 mm = 49 pixels was used.

2.2.5.11 Meibomian gland dysfunction

Meibomian gland dysfunction (MGD) is defined as "chronic, diffuse abnormality of the meibomian glands, commonly characterized by terminal duct obstruction and/or qualitative/ quantitative changes in the glandular secretion" (Daniel Nelson *et al.*, 2011). It is considered a major cause of EDE, whereby the tear lipid layer loses subsequently its protective role in surface desiccation (Lemp *et al.*, 2007).

Meibomian glands are tubuloacinar, holocrine glands that are located within the upper and lower eyelid tarsal plates (Bron *et al.*, 2004). They are similar to sebaceous glands of the skin, but not related to hair follicles (Knop *et al.*, 2011). The duct orifices of the meibomian glands open just anterior to the mucocutaneous junction at the lid margins (Bron *et al.*, 2004).

Meibomian glands' secretion is known as meibum (Bron *et al.*, 2004). The meibum is composed by polar and non-polar lipids (Green-Church *et al.*, 2011) and is believed to be regulated by hormonal and neural influences as well as the contraction of palpebral muscles (Knop *et al.*, 2011). Within a blink, the secreted lipids are released and spread onto the ocular surface to form the lipid layer of the tear film (Bron *et al.*, 2004).

In clinical practice, meibography consists of infrared-imaging of the morphological silhouettes of the meibomian glands of the everted eyelids (Arita *et al.*, 2008). For the present study, the technique was performed using the "Meibography Upper/Lower Lid" setting of the K5M. The absence of the meibomian gland (meibomian gland dropout) was evaluated in both eyelids and graded with a currently recommended (Wolffsohn *et al.*, 2017) and highly reproducible five-point meiboscale: the meiboscore (score 1: \approx 0% loss of meibomian gland area; score 2: \leq 25% loss of

meibomian gland area; score 3: 26 - 50% loss of meibomian gland area; score 4: 51 – 75% loss of meibomian gland area; score 5: > 75% loss of meibomian gland area) (Pult and Riede-Pult, 2013). The relative areas of meibomian gland dropout were previously obtained with ImageJ, dividing the area with no visible glands by the total area of the tarsal conjunctiva (Pult and Riede-Pult, 2013) (Figure 2.16).



Figure 2.16

MGD analysis with ImageJ

MGD = meibomian gland dysfunction.

(A) Meibography of the upper eyelid. (B) Measuring the total area of the upper tarsal conjunctiva. (C) Measuring the area with meibomian dropouts. (D) Presenting both selected areas simultaneously.

A MGD of 17.04% was observed.

3. CHAPTER 3: THE PREVALENCE OF DRY EYE DISEASE IN THE UK

3.1 Overview

The chapter gives an overview of DED in Birmingham (UK). It includes data about the disease prevalence by different diagnostic criteria.

3.2 Introduction

The primary importance of prevalence rates is to gain an understanding of a disease burden to further plan and allocate health sources (Mann, 2003).

In DED, current cross-sectional studies have unfortunately relied on different diagnoses rendering incomparable conclusions about the disease prevalence (Stapleton *et al.*, 2017). Reported DED prevalence rates have widely ranged from 1.3% to 52.9% (Stapleton *et al.*, 2017).

The most consistent diagnostic criteria in the literature has been that first adopted by the WHS (Stapleton *et al.*, 2017). Other diagnostic methods have determined the disease either by the presence of its symptoms, signs or both symptoms and signs (Stapleton *et al.*, 2017). Details about all methods can be found in Chapter 1 (sections Dry eye prevalence by the Women's Health Study criteria1.6.1 - 1.6.4).

In view of standardisation, the TFOS DEWS II proposed a global diagnosis of DED (Wolffsohn *et al.*, 2017). This identifies an individual as having DED by the presence of one ocular sign (determined either by assessing the tear film stability or osmolarity, or ocular surface staining) and a positive result to a validated questionnaire (either the DEQ-5 or OSDI test) (Wolffsohn *et al.*, 2017).

The present study is the first population-based study in the UK that estimates the prevalence of DED following the TFOS DEWS II diagnostic recommendations. Moreover, it determines the prevalence of DED by the WHS criteria to understand to which extent the TFOS DEWS II diagnostic criteria differs from past diagnostic techniques of the disease.

3.3 Methodology

The study methodology described in Chapter 2 was used to study the prevalence of DED by the WHS and TFOS DEWS II criteria. The WHS criteria defined DED by self-report of ocular dryness and irritation either often or constantly, or a previous clinical diagnosis of the disease (Schaumberg *et al.*, 2009; Uchino *et al.*, 2011; Zhang, Chen and Wu, 2012; Ahn *et al.*, 2014). The TFOS DEWS II criteria (Wolffsohn *et al.*, 2017) defined DED by an OSDI score of \geq 13 or DEQ-5 score of \geq 6 and either one of the following signs:

- Non-invasive tear breakup time of <10 s;
- Tear film hyperosmolarity defined either by the highest osmolarity value of ≥308 mOsm/l among eyes or an interocular osmolarity difference of ≥8 mOsm/l;
- Ocular surface damage defined either by ≥5 corneal staining spots, >9 conjunctival staining spots, or a lower/upper LWE staining of ≥2 mm length and ≥25% width.

For the present study, the TFOS DEWS II criteria was adopted for a NIKBUT value of <8 s. The rationale of considering this cut-off value is based on the fact that the K5M has shown to detect tear breakup times 2 s earlier than subjective methods (for what a tear breakup time of <10 s was originally set for) (Markoulli *et al.*, 2018). Also, the TFOS DEWS II strengthened the need for benchmarking techniques' cut-off values when using objective measurements (Wolffsohn *et al.*, 2017). The report stated that tear break-up times "can be as low as 2.7s for automated algorithms, and up to 10s for subjective observation techniques" (Wolffsohn *et al.*, 2017).

3.3.1 Data processing

Collected scores of the DED questionnaires, tear film osmolarity, NIKBUT, and corneal, conjunctival and LWE staining were entered in a common Excel spreadsheet. Non-DED and DED outcomes were calculated by considering the above-mentioned diagnostic criteria and coded into values of 1 and 2, respectively. Diagnosis of DED was only possible if there was no missing data.

3.3.2 Statistical analysis

Statistical analysis was performed with SPSS version 23 (IBM Corp. released in 2015. New York. US). DED prevalence rates were stratified by sex and age decades and presented with their 95% CIs. Differences among prevalence rates were tested with McNemar's (for paired samples) and Chi-square tests (for unpaired samples). Correlations between DED symptoms and signs among DED participants (all previously confirmed to be not normally distributed with Kolmogorov-Smirnov normality tests) were evaluated with Spearman's rank correlation coefficients.

3.4 Results

Two-hundred eighty-two Birmingham residents (43 \pm 19 years, 56% females) participated in the study (Figure 3.1). Recruitment occurred by 60%, 30%, 6%, 3% and 1% in the Aston University campus, Birmingham City Centre, ARCHA, Birmingham City Council and Aston Eye Clinic, respectively. Of all participants

enrolled, thirty-one did not successfully complete the clinical assessment; either because they found the tests too time-consuming or too invasive.



Figure 3.1 Study population distribution

The study population intended to map Birmingham's (UK) population census of 2016 (Figure 3.2).





3.4.1 Dry eye prevalence by the TFOS DEWS II criteria

The prevalence of DED by the TFOS DEWS II criteria varied with the diagnostic method used. DED diagnosis occurred significantly more often where ocular symptoms were assessed with the DEQ-5 than with the OSDI (Figure 3.3). The

highest prevalence rates were observed with those diagnostic methods involving ocular staining (Figure 3.3).





DED = dry eye disease. NIKBUT = non-invasive Keratograph tear break-up time. LWE = lid wiper epitheliopathy. DEQ-5 = 5-item Dry Eye Questionnaire. OSDI = Ocular Surface Disease Index.

DED by the TFOS DEWS II criteria was found significantly more prevalent in females than in males (Figure 3.4). The disease also differed with age, but without statistical significance (Figure 3.5).



Figure 3.4

DED prevalence by the TFOS DEWS II criteria (stratified by sex)

DED = dry eye disease. NIKBUT = non-invasive Keratograph tear break-up time. LWE = lid wiper epitheliopathy. DEQ-5 = 5-item Dry Eye Questionnaire. OSDI = Ocular Surface Disease Index.



DED prevalence (%)

Figure 3.5

DED prevalence by the TFOS DEWS II criteria (stratified by age)

DED = dry eye disease. NIKBUT = non-invasive Keratograph tear break-up time. LWE = lid wiper epitheliopathy. DEQ-5 = 5-item Dry Eye Questionnaire. OSDI = Ocular Surface Disease Index.

3.4.2 Dry eye prevalence by the WHS criteria

The WHS criteria estimated an overall DED prevalence of 29.5% (95%Cl, 24.4-35.1). DED by the WHS criteria differed significantly with sex and age (Figure 3.6). Among all ages, participants of 70 to 79 years-old were the most affected by the disease.



Error bars: 95%Cl. * p-value ≤0.05. *** p-value ≤0.001.

Figure 3.6 DED prevalence by the WHS criteria (stratified by sex and age)

3.4.3 Correlations between DED signs and symptoms

NIKBUT values were significantly correlated to the DEQ-5 and OSDI among DED participants (Table 3.1). In addition, both symptom questionnaires were found to be significantly concurrent with each other (r_s , 0.515; p-value, \leq 0.001).

Ocular signs	Sample size	Correlation with DEQ-5 scores	Correlation with OSDI scores
		Spearman's rank coefficient	Spearman's rank coefficient
NIKBUT mean value (s)	156	-0.187*	-0.165*
Highest osmolarity value (mOsm/L)	155	-0.039	-0.022
Interocular osmolarity difference	155	-0.117	-0.022
(mOsm/L)			
Corneal staining spots	156	0.154	-0.094
Conjunctival staining spots	156	0.055	0.127
Lower LWE width (%)	156	-0.063	0.110
Lower LWE length (mm)	156	-0.019	-0.025
Upper LWE width (%)	156	0.078	-0.003
Upper LWE length (mm)	156	0.079	-0.190
DED = dry eye disease. * p-value ≤0.05.			

Table 3.1 Correlations between DED signs and symptoms

3.5 Discussion

The epidemiology of DED has been challenged by the failure of a standardised diagnostic method to rely on (Stapleton *et al.*, 2017). The present study is the first to determine the disease prevalence in the UK as conforming to the TFOS DEWS II diagnostic criteria (Wolffsohn *et al.*, 2017). The prevalence rates were stratified by sex and age and compared to those obtained with the WHS criteria.

The results showed that the prevalence of DED by the TFOS DEWS II varied considerably with the diagnostic method used, ranging from 19.7% to 56.4%. Prevalence rates were significantly higher where ocular symptoms were assessed with the DEQ-5 than with the OSDI. Also, among all diagnoses, those assessing ocular surface staining reported the highest prevalence rates of DED; 56.4% and 37.1% when combined with the DEQ-5 and OSDI, respectively.

Possible reasons for the lower prevalence rates of DED with the OSDI might lie in the nature of the symptom questionnaire. As opposed to the DEQ-5, the OSDI assesses a smaller number of DED symptoms and hence may be less accurate in detecting symptomatic DED. Additionally, the OSDI measures the impact of environmental triggers on DED, being a less simple self-administered questionnaire than the DEQ-5.

Previous evidence has noted that ocular surface staining might not be only an intrinsic feature of DED but can also be presented in other conditions with eventual DED symptoms (Stapleton *et al.*, 2017). This might explain the higher prevalence rates of DED obtained when describing ocular signs by ocular surface staining compared to tear film instability or hyperosmolarity. On the other hand, significant positive correlations between NIKBUT values and both DEQ-5 and OSDI highlighted the diagnostic suitability of tear film stability.

DED prevalence by symptoms and signs has also been reported in other European countries (Viso, Rodriguez-Ares and Gude, 2009; Hashemi *et al.*, 2014). Hashemi et al., describing DED by an OSDI score of \geq 23 and at least one sign of impaired tear film volume or ocular surface, determined a disease prevalence of 8.7% in Iran; 10.6% in females and 6.1% in males (Hashemi *et al.*, 2014). A similar diagnostic method, involving symptom self-report and the assessment of ocular surface staining or tear film stability, was used in Spain and estimated a disease prevalence of 11.0%. with females more affected than males (11.9% vs. 9.0%) (Viso, Rodriguez-Ares and Gude, 2009).

In agreement with these studies, the present study showed significant differences among DED prevalence rates between sex. Females were by 14.4% to 18.2% significantly more prone to the disease than males, reflecting that sex hormones may play an important role in the disease predisposition. At present, male-specific sex hormones are known to modulate the function of the meibomian and lacrimal glands (Sullivan *et al.*, 2017). Yet, the mechanisms of female-specific sex hormones in the eye are not well understood (Sullivan *et al.*, 2017).

Besides sex, a meta-analysis on DED prevalence data has outlined that DED increases approximately linearly with age, with a steeper rise by decades in DED by ocular signs than by symptoms (Stapleton *et al.*, 2017). In the present study, no obvious linear relationship was observed in the prevalence rates stratified by age, perhaps because the disease was defined by a combination of both ocular symptoms and signs. It is also important to bear in mind that the present study results might have been confounded by selection bias (Wolffsohn *et al.*, 2017).

Not surprisingly, the prevalence of DED differed for the TFOS DEWS II and WHS criteria. The WHS criteria estimated an overall DED prevalence of 29.5%, with significant differences among sex and age groups. Prevalence estimates determined with a DEQ of \geq 6 and NIKBUT of <8 s were the most similar to those obtained with the WHS criteria; either when stratified or not by sex and age.

In conclusion, differences in the diagnostic methods of DED resulted in variations in the disease prevalence. DED diagnosis involving the assessment of symptoms and tear film stability appears to be suitable and similar to the WHS criteria. Further research, considering all proposed diagnostic methods by the TFOS DEWS II, would be useful to assess the burden of DED globally and subsequently plan and allocate worldwide health sources.

4. CHAPTER 4: THE RISK FACTORS OF DRY EYE DISEASE IN THE UK

4.1 Overview

The chapter gives an overview of DED in Birmingham (UK). It includes data about the risk factors of DED by the TFOS DEWS II diagnostic criteria.

4.2 Introduction

Epidemiological research on DED has focused on the assessment of risk factors to effectively prevent and control the disease (Stapleton *et al.*, 2017). A risk factor refers to any internal or external condition of an individual, which increases the likelihood of developing DED (Lemp *et al.*, 2007).

Assessing DED risk factors requires standardisation in obtaining information about individuals' health and lifestyle, as well as in differentiating between affected and unaffected eyes (Stapleton *et al.*, 2017). Yet, the use of different disease diagnoses has hindered to reach conclusive results on DED risk factors (Stapleton *et al.*, 2017).

The present study is the first population-based study in the UK that estimates the risk factors of DED following recent diagnostic recommendations of the TFOS DEWS II (Wolffsohn *et al.*, 2017).

4.3 Methodology

The study methodology described in Chapter 2 was used to study the risk factors of DED. The disease was defined as conforming to the TFOS DEWS II recommendations (Wolffsohn *et al.*, 2017), more specifically, by a DEQ-5 score of \geq 6 or OSDI score of \geq 13 and either one of the following:

- NIKBUT of <8 s;
- Tear film hyperosmolarity defined either by the highest osmolarity value of ≥308 mOsm/L among eyes or an interocular osmolarity difference of ≥8 mOsm/L;
- Ocular surface staining defined by ≥5 corneal spots, >9 conjunctival spots or lower/upper LWE staining of ≥2 mm length and ≥25% width.

4.3.1 Data processing

Risk factors gathered by the DERFS questionnaire were treated as nominal or ordinal variables and coded into numerical scores (Table 4.1). Risk categories with a low frequency of endorsement (less than 5%) were collapsed (rather than being excluded from the start) for the statistical analysis.

DERFS question	Risk factor	Coding instructions
	Ethnicity	1=White. 2=Asian. 3=Black. 4=Others
To which group do you	Sex	1=Male. 2=Female
belong?	Age	1=10s. 2=20s. 3=30s. 4=40s. 5=50s. 6=60s. 6=70s. 7=80s
	Residential area	1=Rural. 2=Urban
	Education	1= Elementary or primary school. 2=Middle or secondary school. 3=High school or 6 th form. 4=University o higher
Do you work?	Employment status	1=Unemployed. 2=Employed
Do you smoke?	Smoking habits	1=No. 2=Yes
Do you wear contact lenses?	Contact lens wear	1=No. 2=Yes
Do you have/have had any health condition?	Health condition	1=No. 2=Yes → Code 2 included any health condition/problem described by the participants.
Do you have/ have had any eye surgery?	Ocular surgery	1=No. 2=Yes → Code 2 included any past ocular surgery described by the participants.
Do you have taken any medication?	Medication intake	1=No. 2=Yes → Code 2 included any medication described by the participants.
Do you have taken any nutritional supplement?	Nutritional supplement intake	1=No. 2=Yes → Code 2 included any nutritional supplement described by the participants.

 Table 4.1
 Recording of DED risk factors

Table 4.2(continued)

How much do you use the computer?	Computer use	1=0-2 hours/day. 2=2-4 hours/day. 3=5-7 hours/day. 4=>7 hours/day
How much sleep do you get?	Sleep quality	1=>8 hours; 2=6-8 hours; 3=<6 hours
How much do you spend outdoors on a leisure day?	Outdoor activity	1=Less than 3 hours; 2= 3-4 hours; 3=> 4 hours
How stressful are your days?	Stress level	1=Least stressful. 2=Moderately stressful. 3=Extremely stressful

4.3.2 Statistical analysis

Statistical analysis was performed with SPSS version 23 (IBM Corp, released in 2015, New York, USA). Univariate analysis, including Chi-square tests, initially determined the significance of all self-reported risk factors. Risk factors with p-values of less than 0.20 (Uchino *et al.*, 2011; Na *et al.*, 2015) were considered for further multivariate analysis using non-hierarchical enter binary logistic regression. Correlations between the selected risk factors were evaluated with point biserial correlation coefficients (between dichotomous and ordinal risk factors), Spearman's rank correlation coefficients (between two ordinal risk factors) and phi coefficients (between two dichotomous risk factors). Finally, the strength of association of the risk factors was summarised using ORs and 95% CIs. ORs with p-values of ≤0.05 were considered statistically significant.

4.4 Results

Two-hundred eighty-two Birmingham residents (43 \pm 19 years, 56% females) participated in the study (Table 4.2). Recruitment occurred mostly at Aston University campus. Clinical assessments and DERFS questionnaires were successfully completed by 89% and 96% of all enrolled participants, respectively.

Table 4.2 Study population characteristics

Risk factor	Category	Frequency (n)	Percentage (%)
Ethnicity	White	166	58.9
	Asian	99	35.1
	Black	6	2.1
	Others	11	3.9
Sex	Male	124	44.0
	Female	158	56.0
Age (decades)	18-19	15	5.3
	20-29	71	25.2
	30-39	54	19.1
	40-49	45	16.0
	50-59	40	14.2
	60-69	28	9.9
	70-79	21	7.4
	80-89	8	2.8
Residential area	Rural	40	14.8
	Urban	230	85.2
Education	Elementary or primary	2	0.7
	school		
	Middle or secondary	24	8.8
	school		
	High school or 6 th form	49	17.9
	University or higher	199	72.6
Employment status	Unemployed	101	36.9
	Employed	173	63.1
Smoking habits	No	259	94.5
	Yes	15	5.5
Contact lens wear	No	206	75.2
	Yes	68	24.8
Health conditions/problems*	No	86	31.4
	Yes	188	68.6
Ocular surgery**	No	86	31.4
	Yes	188	68.6
Medication intake***	No	142	51.8
	Yes	132	48.2
Nutritional supplement	No	134	48.9
intake****	Yes	140	51.1
Computer use	0-2 hours/day	63	23.6
	2-4 hours/day	53	19.9
	5-7 hours/day	85	31.8
	≥7 hours/day	66	24.7
Sleep quality	>8 hours	14	5.1
	6-8 hours	186	67.9
	<6 hours	74	27.0
Outdoors activity	< 3 hours	168	61.5
-	3-4 hours	41	15.0
	>4 hours	64	23.4
Stress level	Least stressful	82	30.0
	Moderately stressful	173	63.4
	Extremely stressful	18	6.6

Table 4.2(continued)

* Recorded health conditions/problems were migraine (n =31). asthma (n =31). eczema (n =23). acne (n =17). rosacea (n =9). psoriasis (n =3). dermatitis (n =1). morphea (n =1). vitiligo (n =1). vitamin D deficiency (n =28). iron deficiency (n =11). anxiety (n =25). depression (n =15). rheumatoid arthritis (n =28). hypertension (n =27). hypercholesterolemia (n =20). thyroid disease (n =14). cancer (n =13). polycystic ovary syndrome (n =4). bladder irritation (n =1). osteoporosis (n =5). irritable bowel syndrome (n =9). diabetes mellitus (n =11). lymphatic drainage problem (n =1). stroke (n =4). prostatitis (n =1). gout (n =1). keratoconus (n =1). pterygium (n =1). insomnia (n =2). Sjögren syndrome (n =1). tuberculosis (n =1). epilepsy (n =1). Ehlers-Danlos syndrome (n =1). sinusitis (n =2). familial dilated cardiomyopathy (n =1). Crown disease (n =1). Carpal tunnel syndrome (n =1). glaucoma (n =4). human immune deficiency virus (n =1). multiple sclerosis (n =1). thoracic outlet syndrome (n =1). audio sclerosis (n =1). diverticulosis (n =1). rhinitis (n =1). bronchiectasis (n =1). Best disease (n =1). age-related macular degeneration (n =1). Parkinson (n =1). traumatic glaucoma (n =1). ulcerative colitis (n =1). retinopathy (n =1). spinal stenosis (n =1). cataracts (n =1). pain in joints (n =1). back (n =8). pelvic (n =3) and hips (n =1). and allergy to pollen (n =44). grass (n =3). dust (n =12). penicillin (n =11). pets (n =7). nuts (n =3). feathers (n =2). flowers (n =1). wool (n =1). mould (n =1). mites (n =2). plasters (n =2). antibiotics (n =1). non-steroidal antiinflammatory drugs (n =1). gluten (n =1). diary (n =1). soy (n =1). fish (n =1). eggs (n =1). zinc (n =1). statins (n = 1). trimethoprim (n = 1). efortil (n = 1). morphine (n = 1) inhaler (n = 1) and opioids (n = 1). ** Documented surgical ocular interventions were strabismus surgery (n =4). refractive surgery (n =13). dacryocystorhinostomy (n =2). cyst removal (n =7). corneal cross-linking (n =1). cataract surgery (n =11) and retinal surgery (n =2).

*** Medication intake included the use of oral contraceptives (n =18). antimigraine drugs (n =4). antihistamine drugs (n =22). pills for skin problems (n =7). antihistamine inhaler (n =11). anxiolytics (n =3). steroids (n =2). painkillers (n =7). blood pressure pills (n =19). antithyroid pills (n =11). pills for asthma (n =1). pills for digestive problems (n =2). pills for bladder control (n =4). cancer treatment (n =2). antidepressant (n =8). statins (n =19). diuretics (n =2). hormone therapy (n =3). pills for irritable bowel syndrome (n =1). diabetes treatment (n =6). aspirins (n =12). prostatitis treatment (n =2). heart treatment (n =1). pills for vertigo (n =1). sleeping tablets (n =5). dermatitis treatment (n =1). arthritis treatment (n =2). antibiotics (n =2). glaucoma drops (n =3). pills for palpitation (n =1). beta blockers (n =1). human immune deficiency virus treatment (n =1). osteoporosis treatment (n =1). stomach protector (n =3). antifungal pills (n =1). antihistamine nasal spray (n =1). antihistamine eyedrops (n =2). Parkinson treatment (n =1). morphine (n =1). epilepsy treatment (n =1). sinusitis nasal spray (n =1). gout treatment (n =1). and contraceptive implant (n =2).

Nutritional supplement intake include the use of vitamin D (n =42). cod liver oil (n =37). iron (n =22). proteins (n =4). multivitamins (n =44). vitamin C (n =16). vitamin B (n =9). calcium (n =5). zinc (n =2). vitamin E (n =1). weight gainer (n =1). folic acid (n =2). echinacea (n =1). glucosamine (n =11). hyaluronic acid (n =1). probiotics (n =1). herbal pills (n =1). magnesium (n =7). primrose oil (n =1). caffeine (n =1). essential amino acids (n =1). electrolytes (n =1). melatonin (n =1). collagen (n =1). lutein (n =2). yin yang (n =1). flaxseed oil (n =1). lysine (n =1). beetroot extract (n =1). turmeric (n =1) and Adalat (n =1).

4.4.1 Dry eye risk factors

Age, sex, education, smoking habits, contact lens wear, health condition, computer use, sleep quality and outdoor activity were considered for the multivariate analysis (Table 4.3). Risk factors which did not initially reach significance included ethnicity, residential area, employment status, medication intake, nutritional supplement intake, ocular surgery and stress level (Table 4.3).

Risk factor	Category	Nnon-DED	NDED	N _{Total}	X ²	p-value
Ethnicity	White	51	90	141	0.441	0.802
•	Asian	38	58	96		
	Black and others	6	8	14		
Sex	Male	53	57	110	8.888	0.003
	Female	42	99	141		
Age (decades)	18-19	11	4	15	9.690	0.138
	20-29	27	42	69		
	30-39	15	30	45		
	40-49	15	27	42		
	50-59	12	22	34		
	60-69	9	15	24		
	70-79 and 80-89	6	16	22		
Residential area	Rural	13	25	38	0 407	0.523
	Urban	81	123	204	0.101	0.020
Education	Elementary primary	6	21	204	3 405	0 182
Education	middle or secondary	0	21	21	0.400	0.102
	High school or 6 th	16	28	44		
	IOIIII	70	107	100		
F		73	107	180	4.040	0.040
Employment status		39	52	91	1.016	0.313
<u> </u>	Employed	56	98	154		a (=a
Smoking habits	No	92	139	231	1.882	0.170
2 4 41	Yes	3	11	14		
Contact lens wear	No	/6	109	185	1.691	0.193
	Yes	19	41	60		
Health	No	42	39	81	8.716	0.003
conditions/problems	Yes	53	111	164		
Ocular surgery	No	80	130	210	0.446	0.504
	Yes	15	19	34		
Medication intake	No	55	76	131	1.221	0.269
	Yes	40	74	114		
Nutritional	No	54	73	127	1.557	0.212
supplement intake	Yes	41	77	118		
Computer use	0-2 hours/day	20	36	56	6.213	0.102
	2-4 hours/day	24	21	45		
	5-7 hours/day	30	49	79		
	≥7 hours/day	18	42	60		
Sleep quality	>8 hours	7	4	11	4.113	0.128
	6-8 hours	66	100	166		
	<6 hours	22	46	68		
Outdoor activity	<3 hours	61	87	148	4.002	0.135
	3-4 hours	17	21	38		0.700
	>4 hours	16	42	58		
Stress level	l east stressful	26	46	72	2 292	0.318
	Moderately stressful	64	91	155	2.202	0.010
	Extremely stressful	4	13	17		
	$p_{n} = p_{n} p_$		toot			

Table 4.3 Distribution of risk factors among non-DED and DED participants

DED associations that were identified statistically significant in the multivariate analysis were female sex, the presence of any health conditions/problems and prolonged outdoor activity (Table 4.4).

Table 4.4 Risk factors for DED

Risk factor	Univaria	te analysis		Multivar	Multivariate analysis			
Category	OR	95%ČI	p-value	OR	95%CI	p-value		
Ethnicity								
White	1			n/a	n/a	n/a		
Asian	0.865	0.507-1.476	0.594					
Black and others	0.756	0.248-2.299	0.622					
Sex								
Male	1	4 000 00 000		1	4 007 4 000	0.005		
Female	2.192	1.303-03.686	0.003	2.328	1.287-4.209	0.005		
Age								
18-19	1	1 005 14 016	0.000	1	0 545 7 000	0.240		
20-29	4.278	1.233-14.810	0.022	2.029	0.010-7.998	0.312		
30-39	5.500	1.497-20.210	0.010	1.999		0.359		
40-49	4.950	1.340-18.289	0.016	1.427	0.309-6.598	0.649		
50-59	5.042	1.316-19.317	0.018	1.428	0.297-6.867	0.657		
60-69	4.583	1.117-18.803	0.035	2.081	0.521-13.798	0.238		
Posidential area	1.333	1.070-32.210	0.008	3.113	0.500-19.400	0.224		
	1			n/o	n/o	n/o		
Kurai	1 0 700	0 383 1 633	0 504	n/a	il/a	n/a		
Education	0.790	0.302-1.033	0.524					
Euucation Elementary primary	1			1				
middle or socondary	I			I				
High school or 6 th form	0 500	0 167 1 406	0.215	0 474	0 125 1 671	0.246		
	0.000	0.107-1.490	0.215	0.474	0.135-1.071	0.240		
Employment status	0.413	0.101-1.000	0.074	0.400	0.137-1.300	0.222		
	1			n/a	n/a	n/a		
Employed	1 312	0 773-2 228	0.31/	11/a	n/a	n/a		
Smoking habits	1.012	0.115-2.220	0.514					
No	1							
Yes	2 4 2 7	0 659-8 936	0 182	3 560	0 789-16 052	0 098		
Contact lens wear	6.761	0.000 0.000	0.102	0.000	5.760 TO.002	5.000		
No.	1			1				
Yes	1.505	0.811-2 791	0.195	1.851	0.866-3.956	0.112		
Health conditions/problems	1.000	5.511 2.101	0.100	1.001	5.000 0.000	5.112		
No	1			1				
Yes	2.255	1.308-3.890	0.003	2.432	1.245-4.748	0.009		
Ocular surgerv								
No	1			n/a	n/a	n/a		
Yes	0.779	0.375-1.621	0.505					
Medication intake								
No	1			n/a	n/a	n/a		
Yes	1.339	0.798-2.247	0.270	-		-		
Nutritional supplement			-					
intake								
No	1			n/a	n/a	n/a		
Yes	1.389	0.828-2.330	0.213	-		-		
Computer use			-					
0-2 hours/dav	1			1				
2-4 hours/day	0.486	0.218-1.083	0.078	0.653	0.233-1.835	0.419		
5-7 hours/day	0.907	0.446-1.847	0.789	1.170	0.426-3.216	0.760		
≥7 hours/dav	1.296	0.596-2.819	0.513	2.188	0.730-6.552	0.162		
·)			-					

Table 4.4	(continue	d)					
Sleep quality							
	>8 hours	1			1		
	6-8 hours	2.652	0.747-9.415	0.131	2.382	0.572-9.920	0.233
	<6 hours	3.659	0.968-13.827	0.056	3.719	0.804-17.194	0.093
Outdoor activity							
	<3 hours	1			1		
	3-4 hours	0.866	0.422-1.776	0.695	0.949	0.402-2.243	0.906
	>4 hours	1.841	0.949-3.569	0.071	2.369	1.102-5.088	0.027
Stress level							
Lea	ist stressful	1			n/a	n/a	n/a
Moderately stressful		0.804	0.451-1.432	0.458			
Extremely stressful		1.837	0.543-6.219	0.328			
DED = dry eye d	lisease. OR	= odds ratio	o. CI = confidence	e interval. I	√a =not ap	plicable.	

4.4.2 Correlations among dry eye risk factors

Most of the selected DED risk factors were significantly correlated with age (Table 4.5). Computer use showed a significant positive and negative association with outdoor activity and education (Table 4.5). A significant positive correlation was also observed between contact lens wear and education (Table 4.5).

Correlations coefficient	Sex	Age	Education	Smoking habits	Contact lens wear	Health condition	Computer use	Sleep Quality	Outdoors activity
sample size	_							-	-
Sex		-0.004	-0.069	-0.29	0.085	0.110	-0.026	0.001	-0.053
		251	251	245	245	245	240	245	244
Age			-0.347***	-0.055	-0.314***	0.362***	-0.290**	0.190**	-0.078
			251	245	245	245	245	240	244
Education				-0.008	0.152*	-0.108	-0.379***	-0.191	0.090
				245	245	245	240	245	244
Smoking					-0.058	-0.089	0.024	-0.006	-0.004
habits					245	240	240	245	244
Contact lens						-0.084	0.090	-0.070	-0.025
wear						245	240	245	244
Health							-0.097	0.079	-0.100
condition							240	245	244
Computer use								-0.40	0.169**
								240	239
Sleep quality									-0.038
									244
DED = dry eye	disease	.* p-value	≤0.05. ** p-va	lue ≤ 0.01. **	* p-value ≤0.0	001.			

 Table 4.5
 Correlations among DED risk factors

4.5 Discussion

The present study is the first to identify DED risk factors as conforming to the TFOS DEWS II diagnostic criteria (Wolffsohn *et al.*, 2017). The criteria is evidence-based and currently recommended to be globally applied in DED research (Wolffsohn *et al.*, 2017).

A cross-sectional study design was chosen as this allowed to evaluate different DED associations simultaneously (Mann, 2003). The associations were found to be significant in previous cross-sectional studies, whereby the disease was diagnosed either by the WHS criteria, symptoms, signs or both symptoms and signs (Lu *et al.*, 2008; Uchino *et al.*, 2008; Jie *et al.*, 2009; Guo *et al.*, 2010; Han *et al.*, 2011; Ahn *et al.*, 2014; Hashemi *et al.*, 2014; Malet *et al.*, 2014; Vehof *et al.*, 2014; Tan *et al.*, 2015). Information about the participants' characteristics was gathered through a self-administered questionnaire in order to record more precisely the risk factors (Wolffsohn *et al.*, 2017).

The result showed that age, education, smoking habits, contact lens wear, computer use, sleep quality, the presence of any health condition/problem, female sex and prolonged outdoors activity were potential risk factors for DED (p-values <0.20). The statistical significances of the last three factors were confirmed in the multivariate analysis (p-values ≤ 0.05).

In agreement with previous epidemiological research (Jie *et al.*, 2009; Han *et al.*, 2011; Ahn *et al.*, 2014), females were 2.317 times more likely to present DED than males, reflecting the importance of sex hormones in the disease predisposition. Males are believed to be less susceptible to DED (Stapleton *et al.*, 2017), as their

predominant sex hormones regulate both tear lipid and aqueous secretions, as well as the immune responses of corneal and conjunctival cells (Sullivan *et al.*, 2017).

Health conditions/problems that were reported in the present study and have been previously identified to be significant in cross-sectional studies using the WHS criteria (Ahn *et al.*, 2014) and a symptomatic diagnosis of DED (Vehof *et al.*, 2014) were hypertension (Ahn *et al.*, 2014), hypercholesterolemia (Ahn *et al.*, 2014), thyroid disease (Ahn *et al.*, 2014; Vehof *et al.*, 2014), asthma (Vehof *et al.*, 2014), eczema (Vehof *et al.*, 2014), any allergy (Vehof *et al.*, 2014), rheumatoid arthritis (Vehof *et al.*, 2014), stroke (Vehof *et al.*, 2014), migraine (Vehof *et al.*, 2014), irritable bowel syndrome (Vehof *et al.*, 2014) and pelvic pain (Vehof *et al.*, 2014). The rationale behind the relationship between each health condition/problem and DED is difficult to ascertain, as these were studied in conjunction.

Participants engaging in out of doors for more than four hours on a regular leisure day were 42.2% at DED risk. Outdoors activity can be related to environmental conditions, such as high altitude, sunlight exposure, temperature, humidity, wind, precipitation and air pollution that have been associated with symptomatic and clinically diagnosed DED (Lu *et al.*, 2008; Guo *et al.*, 2010; Um *et al.*, 2014).

Although the statistical significance of age, education, smoking habits, contact lens wear, computer use and sleep quality disappeared in the multivariate analysis, this does not mean that the risk factors have no clinical importance (Offord and Kraemer, 2000). Indeed, among them, age, contact lens wear and computer use have recently been acknowledged to be consistent risk factors for DED (Stapleton *et al.*, 2017). On the other hand, age and computer use were significantly associated with two factors that remained significant in the multivariate analysis: sex and outdoors activity,

100

respectively. Contact lens wear might have not resulted to be a significant risk factor of DED because the sample size of contact lens wearers was notoriously smaller than that of non-contact lens wearers.

It is worth noting that the risk factor analysis of the present study might have been influenced by the selected study population, as risk factors may be population specific (Offord and Kraemer, 2000). Risk factors which did not initially reach significance in the univariate analysis, including ethnicity, residential area, employment status, medication intake, ocular surgery and stress level, might have been confounded by the recruitment. Participants were mostly recruited at Aston University showing predominantly a study population profile of university students and staff members. Also, DED might have been compensated by the intake of nutritional supplements, such as essential fatty acids, which are currently recommended as treatment options of DED (Roncone, Bartlett and Eperjesi, 2010; Rosenberg and Asbell, 2010; Oleñik, 2014; Bhargava *et al.*, 2015; Gatell-Tortajada, 2016).

In conclusion, female sex, the presence of any health condition/problem and prolonged outdoor activity were significant risk factors for the DED. Further research, using the same diagnostic criteria, would be of great value to aid a better understanding of DED risk factors among different populations and subsequently assist with the disease amelioration.

101

5. CHAPTER 5: SUBCLASSIFICATION OF DRY EYE DISEASE IN THE UK

5.1 Overview

The chapter gives an overview of DED in Birmingham (UK). It includes data about the prevalence and potential risk factors of DED subtypes.

5.2 Introduction

Prevalence studies assessing risk factors of ADDE and EDE may be useful to develop an effective treatment plan for both DED subtypes (Jones *et al.*, 2017). Both ADDE and EDE have similar ocular symptoms and general DED signs, however, they may be related to different risk factors and hence require a different therapeutical approach (Jones *et al.*, 2017).

The latest evidence on DED classification supports that ADDE and EDE may coexist with increasing disease severity and thus characteristics of each need to be considered in clinical practice (Craig *et al.*, 2017). Tests specific to ADDE and EDE are those evaluating the tear film volume (including the PRT test, Schirmer test and TMH) and the tear film evaporation, lipid layer thickness and meibomian gland dysfunction, respectively (Wolffsohn *et al.*, 2017). The tests should not override a clinical diagnosis of DED but should assist in the disease amelioration (Wolffsohn *et al.*, 2017).

Unfortunately, although specific clinical tests have been assigned to diagnose ADDE and EDE, there is no apparent consistency in categorizing both DED subtypes (Jones *et al.*, 2017). For instance, in DED epidemiology, different diagnostic cut-off values and/or subclassification tests were used, hindering direct comparisons of prevalence rates of ADDE and EDE (Albietz, 2000; Rege *et al.*, 2013; Asiedu, Dzasimatu and

Kyei, 2018) (Table 5.1). Also, DED diagnosis has been addressed somewhat subjectively (Wolffsohn et al., 2017) (Table 5.1).

Study	Population	DED subtypes					
	characteristics	ADDE		EDE			
	Age (years) Sex (n)	Diagnosis	Prevalence (%[95%Cl])	Diagnosis	Prevalence (%[95%CI])		
Albietz 2000 ^A	3-96 ♀ 912 ♂ 672	Lipid layer without colour fringes and meibomian glands without particulate, frothy or cloudy meibum, and PRT test of <10 mm/ 15s and TMH of <0.10 mm	1.7 [n/a]	Lipid layer with colour fringes and meibomian glands with particulate, frothy or cloudy meibum, and PRT test of ≥ 10 mm/ 15s and TMH of ≥ 0.10 mm	4.0 [n/a]		
Lemp et al. 2012 ^в	46.3 ± 16.9 ♀ 218 ♂ 81	MGD score of ≤5 and Schirmer test II of <7 mm/5 min	35.3 [n/a]	MGD score of >5 and Schirmer test II 7 mm/5 min	10.3 [n/a]		
Rege et al. 2013 ^c	≥18 ♀ 2585 ♂ 2165	Meibomian glands without inspissated or toothpaste-like meibum, and Schirmer test II of <10 mm/ 5 min	13.36 [n/a]	Meibomian glands with inspissated or toothpaste-like meibum, and Schirmer test II of ≥10 mm/ 5 min	14.48 [n/a]		
Asiedu. Dzasimatu and Kyei 2018 ^p	17-35 ♀ 89 83 ♂	Meibomian glands without low expressibility and cloudy or toothpaste-like meibum. and Schirmer test I of ≤5 mm/5 min	5.2 [n/a]† 5.2 [n/a]‡	Meibomian glands with low expressibility and cloudy or toothpaste-like meibum. and Schirmer test I of >5 mm/5 min	11.6 [n/a]† 7.0 [n/a]‡		

Table 5.1 Previous large-scale clinical-population-based studies on DED subtypes

DED = dry eye disease. ADDE = aqueous deficient dry eye. EDE = evaporative dry eye. PRT = phenol red thread. TMH = tear meniscus height.

A. DED was defined by at least one of five primary symptoms of the McMonnies questionnaire (soreness, scratchiness, dryness, grittiness and burning) either often or constantly, an FBUT of <10s and a rose bengal score of ≥1 (van Bjisterveld staining score) (Albietz, 2000).

B. DED was defined by an OSDI score of ≥5 and at least two of five signs: FBUT <7s, Schirmer test I <7 mm/5 min, corneal staining >0 (National Eye Institute/Industry Workshop scale), conjunctival staining >0 (National Eye Institute/Industry Workshop scale) and meiboscore of >5 (Bron/Foulks scoring system) (Sullivan et al., 2010; Lemp et al., 2012).

C. DED was defined by presenting a MQ score of ≥14.5 (Rege et al., 2013).

D. DED was classified into symptomatic† and asymptomatic‡ DED. Symptomatic DED was defined by an OSDI score of ≥13 and fluorescein tear break-time of <10s or corneal and conjunctival fluorescein staining of ≥1 (Oxford grading scale). Asymptomatic DED was defined by an OSDI score of <13 and fluorescein tear break-time of <10s or corneal and conjunctival fluorescein staining of ≥1 (Oxford grading scale) (Asiedu, Dzasimatu and Kyei, 2018).

It is clear that a well-standardized initial DED diagnosis is crucial to attempt towards

an accurate disease classification (Wolffsohn et al., 2017). To this purpose, the TFOS

DEWS II proposed an evidence-based DED diagnostic criteria (Wolffsohn *et al.*, 2017) and recommended its use with additional measurements of TMH, LLT, tear evaporation and MGD to aid DED classification (Wolffsohn *et al.*, 2017); however, without established diagnostic subclassification cut-off values.

The present study is the first in proposing a differential diagnosis for DED that follows current diagnostic recommendations of the TFOS DEWS II. DED was diagnosed by the TFOS DEWS II criteria and the diagnostic cut-off values of TMH, LLT, tear evaporation and MGD were defined. Moreover, the differential diagnosis was used to determine the prevalence and potential risk factors of ADDE and EDE among a single population of UK.

5.3 Methodology

The study methodology described in Chapter 2 was used to study the prevalence and potential risk factors of DED subtypes. DED was diagnosed by the TFOS DEWS II criteria (Wolffsohn *et al.*, 2017). The criteria defined the disease by an OSDI score of \geq 13 or DEQ-5 score of \geq 6 and either the presence of:

- Tear film instability (determined by a NIKBUT of <8s);
- Tear film hyperosmolarity (characterized either by the highest osmolarity value of ≥308 mOsm/L among eyes or an interocular osmolarity difference of ≥8 mOsm/L);
- Ocular surface damage (described either by ≥5 corneal staining spots, >9 conjunctival staining spots, or a lower/upper LWE staining of ≥2 mm length and ≥25% width).

Measurements of LLT, lower/upper MGD, tear evaporation and TMH were included to classify DED into ADDE and EDE. The diagnostic methods were formerly suggested by the TFOS DEWS II for attempting DED classification (Wolffsohn *et al.*, 2017). In line with current definitions of ADDE and EDE (Craig *et al.*, 2017). ADDE was described by a reduced TMH, whereas EDE was described by a reduced LLT or an increased tear evaporation or lower/upper MGD (Wolffsohn *et al.*, 2017).

Although MGD has been graded by the quality of the meibum, more specifically, by its expressibility and appearance (Albietz, 2000; Rege *et al.*, 2013; Asiedu, Dzasimatu and Kyei, 2018), the condition was defined by meibomian gland dropouts. Meibomian gland dropouts have been previously correlated with altered meibum (Finis *et al.*, 2015) and hence explains the rationale behind the used approach. Besides, it was believed that the meibum might have been already confounded by previous tests involving eyelid eversion and the instillation of ocular dyes.

Sex, age, education, smoking habits, contact lens wear, health conditions/problems, computer use, sleep quality and outdoor activity were gathered by the DERFS questionnaire (section 2.2.5.2) and considered in the risk factor analysis of both DED subtypes. As resulted from Chapter 4, the factors have shown to be potential risk factors of DED and, amongst these, sex and health conditions/problems had the greatest statistical significance (p-value ≤ 0.01).

Cut-off values of subclassification tests were determined from LLT, MGD, tear evaporation rates and TMH readings of non-DED participants. The readings were initially stratified by sex and by the presence/absence of health conditions/problems to understand whether both factors might have confounded normal tear film characteristics. Data of at least 75% non-DED participants were referred as normal

105
to achieve cut-off values that were as specific as possible. The combination of these would give greater confidence in the differential diagnosis of the disease (Wolffsohn *et al.*, 2017).

5.3.1 Data processing

Collected scores of DED and DERFS questionnaires, NIKBUT, tear film osmolarity, ocular staining, LLT, MGD, tear evaporation and TMH were entered in a common Excel spreadsheet. Initial and differential diagnoses of DED were performed in participants that have successfully completed the clinical assessment. Negative and positive diagnoses were coded as values of 1 and 2, respectively. A dichotomous variable encompassing positive EDE and ADDE outcomes was created to study the risk factors of pure DED subtypes. Risk factors were identically categorized as in Chapter 4.

5.3.2 Statistical analysis

Statistical analysis was performed with SPSS version 23 (IBM Corp. released in 2015. New York. US). All ocular parameters were confirmed to be not normally distributed using Kolmogorov-Smirnov tests. Differences between ADDE and EDE signs of female and male non-DED participants with and without health conditions/problems were analysed with U-Mann Whitney tests. Prevalence rates of DED subtypes were presented with 95% CIs. Associations between ADDE and EDE signs and between the subclassification signs and DED symptoms of DED participants were evaluated with Spearman's rank correlation coefficients. Finally, within DED participants, risk factors of pure ADDE and EDE were determined through

phi (for dichotomous risk factors) and point biserial correlation coefficients (for ordinal risk factors).

5.4 Results

Two-hundred eighty-two Birmingham residents (42.4 ± 18.7 years, 56% females) participated in the study (Figure 5.1). Recruitment occurred mostly at Aston University campus. DERFS questionnaires were successfully completed by 96% participants. One hundred and fifty-six positive and ninety-five negative diagnoses of DED were concluded. Missing data resulted from any instrumentation failure or participants' poor collaboration in the clinical assessment.

5.4.1 Sub-classification signs of non-dry eye participants

Measurements of LLT, lower/upper MGD, tear evaporation and TMH of non-DED participants with health conditions/problems differed significantly among females and males (Table 5.2). However, this was not the case for non-DED participants without health conditions/problems.

Subclassification signs	Non-DED participants								
(mean ± SD)	Without health conditions/problems		With health conditions/problems				s		
	Ŷ	n	8	N	Ŷ	n	8	n	
LLT score	3.82 ±	17	3.27 ±	26	3.85 ±	26	3.22 ±	27	*
	1.07		1.15		1.32		1.12		
Lower MGD (%)	19.12 ±	17	17.88 ±	26	20.96 ±	26	21.67 ±	27	
	14.28		12.72		14.00		12.93		
Upper MGD (%)	24.5 ±	16	21.54 ±	26	30.85 ±	26	27.33 ±	27	
	16.49		10.83		17.91		13.36		
Tear evaporation	41.58 ±	17	37.76 ±	25	59.20 ±	26	47.58 ±	27	
(g/m²/h)	12.08		9.49		39.42		31.47		
ŤMH (mm)	0.27 ±	17	0.29 ±	26	0.27 ±	26	0.41 ±	27	***
	0.10		0.11		0.08		0.21		
DED = dry eye diseas standard deviation.	DED = dry eye disease. * p-value ≤0.05. *** p-value ≤0.001. ♀ = female. ♂ = male. n = sample size. SD = standard deviation.								

 Table 5.2
 Subclassification DED signs of non-DED participants (stratified by sex and the absence/presence of health conditions/problems)

5.4.2 Cut-off values of dry eye subclassification tests

The diagnostic cut-off values of the subclassification tests were based on the distribution of LLT, MGD, tear evaporation rates and TMH of non-DED participants without health conditions (Figure 5.1). The first or third quartile were adopted to obtain cut-off values that were as specific as possible. These were:

- TMH of <0.2 mm;
- LLT of grade <3;
- MGD of >29;
- Tear evaporation of >46 g/m²/h.

Non-DED participants without health were selected to ensure that the cut-off values were applicable for both sexes (section 5.4.1).

5.4.3 Presumed differential dry eye diagnosis

DED participants with a TMH of <0.2 mm and normal LLT (a grade of \geq 3), lower/upper MGD (\leq 28%) and tear evaporation rate (\leq 46 g/m²/h) were diagnosed with ADDE. In contrast, EDE was defined by a LLT of grade <3, lower/upper MGD of >29% and tear evaporation rate of >46 g/m²/h, but a normal TMH (\geq 0.2 mm).

Where the criteria of both ADDE and EDE was met, DED was classified into a third disease subtype representing an aqueous-deficient/evaporative DED. Conversely, where the criteria of both ADDE and EDE was not met, DED was classified into an unclassified DED.





LLT = lipid layer thickness. MGD = meibomian gland dysfunction.

Box and whisker diagrams (also known as box plots) were used to display the distribution of LLT, lower/upper MGD, tear evaporation and TMH of healthy non-DED participants based on six-number summary: minimum (minimum value of the dataset), first quartile (middle number between the smallest value (not the "minimum") and the median of the dataset), median (middle value of the dataset), third quartile (middle value between the median and the highest value (not the "maximum") of the dataset), maximum (maximum value of the dataset) and means (average of all values of the dataset). The means are illustrated by crosses. The first quartile, median and third quartile of LLT (3.4.4), lower MGD (9.25%. 16.0%. 28.75%), upper MGD (13.0%. 20.0%. 28.0%), tear evaporation (32.3 g/m²/h. 38.3 g/m²/h. 45.5 g/m²/h) and TMH (0.20 mm. 0.28 mm and 0.30 mm) are shown in brackets. All five box plots span from the first quartile to the third quartile. The segments inside the boxes represent the medians and the "whiskers" above and below the boxes indicate the locations of minimums and maximums, respectively. In LLT, the third quartile coincided with the median. Cut-off values of each subclassification sign were either based on the first quartile (LLT and TMH) or third quartile (upper MGD and tear evaporation). The cut-off value for upper MGD was also applied for lower MGD.

5.4.4 Prevalence of dry eye subtypes

DED was classified either into EDE (62.8%), ADDE (9.0%), both ADDE and EDE (10.9%) and unclassified DED (17.3%) (Figure 1.1). Amongst all, EDE was the most prevalent DED subtype.





DED = dry eye disease. ADDE = aqueous deficient dry eye. EDE = evaporative dry eye.

5.4.5 Frequency of evaporative dry eye signs in evaporative dry eye participants

Altered tear evaporation was the most common sign observed in EDE participants (62.2%), followed by upper MGD (48.0%), decreased LLT (30.6%) and lower MGD (25.5%) (Figure 5.3).





5.4.6 Relationship between subclassification signs in dry eye participants

Tear evaporation and TMH were significantly positive correlated with each other, as well as with MGD (Table 5.3). LLT did not significantly correlate with any other signs specific to ADDE or EDE (Table 5.3).

Table 5.3Co	orrelatio	ns of s	subclassifi	cation s	igns in D	ED part	icipants			
Correlation of subclassification DED signs	LLT scor	LLT Lower MGD score (%)		Upper (%)	Upper MGD Tear (%) evaporation (g/m ² /h)		tion	TMH (mm)		
	rs	n	rs	n	rs	n	rs	n	rs	n
LLT score			-0.012	155	0.013	155	-0.115	153	0.038	156
Lower MGD (%) Upper MGD (%) Tear evaporation					0.152	154	0.182* 0.023	0.025 152	0.066 0.188* 0.251**	155 155 153
$\frac{(g/m^2/h)}{DED = dry eye diseas}$ p-value ≤ 0.01 . r _s = sp	se. LLT bearmar	= lipid n rank	layer thick correlation	ness. I coeffic	/IGD = m cient. n =	eibomia sample	n gland dy: size.	sfunction.	* p-value ≤0	0.05. **

5.4.7 Relationship between subclassification signs and symptoms of dry eye disease

Within dry eye participants. higher DEQ-5 scores were significantly associated to higher TMH values (Table 5.4). However. no other ADDE and EDE sign was significantly related to DED symptoms (Table 5.4).

Table 5.4 Correlations of subclassification DED signs and symptoms in DED participants

DED symptoms	Correla	Correlation with subclassification DED signs								
	Lower (%)	MGD	GD Upper MGD (%)		Tear evaporation (g/m²/h)		TMH (mm)		LLT score	
	ľs	n	ľs	n	r s	n	ľs	n	rs	Ν
DEQ-5 score	-0.082	156	0.034	155	0.035	155	0.193*	153	0.008	156
OSDI score	0.020	156	-0.053	155	0.135	155	0.136	153	-0.007	156
DED = dry eye disease. LLT = lipid layer thickness. MGD = meibomian gland dysfunction. DEQ-5 = 5-item										
Dry Eye Questionnaire. OSDI = Ocular Surface Disease Index. * p-value ≤ 0.05 . r _s = spearman rank correlation coefficient n = sample size										

5.4.8 Potential risk factors of dry eye subtypes

Aging was significantly associated with EDE (Table 5.5). In contrast. contact lens wear and computer use were significantly related to ADDE (Table 5.5).

 Table 5.5
 Correlations between pure DED subtypes† and potential risk factors of DED

Risk factors	Correlation with DED subtypes			
	rs/ _φ	n		
Sex	-0.177	112		
Age	-0.336	112	**	
Education	0.136	112		
Smoking habits	-0.107	110		
Contact lens wear	0.236	110	*	
Health conditions/problems	-0.036	110		
Computer use	0.205	108	*	
Sleep quality	-0.031	110		
Outdoor activity	0.045	110		
				-

DED = dry eye disease. ADDE = aqueous deficient dry eye. EDE = evaporative dry eye. † EDE was coded as 1 and ADDE as 2.

* p-value ≤0.05; ** p-value ≤0.01.

 r_s = spearman rank correlation coefficient (used for age. education. sleep quality and outdoor activity). r_a = phi correlation coefficient (used for sex. contact lens wear and health conditions/problems).

n = sample size.

Sex, education, smoking habits, health conditions/problems, sleep quality and outdoor activity did not result to be significant risk factors of either ADDE or EDE (Table 5.5).

5.5 Discussion

DED can be classified into ADDE and EDE, where the aqueous and lipid layer of the tear film are respectively altered (Craig *et al.*, 2017). Both DED subtypes can be confused as they present similar symptoms and general DED signs, however, their differential diagnosis is of utmost importance for making right decisions when treating and managing the disease (Jones *et al.*, 2017).

At present, the TFOS DEWS II globally recommends an initial DED diagnosis involving the assessment of ocular symptoms (using either the DEQ-5 or OSDI questionnaire) and signs (including the assessment of NIKBUT, tear hyperosmolarity or ocular surface staining) (Wolffsohn *et al.*, 2017). The present study is the first in adopting the recommended diagnostic criteria to further propose a differential diagnosis of DED.

The proposed differential diagnosis was used to determine the prevalence and potential risk factors of ADDE and EDE among a single population of UK. It included the evaluation of the TMH, LLT, tear evaporation and upper/lower MGD described by meibomian gland dropouts. The diagnostic tests were also formerly suggested by the TFOS DEWS II for attempting DED classification (Wolffsohn *et al.*, 2017); however, with no established diagnostic cut-off values.

In the present study, diagnostic cut-off values of TMH, LLT, tear evaporation and upper/lower MGD were determined from clinical data of non-DED participants without any health conditions/problems. Health conditions/problems were excluded as these confounded normal tear film functions. Non-DED participants were considered to obtained cut-off values that were as specific as possible. This would allow greater confidence in the differential diagnosis of the disease when combining the subclassification tests (Wolffsohn *et al.*, 2017).

A TMH of <0.2 mm and LLT of grade ≥3, lower/upper MGD of ≤28% or tear evaporation rate of ≤46 g/m²/h were used to diagnose DED participants with ADDE. Conversely, EDE was diagnosed by a TMH of ≥0.2 mm and LLT of grade <3, lower/upper MGD of >29% or tear evaporation rate of >46 g/m²/h. The TMH cut-off value was consistent with that of Uchida et al. (Uchida *et al.*, 2007). The cut-off values for LLT, MGD and tear evaporation were also in good agreement with previous studies associating LLT of ≥ 75 nm (Blackie *et al.*, 2009), meibomian gland dropouts

of $30.1 \pm 17.4\%$ (Pult, 2018) and tear evaporation rates of 48.85 ± 23.47 g/m²/h (Tomlinson, Doane and McFadyen, 2009) to non-DED individuals.

The study showed that EDE was the most common form of DED, with a prevalence rate of 62.8%. The findings were in accordance with previous research (Albietz, 2000; Rege *et al.*, 2013; Asiedu, Dzasimatu and Kyei, 2018) and suggest that, in a major cohort of DED participants, the aqueous layer may be less compromised compared to the lipid layer of the tear film.

Increased tear evaporation was most commonly seen in 62.2% of EDE participants followed by upper MGD, decreased LLT and lower MGD, found in 48.0%, 30.6% and 25.5% EDE participants, respectively. From the results, tear evaporation can be highlighted as a more important indicative subclassification sign for EDE than LLT and MGD. However, it should be mentioned that, because there was a significant positive relationship between tear evaporation and TMH, tear evaporation rates might have been confounded by watery eyes, which, in turn, has been considered a compensatory mechanism in DED (Arita *et al.*, 2015). Moreover, high tear evaporation rates might have arisen from additional evaporation coming from the eyes' surrounding skin (Wolffsohn *et al.*, 2017).

It is worthy to note that 17.3% DED participants showed no obvious signs of ADDE and EDE. Unclassified DED might have exhibited EDE due to poor lipid expression or quality, not assessed in this study. On the other hand, because the tear film is variable over time, it might be possible that the lack of evidence of LLT, TMH and tear evaporation was caused by stochastic or measurement noise.

Unclassified cases of DED have been observed in previous studies attempting DED classification (Lemp *et al.*, 2012; Asiedu, Dzasimatu and Kyei, 2018). Asiedu et al.

have reported 23.8% unclassified symptomatic DED participants and 25% unclassified asymptomatic DED participants (Asiedu, Dzasimatu and Kyei, 2018). Lemp et al. also could not categorise 29% of the study participants into evaporative, aqueous-deficient or mixed DED (Lemp *et al.*, 2012). Nevertheless, the percentage of unclassified DED subtypes in the present study was lower (17.3%), suggesting that the used differential diagnosis was more efficient. Having based the disease classification on the TFOS DEWS II criteria might have influenced positively the results.

Notably, the differential DED diagnosis used includes a composite of subclassification tests. Significant associations between most subclassification tests, including MGD, tear evaporation and TMH, underline their combined diagnostic contributions. However. for ADDE, only one non-invasive clinical sign has been proposed (Wolffsohn *et al.*, 2017). LLT was not significantly associated with any other subclassification sign and hence its use is essential for diagnosing EDE.

Coexistence of both DED subtypes has been associated with increasing disease severity (Craig *et al.*, 2017). A severity matrix was proposed (Bron *et al.*, 2007), however, due to the apparent severity differences in an individual in different elements of the matrix, DED severity has been rather assessed from the participants' perspective by using symptom self-reports (Wolffsohn *et al.*, 2017). Sullivan et al.. (2010) proposed severity was a continuum rather than distinct grades (Sullivan *et al.*, 2010). This approach is supported by the poor associations between the subclassification test and DED symptoms, as only TMH and DEQ-5 scores were significantly related to each other.

116

Overall, the primary goal of DED treatment and management is to reconstruct the homeostasis of the tear film (Jones *et al.*, 2017). Artificial tears of different compositions account the mainstay of DED therapy (Jones *et al.*, 2017). Punctual plugging or tear stimulation, via topical medications, heating eyebags or essential fatty acid supplementation, are also of growing interest (Jones *et al.*, 2017). Other treatment options focus on lid hygiene or avoiding DED risk factors (Jones *et al.*, 2017). One study has shown that subclassification of DED can help to identify effectiveness of different formulations of artificial tears in individuals with DED (Essaa, 2015). Further studies are needed to test other products using the new approach and cut-offs developed in this study.

Several large-scale population-based studies have associated DED to different risk factors (Stapleton *et al.*, 2017), but not specifically to DED subtypes. In the present study, EDE was found to be related to aging, whereas ADDE was to contact lens wear and computer use. The nature of association between EDE and aging can be attributed by functional and structural changes of meibomian glands occurring with increasing age (Sharma and Hindman, 2014). DED symptoms that are related to decreased TMH have been previously observed in office workers using soft or rigid contact lenses and spending more than four hours engaged with computer use (Kojima *et al.*, 2011), which, in turn, explains the rationale behind the obtained ADDE risk factors.

In conclusion, the study has demonstrated that EDE, as characterized by signs of LLT, tear evaporation and MGD, is far more common than ADDE in Birmingham residents. Accordingly. the first treatment of choice for DED individuals identified to have the EDE form of the disease would be those which enhance the lipid layer of the tear film. Reducing the use of contact lenses and computer might also be more

advisable for DED individuals identified to have the ADDE form. Further research, applying the differential diagnosis used, is of interest for expanding the knowledge on DED subtypes in different study populations.

6. CHAPTER 6: IMPROVING DRY EYE EPIDEMIOLOGICAL RESEARCH

6.1 Overview

The present chapter is a collaborative study between Aston University (Birmingham, UK) and the University of Auckland (Auckland, New Zealand) (Wolffsohn *et al.*, 2018). It discusses a cost-effective diagnostic method for DED by ocular symptoms and signs.

6.2 Introduction

Different epidemiological study designs exit to investigate the burden of DED and subsequently plan and allocate health sources (Mann, 2003; Stapleton *et al.*, 2017). The study designs are divided into experimental and observational and can be further sub-categorised as cross-sectional studies, case-control studies, and cohort studies (Mann, 2003).

Observational cross-sectional studies are the most commonly used approach in the epidemiology of DED, whereby the disease prevalence and risk factors are evaluated at one point in time (Stapleton *et al.*, 2017). However, common inferences are difficult to make since the studies have relied on different disease diagnoses (Stapleton *et al.*, 2017).

In view to standardization, the TFOS DEWS II recommended a global diagnosis of the disease (Wolffsohn *et al.*, 2017). This identifies an individual as having DED by a positive result to a validated questionnaire (either the DEQ-5 or OSDI test) and the presence of one ocular sign (determined either by assessing the NIKBUT, tear osmolarity or ocular surface staining) (Wolffsohn *et al.*, 2017).

The TFOS DEWS II criteria has unfortunately not been used in large-scale population studies yet. Cost and limited accessibility of the required clinical instrumentation might have been a barrier to its use. In fact, researchers' tendency is often to move away from high-cost diagnostic techniques towards economical diagnoses of DED that are commercially available in all parts of the world (Savini *et al.*, 2008).

Recently, the Optrex[™] dry eye blink test has been advertised as a free rapid selfadministered online test that indicates whether an individual might suffer from DED. Like the NIKBUT, it assesses the stability of the tear film, but based on the time that takes for the eyes to sense ocular discomfort when staring up to 15 seconds at a digital screen and without blinking.

The present study is the first to validate the diagnostic ability of the Optrex[™] dry eye blink test. The aim of the study was to propose a cost-effective DED diagnostic method involving the DEQ-5, OSDI and Optrex[™] dry eye blink test that conforms to the TFOS DEWS II criteria and is cost-effective for DED epidemiological research.

6.3 Methodology

The study was performed in accordance with the principles of the Declaration of Helsinki and approved by the institutional ethics committees of Aston University (Birmingham, UK) and University of Auckland (Auckland, New Zealand).

Study participants were recruited from both centres and enrolled after written consent inform. Participants were excluded if they had any active ocular diseases or were currently using ocular medications. The exclusion criteria did not include any further risk factors of DED as the study intended to involve participants of different DED severities in order to reduce spectrum bias (Wolffsohn *et al.*, 2017).

All investigators received substantial clinical training prior to the study. Ocular symptoms were gathered using both DEQ-5 and OSDI questionnaires. In the following order, tear osmolarity, NIKBUT, the Optrex[™] dry eye blink test and ocular surface staining (including the cornea, conjunctiva and upper/lower LWE) were assessed on participants' right eye.

Clinical assessment was conducted as described in Chapter 2. However, subjective methods, including two four-point grading scale (Korb *et al.*, 2005; Whitcher *et al.*, 2010) (Table 6.1), were used to score ocular surface staining. The rationale behind this amendment was to ease the clinical study performance between both sites.

Table 6.1 Ocular surfa	ace grading scales used	ł
------------------------	-------------------------	---

Ocular surface grading scales	Scores
Whitcher et al 2010	score 0: 0-9 corneal/conjunctival staining dots
	score 1: 10-32 corneal/conjunctival staining dots
	score 2: 33-100 corneal/conjunctival staining dots
	score 3: >100 corneal/conjunctival staining dots
Korb et al 2005	score 0: <2 mm long and 25% wide LWE staining
	score 1: 2 – 4 mm long and 25 – 49% wide LWE staining
	score 2: 5 – 9 mm long and 50 – 74 % wide LWE staining
	score 3: > 10 mm long and ≥ 75% wide LWE staining

The Optrex[™] dry eye blink test was displayed on a 14-inch computer monitor (Lenovo[™] ThinkPad® T470p) at approximately 40 cm (Figure 6.1). The gaze angle varied depending on participants height and sitting posture.



Figure 6.1 The Optrex[™] dry eye blink test (reproduced with permission of Reckitt Benckiser)

Study participants were asked to deliver two non-force blinks and hold their blinking after having started the Optrex[™] dry eye blink test. Testing with the Optrex[™] dry eye blink test ended either after 15 seconds or when ocular discomfort was felt. Three consecutive measurements were taken, and the mean was recorded.

NIKBUT and Optrex[™] dry eye blink test readings were compared to understand the level of interchangeability of both tear film stability measurements. Also, correlations of DED signs and symptoms with the Optrex[™] dry eye blink test were examined.

DED was defined by the TFOS DEWS II criteria (Wolffsohn *et al.*, 2017), more specifically, by a DEQ-5 score of \geq 6 or OSDI score of \geq 13 and either one of the following:

- A NIKBUT of <10 s.
- A tear film osmolarity of ≥308 mOsm/L or an intraocular osmolarity difference of ≥8 mOsm/L, or

 Ocular surface staining described by >5 corneal spots, >9 conjunctival spots or the presence of LWE at the inner eyelid margin (≥25% wide and ≥2mm long).

The diagnostic performance of the OptrexTM dry eye blink test was examined against the TFOS DEWS II criteria. An OptrexTM dry eye blink test cut-off score was subsequently determined. The cut-off value together with a DEQ-5 score of \geq 6 or OSDI score of \geq 13 were adopted to further define DED by ocular symptoms and signs following TFOS DEWS II diagnostic recommendations.

6.3.1 Power calculation

The required sample size of eighty-five participants was calculated using following formula: $n = [(Z_{\alpha} + Z_{\beta})/(0.5xln[(1+r)/(1-r)]]^2 +3$, where n was the sample size, α the rate of false positives of DED, Z_{α} the standard deviation of α , β the rate of false negatives of DED, Z_{β} the standard deviation of β and r the correlation coefficient (Hulley *et al.*, 2013). The sample size was determined to seek a sizeable correlation coefficient of at least 0.30 between the OptrexTM dry eye blink test and NIKBUT (Jacob Cohen, 1992). Conventional values of α and β were used (α , 0.05; β , 0.20).

6.3.2 Data processing

Because of the Optrex[™] dry eye blink test having a maximum duration of 15s, NIKBUT readings of >15 s were capped into values of 15s. Moreover, for statistical purposes, both Optrex[™] dry eye blink test and NIKBUT readings underwent logarithmic (log) transformation.

6.3.3 Statistical analysis

Statistical analysis was performed using SPSS version 23 (IBM Corp. 2015). Except for tear film stability measurements, DED symptoms and signs were found to be not normally distributed using Kolmogorov-Smirnov tests.

Measurements of Optrex[™] dry eye blink test and NIKBUT were compared using paired t and F tests. Correlations of DED signs and symptoms with the Optrex[™] dry eye blink test were evaluated with Spearman correlation coefficients. For NIKBUT though, Pearson correlation coefficients were used.

A receiver operative characteristics (ROC) curve of the OptrexTM dry eye blink test was illustrated. The ROC curve was constructed by plotting the rate of true positives against the rate of false positives of DED by the TFOS DEWS II criteria for every possible OptrexTM dry eye blink test value. The area under the ROC curve determined the diagnostic ability of the OptrexTM dry eye blink test. Younden's J indexes (computed as $J = \frac{true positives}{true positives + false negatives} + \frac{true negatives}{true negatives + false positives} - 1 =$ *sensitivity* + *specificity* - 1) were calculated for all OptrexTM dry eye blink test values. The OptrexTM dry eye blink test value with the greatest Younden's J index (and hence with maximal diagnostic sensitivity and specificity) was defined as the cut-off score.

Finally, both diagnostic sensitivity and specificity of the proposed DED diagnostic method involving the Optrex[™] dry eye blink test and DEQ-5 or OSDI questionnaire were evaluated.

6.4 Results

Eighty-seven participants (38 \pm 17 years, 44 females) were included in the present study (Table 6.2). Of these, 71% fulfilled the TFOS DEWS II diagnostic criteria of DED.

Table 6.2	Tear film and ocula	ar surface characteristics	of the study	v participants

Characteristics	n	mean ± SD/ median (range)			
DEQ-5 score	87	8.72 ± 4.46			
OSDI score	87	19.19 ± 15.85			
Highest tear film osmolarity value (mOsm/L)	87	305.08 ± 13.57			
Interocular osmolarity difference (mOsm/L)	87	8.71 ± 7.40			
NIKBUT (s)	87	9.52 ± 7.33			
Optrex™ dry eye blink test (s)	87	9.83 ± 3.95			
Corneal staining score	87	0 (0-1)			
Conjunctival staining score	87	0 (0-1)			
Upper LWE score	87	0 (0-0)			
Lower LWE score	87	0 (0-2)			
DEQ-5 = 5-item Dry Eye Questionnaire, OSDI = Ocular Surface Disease Index. NIKBUT = non-invasive					
Keratograph tear break-up time. LWE = lid wiper epitheliopat	hy. n = sam	ple size. SD = standard			
deviation.	-	-			

Measurements of the Optrex[™] dry eye blink test and NIKBUT were not significantly different (p-value, 0.150). Nevertheless, the Optrex[™] dry eye blink test showed a significantly narrower distribution compared to that of the NIKBUT (p-value, <0.001).

Among all DED parameters, significant correlations with the Optrex[™] dry eye blink test were observed with OSDI, DEQ-5, NIKBUT, conjunctival staining and lower LWE (Table 6.3).

Table 6.3	Correlations of DED symptoms and signs with the Optrex [™] dry eye blink test
-----------	--

	Corre	elation with Optrex [™] dry eye	e blink test
Characteristics	n	Correlation coefficient	p-value
DEQ-5 score	87	-0.364	0.004**
OSDI score	87	-0.290	0.006**
Highest tear film osmolarity value (mOsm/L)	87	-0.066	0.55
Interocular osmolarity difference (mOsm/L)	87	-0.010	0.93
NIKBUT (s)	87	0.470	0.001***
Corneal staining score	87	-0.163	0.13
Conjunctival staining score	87	-0.237	0.03*
Upper LWE score	87	0.018	0.87
Lower LWE score	87	-0.251	0.02*
DEQ-5 = 5-item Dry Eye Questionnaire. OSDI	= Ocula	r Surface Disease Index. NIKE	3UT = non-invasive
Keratograph tear break-up time. LWE = lid wip	er epithe	eliopathy. * p-value ≤0.05. ** p	-value ≤0.01. *** p-

value ≤ 0.001 . n = sample size. SD = standard deviation.

The diagnostic ability of the Optrex[™] dry eye blink test was significant moderately strong (p-value, <0.001), showing an area under the ROC curve of 0.77 (Figure 6.2).



Figure 6.2 ROC curve assessing the diagnostic ability of the Optrex[™] dry eye blink test

The greatest Younden's J index of 0.54 was found with an $Optrex^{TM}$ dry eye blink test value of ≤ 10 s. The $Optrex^{TM}$ dry eye blink test value presented a sensitivity of 66% and specificity of 88%.

DED diagnosis by an OptrexTM dry eye blink test of ≤ 10 s and either by DEQ-5 score of ≥ 6 or OSDI score of ≥ 13 presented a diagnostic sensitivity and specificity of 100% and 54%, respectively (Table 6.4).
 Table 6.4
 DED outcomes by the proposed DED diagnostic method and the TFOS DEWS II criteria

DED outcomes of the proposed diagnostic	DED outcomes	of the TFOS DEWS II criteria	
method	Negative	Positive	Total
Negative	25	21	46
Positive	0	41	41
Total	25	62	87

6.5 Discussion

Researchers take specially care in balancing the costs and diagnostic accuracy of clinical tests for DED (Savini *et al.*, 2008). In the present study, a rapid online test assessing tear film stability (the OptrexTM dry eye blink) was validated to further propose a DED diagnostic method by ocular symptoms and signs. The proposed method involved the use of the DEQ-5, OSDI and OptrexTM dry eye blink test. It should serve as a simple self-administered DED diagnostic method that conforms to the TFOS DEWS II criteria (Wolffsohn *et al.*, 2017) and is cost-effective for DED epidemiological research.

The results showed that NIKBUT and Optrex's dry eye blink test readings were similar, enforcing the idea that the Optrex's dry eye blink test constitutes a feasible alternative method for assessing tear film stability. It is important to note, however, that the Optrex's dry eye blink test had a significantly narrower distribution than the NIKBUT, even when NIKBUT values were capped at 15s (Wolffsohn *et al.*, 2018). Hence the disagreement between both tests would probably increase beyond this point (Wolffsohn *et al.*, 2018).

As expected, there was a significant positive correlation between the NIKBUT and Optrex's Dry Eye Blink test. It is believed that any tear disruption results in a transient and localised tear osmolarity increase that stimulates nociceptors responsible for driving the blink reflex to replenish the tear film (Varikooty and Simpson, 2009). If tear disruptions account as well as a direct trigger to ocular discomfort, it would be

expected that the correlation between the NIKBUT and Optrex's Dry Eye Blink test would have been greater than moderate (Wolffsohn *et al.*, 2018). Accordingly, the results suggest that symptom self-report might have been influenced by patients' high tolerance to pain (Wolffsohn *et al.*, 2018).

Higher Optrex's dry eye blink test readings were also significantly associated with decreasing ocular symptoms, either assessed by the OSDI or DEQ-5 questionnaire, and conjunctival and lower LWE staining. The associations are supported by current literature (Yeniad, Beginoglu and Bilgin, 2010; Zhang *et al.*, 2017). Other DED signs showed similarly negative trends with higher Optrex's dry eye blink test readings but without statistical significance.

Generally, the diagnostic ability of a test can be described by its sensitivity and specificity (Lalkhen and McCluskey, 2008). The sensitivity and specificity are measures that describe how well a test correctly identified those with and without a disease, respectively (Lalkhen and McCluskey, 2008). A trade-off typically exists between the two measures with the precise values for each selected cut-off value for a positive diagnosis (Lalkhen and McCluskey, 2008). In the present study, the OptrexTM Dry Eye Blink test showed a significant moderately strong diagnostic ability when performed against the TFOS DEWS II criteria. The diagnostic ability was given graphically by the area under the ROC curve of 0.77, showing a maximal sensitivity and specificity for an OptrexTM Dry Eye Blink test cut-off value of ≤ 10 s. Interestingly, the cut-off value is close to the NIBUT cut-off value considered in the TFOS DEWS II criteria (Wolffsohn *et al.*, 2018).

Because the last updated definition of DED describes the disease by a combination of symptoms and signs, the Optrex[™] Dry Eye Blink test of <10s on its own can only

be considered as an indicative diagnostic method for DED. The TFOS DEWS II recommended to globally diagnose DED based on ocular symptoms gathered with the DEQ-5 or OSDI questionnaire and either one ocular sign of tear instability, tear hyperosmolarity or ocular surface staining (Wolffsohn *et al.*, 2017). In the present study, DED diagnosis by an OSDI score of ≥13 or DEQ-5 score of ≥6 and OptrexTM Dry Eye Blink test of ≤10s was 100% sensitive and 54% specific to the TFOS DEWS II. High sensitivity is clearly important to effectively detect individuals with DED (Lalkhen and McCluskey, 2008), and hence the proposed diagnostic method becomes attractive to be used in DED research. It may be used as a screening tool as it is rapid and simple to administer in both non-clinical and clinical settings.

In conclusion, the Optrex[™] Dry Eye Blink test combined with symptoms self-reports works as a cost-effective diagnostic method for DED that can be useful for DED research, including future epidemiological research about the disease.

7. CHAPTER 7: DISCUSSION AND CONCLUSIONS

The epidemiology of dry eye disease (DED) aims to answer basic research questions – How many people are affected by the disease? Which are the risk factors for the disease? Which are the care health sources needed? These questions, however, encompass enormous methodological and interpretive complexity.

Researchers have assessed DED prevalence and risk factors differently, using a range of disease diagnoses and risk factor assessments. The inconsistencies across published cross-sectional studies have created barriers to interpreting the results. Moreover, the heterogeneity in the characteristics of the population studied has further complicated the research.

A thorough evaluation of existing differences in epidemiological research on DED is essential. In providing such information, researchers would gain a better understanding on DED epidemiology and identify research gaps that need to be filled for future research improvement.

This thesis initially includes a literature review of current DED prevalence rates and risk factors (Chapter 1). It extracted information of cross-sectional studies that have been published since the last decade, emphasizing on the DED diagnostic methods used, the characteristics of the population studied and logistic regression analyses of DED risk factors.

Given the limitations of the current state of epidemiological literature on DED, the overarching goal of this thesis was to perform a well-standardized DED crosssectional study. Accordingly, a study methodology following global Tear Film Ocular Surface Dry Workshops II (TFOS DEWS II) diagnostic recommendations of the

130

disease published in 2017 was considered (Chapter 2). This should ensure comparability with future reports.

Prevalence rates of DED (Chapter 3) and DED subtypes (Chapter 5) were estimated among a single population in the UK. Potential risk factors of DED (Chapter 4) and DED subtypes (Chapter 5) were also assessed using a self-developed evidencebased dry eye risk factor survey (DERFS). Lastly, a simple, cost-effective and selfadministered DED diagnostic criteria by the TFOS DEWS II diagnostic criteria was developed (Chapter 2).

A summary of the main findings of this thesis by chapter is detailed below:

- Chapter 1. This chapter reviewed prevalence rates and risk factors reported in recent epidemiological studies of DED. The prevalence of DED was found to range from 1.3% to 52.9%. Identified risk factors for DED were either modifiable or non-modifiable and included age, sex, health conditions/problems, ambient conditions, contact lens wear, VDT use, diet and sleep duration. The chapter highlighted that the reported prevalence rates and risk factors of the disease varied with the diagnostic methods used and the characteristics of the population studied. DED diagnosis was based either on the WHS criteria, symptoms, signs or both symptoms and signs. Asians were the most commonly studied population in the epidemiology of the disease.
- Chapter 2. Having noted the influence of the diagnostic methodology (Chapter 1), the next key aspect was to optimise this based on the current consensus around diagnosis, but also to consolidate previously identified risk factors into a simple to complete questionnaire as no suitable 'validated' form currently existed.

Hence Chapter 2 included a broad summary of the study methodology used for this thesis. DED questionnaires, including the Ocular Surface Disease Index (OSDI) and Dry Eye Questionnaire-5 item (DEQ-5), and measurements of tear osmolarity, tear evaporation, lipid layer thickness (LLT), tear meniscus height (TMH), non-invasive Keratograph tear break-up time (NIKBUT), ocular surface staining and meibomian gland dysfunction (MGD) were considered. The use of these tests for the initial and differential diagnosis of DED is supported by previous clinical research. According to the TFOS DEWS II they account together the most efficient battery to diagnose DED as per the last updated disease definition and classification. Moreover, the DERFS questionnaire was used to assess potential risk factors for DED. The survey was developed based on current evidence on DED risk factors discussed in Chapter 1.

• Chapter 3. Having clarified the appropriate methodology for studying DED epidemiological estimates and developed the DERFS (Chapter 2), an ethical opinion and governance procedure for the study was sought and granted allowing a cross-sectional study to commence. As such. Chapter 3 determined the prevalence of DED at a single point in time. The diagnostic criteria used was the TFOS DEWS II criteria. The study population included female and male Birmingham (UK) residents aged 18 to 88 years-old. These were stratified in recruitments so that they were representative to the Birmingham population census of 2016. The prevalence of DED varied with the diagnostic method used, ranging from to 19.7% to 56.4, and was significantly higher where ocular symptoms were assessed with the DEQ-5 than with the OSDI test. Notably, the study was the first in estimating the prevalence of DED by the TFOS DEWS II criteria. The estimates obtained ranged similar to those found in Chapter 1.

- Chapter 4. Having assessed the prevalence of DED population by the TFOS DEWS II criteria. DED and non-DED participants were identified to allow risk factors to be assessed from the DERFS. Sex, age, education, smoking habits, contact lens wear, health conditions/problems, computer use, sleep quality and outdoor activity were found to be significant risk factors of DED. Amongst these, sex and health conditions/problems had the greatest statistical significance. The results were in accordance with other studies reporting risk factors of DED by either the WHS criteria, symptoms, signs or symptoms and signs.
- Chapter 5. DED is subclassified as having aqueous deficient (ADDE) and evaporative (EDE) forms. The forms are intended to inform management decisions and hence are important to be clinically distinguished. Unfortunately, a review of the literature acknowledged no apparent consistency in the subclassification of DED. To this purpose, Chapter 5 proposed a differential diagnosis of ADDE and EDE. The differential diagnosis was in line with current TFOS DEWS II diagnostic recommendations. DED and non-DED participants were identified in Chapter 3. ADDE was characterized by a reduction in TMH; conversely, EDE was defined by signs of LLT, tear evaporation and MGD. Diagnostic cut-off values of the subclassification tests, that were as specific as possible in discriminating ADDE and EDE, were determined from clinical data of healthy non-DED participants. Whereas older DED participants were at major risk of ADDE. DED participants using computer and contact lenses were at major risk of EDE. Prevalence rates of 9.0% for ADDE. 62.8% for EDDE and 10.9% for both ADDE and EDE were estimated. This was in accordance with previous research reporting EDE as the more common form of DED. The approach taken will allow

clinicians to make a more informed choice for an initial DED management for individual patients. although further research is needed to warrant advocating this.

Chapter 6. So far, the chapters involved complex clinical testing which is not available to many eye care practitioners and other health care professionals, such as pharmacists and general medical practitioners, who are often approached by patients about DED symptoms and need to be able to make an informed differential diagnosis. Chapter 6 proposed a self-administered diagnostic method for DED that conformed to the TFOS DEWS II criteria. DED was diagnosed by an OSDI score of ≥13 or DEQ-5 score of ≥6 and Optrex[™] Dry Eye Blink test of ≤10s. This last test assessed the tear film stability based on the time that takes for the eyes to sense ocular discomfort. The proposed DED diagnosis was found to be 100% sensitive and 54% specific to the TFOS DEWS II diagnostic criteria. The diagnostic method should help patients in empowering their selfmanagement of symptoms with the caveat that, if these persist, a full examination with a suitably equipped and skilled eye-care professional should be sought. Moreover, the diagnostic method could be used for DED epidemiological research, as it is rapid and cost-effective and hence reduces both cost and time boundaries that are usually faced in the disease epidemiology.

At the first of its kind, this thesis serves as an insight into prevalence and risk factors of DED and DED subtypes of a single population in the UK, following current global diagnostic recommendations of the TFOS DEW II.

The main limitations of this thesis are intrinsic to the study design. The association and certainty of the obtained cross-sectional risk factors of DED and DED subtypes 134

would be stronger if a longitudinal study is conducted. Moreover, both the prevalence rates and risk factors of DED and DED subtypes are specific to the Birmingham, UK population.

In view to future directions in DED research, the author has collected equivalent data in Valencia, Spain. The developed protocol was also facilitated to other colleagues of the European Dry Eye Network (EDEN) and researchers based in New Zealand, China and Mexico to further allow similar data collection and hence future reliable and comparable research data on the prevalence and sub-classification of DED.

8. REFERENCES

Abusharha, A. A. and Pearce, E. I. (2013) 'The effect of low humidity on the human tear film', *Cornea*. doi: 10.1097/ICO.0b013e31826671ab.

Abusharha, A. A., Pearce, E. I. and Fagehi, R. (2016) 'Effect of Ambient Temperature on the Human Tear Film', *Eye and Contact Lens.* doi: 10.1097/ICL.000000000000210.

Ahn, J. M. *et al.* (2014) 'Prevalence of and risk factors associated with dry eye: The Korea National Health and Nutrition Examination Survey 2010-2011', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2014.08.021.

Albietz, J. M. (2000) 'Prevalence of dry eye subtypes in clinical optometry practice', *Optometry and Vision Science*. doi: 10.1097/00006324-200007000-00010.

Argilés, M. *et al.* (2015) 'Blink rate and incomplete blinks in six different controlled hard-copy and electronic reading conditions', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.15-16967.

Arita, R. *et al.* (2008) 'Noncontact Infrared Meibography to Document Age-Related Changes of the Meibomian Glands in a Normal Population', *Ophthalmology*. doi: 10.1016/j.ophtha.2007.06.031.

Arita, R. *et al.* (2015) 'Increased tear fluid production as a compensatory response to meibomian gland loss: A multicenter cross-sectional study', *Ophthalmology*. doi: 10.1016/j.ophtha.2014.12.018.

Arya, R., Antonisamy, B. and Kumar, S. (2012) 'Sample size estimation in prevalence studies', *Indian Journal of Pediatrics*. doi: 10.1007/s12098-012-0763-3.

Asiedu, K., Dzasimatu, S. K. and Kyei, S. (2018) 'Clinical subtypes of dry eye in youthful clinical sample in Ghana', *Contact Lens and Anterior Eye*. doi: 10.1016/j.clae.2018.10.005.

Ayaki, M. *et al.* (2016) 'Sleep and mood disorders in dry eye disease and allied irritating ocular diseases', *Scientific Reports*. doi: 10.1038/srep22480.

Baudouin, C. *et al.* (2010) 'Preservatives in eyedrops: The good, the bad and the ugly', *Progress in Retinal and Eye Research*. doi: 10.1016/j.preteyeres.2010.03.001.

Belmonte, C. *et al.* (2017) 'TFOS DEWS II Pain and sensation report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.05.002.

Belmonte, C., Acosta, M. C. and Gallar, J. (2004) 'Neural basis of sensation in intact and injured corneas', *Experimental Eye Research*. doi: 10.1016/j.exer.2003.09.023.

Bhargava, R. *et al.* (2015) 'Oral omega-3 fatty acids treatment in computer vision syndrome related dry eye', *Contact Lens and Anterior Eye.* doi: 10.1016/j.clae.2015.01.007.

Blackie, C. A. *et al.* (2009) 'The Relationship Between Dry Eye Symptoms and Lipid Layer Thickness', *Cornea*. doi: 10.1097/ico.0b013e318191b870.

Bron, A. J. *et al.* (2002) 'Using osmolarity to diagnose dry eye: a compartmental hypothesis and review of our assumptions', in *Advances in Experimental Medicine and Biology*, pp. 1087–95.

Bron, A. J. *et al.* (2004) 'Functional aspects of the tear film lipid layer', *Experimental Eye Research*. doi: 10.1016/j.exer.2003.09.019.

Bron, A. J. *et al.* (2007) 'Methodologies to Diagnose and Monitor Dry Eye Disease', *The Ocular Surface*. doi: 10.1590/S0004-27492011000500016.

Bron, A. J. *et al.* (2014) 'Rethinking dry eye disease: a perspective on clinical implications', *The Ocular Surface*, 12 (2S), pp. S1-31.

Browner, W. S. and Newman, T. B. (1986) 'Confidence intervals.', *Annals of internal medicine*.

Calonge, M. *et al.* (2018) 'Controlled Adverse Environment Chambers in Dry Eye Research', *Current Eye Research*. doi: 10.1080/02713683.2017.1420197.

Chalmers, R. L., Begley, C. G. and Caffery, B. (2010) 'Validation of the 5-Item Dry Eye Questionnaire (DEQ-5): Discrimination across self-assessed severity and aqueous tear deficient dry eye diagnoses', *Contact Lens and Anterior Eye.* doi: 10.1016/j.clae.2009.12.010.

Chen, Q. *et al.* (2017) 'Effects of tear film lipid layer thickness and blinking pattern on tear film instability after corneal refractive surgery', *Cornea*. doi: 10.1097/ICO.000000000001207.

Chu, C. A., Rosenfield, M. and Portello, J. K. (2014) 'Blink patterns: Reading from a computer screen versus hard copy', *Optometry and Vision Science*. doi: 10.1097/OPX.00000000000157.

Craig, J. P. *et al.* (2017) 'TFOS DEWS II Definition and Classification Report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.05.008.

Craig, J. P. and Tomlinson, A. (1997) 'Importance of the lipid layer in human tear film stability and evaporation', *Optometry and Vision Science*. doi: 10.1097/00006324-199701000-00014.

Daniel Nelson, J. *et al.* (2011) 'The international workshop on meibomian gland dysfunction: Report of the definition and classification subcommittee', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.10-6997b.

Doane, M. G. (1994) 'Abnormalities of the Structure of the Superficial Lipid Layer on the in Vivo Dry-Eye Tear Film.', in Sullivan D.A. (ed.) *Lacrimal Gland, Tear Film, and Dry Eye Syndromes.* USA: Springer, pp. 489–493.

Doughty, M. J. et al. (2004) 'Visualisation of "Marx's line" along the marginal eyelid conjunctiva of human subjects with lissamine green dye', *Ophthalmic and*

Physiological Optics. doi: 10.1046/j.1475-1313.2003.00160.x.

Drouault-Holowacz, S. *et al.* (2009) 'Antioxidants intake and dry eye syndrome: A crossover, placebo-controlled, randomized trial', *European Journal of Ophthalmology*.

Efron, N. *et al.* (2013) 'The TFOS International Workshop on Contact Lens Discomfort: Report of the contact lens interactions with the ocular surface and adnexa subcommittee', *Investigative Ophthalmology and Visual Science.* doi: 10.1167/iovs.13-13187.

Efron, N. *et al.* (2016) 'Lid wiper epitheliopathy', *Progress in Retinal and Eye Research*. doi: 10.1016/j.preteyeres.2016.04.004.

Essaa, L. (2015) What is the optimum artificial treatment for dry eye disease?

Feenstra, R. P. G. and Tseng, S. C. G. (1992) 'Comparison of Fluorescein and Rose Bengal Staining', *Ophthalmology*. doi: 10.1016/S0161-6420(92)31947-5.

Finis, D. *et al.* (2015) 'Evaluation of Meibomian Gland Dysfunction and Local Distribution of Meibomian Gland Atrophy by Non-contact Infrared Meibography', *Current Eye Research*. doi: 10.3109/02713683.2014.971929.

Galor, A. *et al.* (2015) 'Dry eye symptoms align more closely to non-ocular conditions than to tear film parameters', *British Journal of Ophthalmology*. doi: 10.1136/bjophthalmol-2014-306481.

Galor, A. *et al.* (2018) 'The Association of Dry Eye Symptom Severity and Comorbid Insomnia in US Veterans', *Eye & contact lens*. doi: 10.1097/ICL.00000000000349.

Gatell-Tortajada, J. (2016) 'Oral supplementation with a nutraceutical formulation containing omega-3 fatty acids, vitamins, minerals, and antioxidants in a large series of patients with dry eye symptoms: Results of a prospective study', *Clinical Interventions in Aging*. doi: 10.2147/CIA.S98102.

Gokhale, M., Stahl, U. and Jalbert, I. (2013) 'In situ osmometry: Validation and effect of sample collection technique', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e31828aaf10.

González-García, M. J. *et al.* (2007) 'Exposure to a controlled adverse environment impairs the ocular surface of subjects with minimally symptomatic dry eye', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.06-0817.

Gothwal, V. K. *et al.* (2010) 'McMonnies questionnaire: Enhancing screening for dry eye syndromes with rasch analysis', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.09-4180.

Goto, E. *et al.* (2003) 'Computer-Synthesis of an Interference Color Chart of Human Tear Lipid Layer, by a Colorimetric Approach', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.03-0260.

Gowrisankaran, S. and Sheedy, J. E. (2015) 'Computer vision syndrome: A review',

Work. doi: 10.3233/WOR-152162.

Gowrisankaran, S., Sheedy, J. E. and Hayes, J. R. (2007) 'Eyelid squint response to asthenopia-inducing conditions', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e3180dc99be.

Green-Church, K. B. *et al.* (2011) 'The international workshop on meibomian gland dysfunction: Report of the subcommittee on tear film lipids and lipid-protein interactions in health and disease', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.10-6997d.

Guillemin, I. *et al.* (2012) 'Appraisal of patient-reported outcome instruments available for randomized clinical trials in dry eye: Revisiting the standards', *Ocular Surface*. doi: 10.1016/j.jtos.2012.01.007.

Guillon, J. P. (1982) 'Tear film photography and contact lens wear', *Journal of the British Contact Lens Association*. doi: 10.1016/S0141-7037(82)80022-0.

Guillon, J. P. (1998) 'Non-invasive tearscope plus routine for contact lens fitting', *Contact Lens and Anterior Eye*. doi: 10.1016/S1367-0484(98)80035-0.

Guo, B. *et al.* (2010) 'Prevalence of dry eye disease in Mongolians at high altitude in China: The Henan eye study', *Ophthalmic Epidemiology*. doi: 10.3109/09286586.2010.498659.

Hamrah, P. *et al.* (2011) 'Optimizing evaluation of Lissamine Green parameters for ocular surface staining', *Eye*. doi: 10.1038/eye.2011.184.

Han, S. B. *et al.* (2011) 'Prevalence of dry eye disease in an elderly Korean population', *Archives of Ophthalmology*. doi: 10.1001/archophthalmol.2011.78.

Hashemi, H. *et al.* (2014) 'Prevalence of dry eye syndrome in an adult population', *Clinical and Experimental Ophthalmology*. doi: 10.1111/ceo.12183.

Himebaugh, N. L. (2009) 'Blinking and tear break-up during four visual tasks', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e318194e962.

Holly, F. J. (1985) 'Physical chemistry of the normal and disordered tear film.', *Transactions of the ophthalmological societies of the United Kingdom*.

Holly, F. J. and Lemp, M. A. (1977) 'Tear physiology and dry eyes', *Survey of Ophthalmology*. doi: 10.1016/0039-6257(77)90087-X.

Hulley, S. B. et al. (2013) Designing clinical research: an epidemiologic approach. *4th ed. Philadelphia, PA: Lippincott Williams & Wilkins, Optometry Vision Science.* doi: 10.1097/00006982-199010000-00024.

Hwang, H. Bin and Kim, H. S. (2014) 'Phototoxic effects of an operating microscope on the ocular surface and tear film', *Cornea*. doi: 10.1097/ICO.000000000000000.

Hwang, S. H. *et al.* (2016) 'Potential importance of ozone in the association between outdoor air pollution and dry eye disease in South Korea', *JAMA Ophthalmology*. doi:

10.1001/jamaophthalmol.2016.0139.

Ipek, T. *et al.* (2018) 'Dry eye following cataract surgery: The effect of light exposure using an in-vitro model', *Contact Lens and Anterior Eye.* doi: 10.1016/j.clae.2017.11.003.

Jacob Cohen (1992) 'A Power Primer', *Psychological Bulletin*. doi: 10.1037/0033-2909.112.1.155.

Jansen, M. E. *et al.* (2010) 'Effect of contact lens wear and a near task on tear film break-up', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e3181d951df.

Jie, Y. *et al.* (2009) 'Prevalence of dry eye among adult Chinese in the Beijing Eye Study', *Eye*. doi: 10.1038/sj.eye.6703101.

Jones, L. *et al.* (2017) 'TFOS DEWS II Management and Therapy Report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.05.006.

Kasctsuwan, N. *et al.* (1999) 'Effect of topical ascorbic acid on free radical tissue damage and inflammatory cell influx in the cornea after excimer laser corneal surgery', *Archives of Ophthalmology*.

Keech, A., Senchyna, M. and Jones, L. (2013) 'Impact of time between collection and collection method on human tear fluid osmolarity', *Current Eye Research*. doi: 10.3109/02713683.2013.763987.

Kim, J. and Foulks, G. N. (1999) 'Evaluation of the effect of lissamine green and rose bengal on human corneal epithelial cells', *Cornea*. doi: 10.1097/00003226-199905000-00015.

Knop, E. *et al.* (2011) 'The international workshop on meibomian gland dysfunction: Report of the subcommittee on anatomy, physiology, and pathophysiology of the meibomian gland', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.10-6997c.

Kojima, T. *et al.* (2011) 'The impact of contact lens wear and visual display terminal work on ocular surface and tear functions in office workers', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2011.05.025.

Korb, D. R. *et al.* (1994) 'Tear film lipid layer thickness as a function of blinking', *Cornea*. doi: 10.1097/00003226-199407000-00012.

Korb, D. R. *et al.* (2002) 'Lid-wiper epitheliopathy and dry-eye symptoms in contact lens wearers.', *Cont Lens Anterior Eye.* doi: 10.1097/01.ICL.0000029344.37847.5A.

Korb, D. R. *et al.* (2005) 'Lid wiper epitheliopathy and dry eye symptoms', *Eye and Contact Lens*. doi: 10.1097/01.ICL.0000140910.03095.FA.

Korb, D. R. *et al.* (2008) 'An evaluation of the efficacy of fluorescein, rose bengal, lissamine green, and a new dye mixture for ocular surface staining', *Eye and Contact Lens*. doi: 10.1097/ICL.0b013e31811ead93.

Korb, D. R. *et al.* (2010) 'Prevalence of lid wiper epitheliopathy in subjects with dry eye signs and symptoms', *Cornea*. doi: 10.1097/ICO.0b013e3181ba0cb2.

Labetoulle, M. *et al.* (2019) 'Role of corneal nerves in ocular surface homeostasis and disease', *Acta Ophthalmologica*. doi: 10.1111/aos.13844.

Lalkhen, A. G. and McCluskey, A. (2008) 'Clinical tests: Sensitivity and specificity', *Continuing Education in Anaesthesia, Critical Care and Pain.* doi: 10.1093/bjaceaccp/mkn041.

Lemp, A. *et al.* (2007) 'The definition and classification of dry eye disease: report of the definition and classification of the Dry Eye WorkShop (2007)', *The Ocular Surface*. doi: 10.1080/09273940701486803.

Lemp, M. A. *et al.* (1970) 'The Precorneal Tear Film: I. Factors in Spreading and Maintaining a Continuous Tear Film Over the Corneal Surface', *Archives of Ophthalmology*. doi: 10.1001/archopht.1970.00990030091017.

Lemp, M. A. (1995) 'Report of the National Eye Institute/Industry workshop on Clinical Trials in Dry Eyes.', *The CLAO journal: official publication of the Contact Lens Association of Ophthalmologists, Inc.*

Lemp, M. A. *et al.* (2011) 'Tear osmolarity in the diagnosis and management of dry eye disease', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2010.10.032.

Lemp, M. A. *et al.* (2012) 'Distribution of aqueous-deficient and evaporative dry eye in a clinic-based patient cohort: A retrospective study', *Cornea*. doi: 10.1097/ICO.0b013e318225415a.

López-Miguel, A. *et al.* (2014) 'Dry eye exacerbation in patients exposed to desiccating stress under controlled environmental conditions', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2014.01.001.

Lu, P. *et al.* (2008) 'Dry eye syndrome in elderly tibetans at high altitude: A populationbased study in China', *Cornea*. doi: 10.1097/ICO.0b013e318165b1b7.

Machado, L. M., Castro, R. S. and Fontes, B. M. (2009) 'Staining Patterns in Dry Eye Syndrome: Rose Bengal Versus Lissamine Green', *Cornea*. doi: 10.1097/ico.0b013e3181930c03.

Malet, F. *et al.* (2014) 'Dry eye disease in French elderly subjects: The Alienor Study', *Acta Ophthalmologica*. doi: 10.1111/aos.12174.

Mann, C. J. (2003) 'Observational research methods. Research design II: cohort, cross sectional, and case-control studies', *Emergency Medicine Journal*. doi: 10.1136/emj.20.1.54.

Manning, F. J., Wehrly, S. R. and Foulks, G. N. (1995) 'Patient Tolerance and Ocular Surface Staining Characteristics of Lissamine Green versus Rose Bengal', *Ophthalmology*. doi: 10.1016/S0161-6420(95)30769-5.

Markoulli, M. et al. (2018) 'Imaging the Tear Film: A Comparison Between the
Subjective Keeler Tearscope-Plus[™] and the Objective Oculus® Keratograph 5M and LipiView® Interferometer', *Current Eye Research*. doi: 10.1080/02713683.2017.1393092.

Martín-Montañez, V. *et al.* (2016) 'Effect of environmental conditions on the concentration of tear inflammatory mediators during contact lens wear', in *Cornea*. doi: 10.1097/ICO.0000000000000960.

McDonald, J. E. (1969) 'Surface phenomena of the tear film', *American Journal of Ophthalmology*. doi: 10.1016/0002-9394(69)90008-7.

Mengher, L. S. *et al.* (1985) 'Effect of fluorescein instillation on the pre-corneal tear film stability', *Current Eye Research*. doi: 10.3109/02713688508999961.

Miljanović, B. et al. (2007) 'Impact of Dry Eye Syndrome on Vision-Related Quality of Life', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2006.11.060.

Mooi, J. K. *et al.* (2017) 'Minimising instilled volume reduces the impact of fluorescein on clinical measurements of tear film stability', *Contact Lens and Anterior Eye.* doi: 10.1016/j.clae.2017.01.004.

Moore, J. E. *et al.* (2009) 'Concordance between common dry eye diagnostic tests', *British Journal of Ophthalmology*. doi: 10.1136/bjo.2007.131722.

Na, K. S. *et al.* (2015) 'Depression, stress, quality of life, and dry eye disease in korean women: A population-based study', *Cornea.* doi: 10.1097/ICO.000000000000464.

Nettune, G. R. and Pflugfelder, S. C. (2010) 'Post-LASIK tear dysfunction and dysesthesia', *Ocular Surface*. doi: 10.1016/S1542-0124(12)70224-0.

Nichols, J. J. *et al.* (2002) 'Evaluation of tear film interference patterns and measures of tear break-up time', *Optometry and Vision Science*. doi: 10.1097/00006324-200206000-00009.

Nichols, K. K. *et al.* (2013) 'The TFOS International Workshop on Contact Lens Discomfort: Report of the definition and classification subcommittee', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.13-13074.

Nichols, K. K., Mitchell, G. L. and Zadnik, K. (2004) 'The Repeatability of Clinical Measurements of Dry Eye', *Cornea*. doi: 10.1097/00003226-200404000-00010.

Norn, M. S. (1969) 'DESICCATION OF THE PRECORNEAL FILM: I. Corneal Wetting-Time', *Acta Ophthalmologica*. doi: 10.1111/j.1755-3768.1969.tb03711.x.

Novaes, P. *et al.* (2010) 'The effects of chronic exposure to traffic derived air pollution on the ocular surface', *Environmental Research*. doi: 10.1016/j.envres.2010.03.003.

Offord, D. R. and Kraemer, H. C. (2000) 'Risk factors and prevention', *Evidence-Based Mental Health*. doi: 10.1136/ebmh.3.3.70.

Oleñik, A. (2014) 'Effectiveness and tolerability of dietary supplementation with a

combination of omega-3 polyunsaturated fatty acids and antioxidants in the treatment of dry eye symptoms: Results of a prospective study', *Clinical Ophthalmology*. doi: 10.2147/OPTH.S54658.

De Paiva, C. S. (2017) 'Effects of aging in dry eye', *International Ophthalmology Clinics*. doi: 10.1097/IIO.00000000000170.

Patel, S. *et al.* (1998) 'The value of a phenol red impregnated thread for differentiating between the aqueous and non-aqueous deficient dry eye', *Ophthalmic and Physiological Optics*. doi: 10.1016/S0275-5408(98)00005-2.

Patel, S., Plaskow, J. and Ferrier, C. (1993) 'The influence of vitamins and trace element supplements on the stability of the pre-corneal tear film', *Acta Ophthalmologica*. doi: 10.1111/j.1755-3768.1993.tb08607.x.

Paulsen, A. J. *et al.* (2014) 'Dry eye in the beaver dam offspring study: Prevalence, risk factors, and health-related quality of life', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2013.12.023.

Peterson, R. C., Wolffsohn, J. S. and Fowler, C. W. (2006) 'Optimization of Anterior Eye Fluorescein Viewing', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2006.04.062.

Portello, J. K., Rosenfield, M. and Chu, C. A. (2013) 'Blink rate, incomplete blinks and computer vision syndrome', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e31828f09a7.

Pult, H. *et al.* (2015) 'Spontaneous Blinking from a Tribological Viewpoint', *Ocular Surface*. doi: 10.1016/j.jtos.2014.12.004.

Pult, H. (2018) 'Relationships Between Meibomian Gland Loss and Age, Sex, and Dry Eye', *Eye & contact lens*. doi: 10.1097/ICL.00000000000467.

Pult, H. and Riede-Pult, B. (2013) 'Comparison of subjective grading and objective assessment in meibography', *Contact Lens and Anterior Eye*. doi: 10.1016/j.clae.2012.10.074.

Rege, A. *et al.* (2013) 'A clinical study of subtype-based prevalence of dry eye', *Journal of Clinical and Diagnostic Research*. doi: 10.7860/JCDR/2013/6089.3472.

Roncone, M., Bartlett, H. and Eperjesi, F. (2010) 'Essential fatty acids for dry eye: A review', *Contact Lens and Anterior Eye*. doi: 10.1016/j.clae.2009.11.002.

Rosenberg, E. S. and Asbell, P. A. (2010) 'Essential fatty acids in the treatment of dry eye', *Ocular Surface*. doi: 10.1016/S1542-0124(12)70214-8.

Savini, G. *et al.* (2008) 'The challenge of dry eye diagnosis', *Clinical Ophthalmology*. doi: 10.2147/OPTH.S1496.

Schaumberg, D. A. *et al.* (2009) 'Prevalence of dry eye disease among US men: Estimates from the physicians' health studies', *Archives of Ophthalmology*. doi: 10.1001/archophthalmol.2009.103.

Schiffman, R. M. *et al.* (2000) 'Reliability and validity of the ocular surface disease index', *Archives of Ophthalmology*. doi: 10.1001/archopht.118.5.615.

Schirmer, O. (1903) 'Studien zur Physiologie und Pathologie der Tränenabsonderung und Tränenabfuhr', *Albrecht von Græfe's Archiv für Ophthalmologie*. doi: 10.1007/BF01946264.

Seen, S. and Tong, L. (2018) 'Dry eye disease and oxidative stress', *Acta Ophthalmologica*. doi: 10.1111/aos.13526.

Senchyna, M. and Wax, M. B. (2008) 'Quantitative assessment of tear production: A review of methods and utility in dry eye drug discovery', *Journal of Ocular Biology, Diseases, and Informatics*. doi: 10.1007/s12177-008-9006-2.

Sharma, A. and Hindman, H. B. (2014) 'Aging: A Predisposition to Dry Eyes', *Journal of Ophthalmology*. doi: 10.1155/2014/781683.

Shiraishi, A., Yamaguchi, M. and Ohashi, Y. (2014) 'Prevalence of upper- and lowerlid-wiper epitheliopathy in contact lens wearers and non-wearers', *Eye and Contact Lens*. doi: 10.1097/ICL.000000000000040.

Sook Chun, Y. and Park, I. K. (2014) 'Reliability of 4 clinical grading systems for corneal staining', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2014.02.012.

Stapleton, F. *et al.* (2017) 'TFOS DEWS II Epidemiology Report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.05.003.

Sullivan, B. D. *et al.* (2010) 'An objective approach to dry eye disease severity', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.10-5390.

Sullivan, B. D. *et al.* (2012) 'Clinical utility of objective tests for dry eye disease: Variability over time and implications for clinical trials and disease management', *Cornea.* doi: 10.1097/ICO.0b013e318242fd60.

Sullivan, D. A. *et al.* (2017) 'TFOS DEWS II Sex, Gender, and Hormones Report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.04.001.

Szczesna, D. H. *et al.* (2011) 'Predicting dry eye using noninvasive techniques of tear film surface assessment', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.10-5173.

Szumilas, M. (2010) 'Explaining odds ratios', *Journal of the Canadian Academy of Child and Adolescent Psychiatry*.

Tan, L. L. *et al.* (2015) 'Prevalence of and risk factors for symptomatic dry eye disease in Singapore', *Clinical and Experimental Optometry*. doi: 10.1111/cxo.12210.

Tesón, M. *et al.* (2013) 'Influence of a controlled environment simulating an in-flight airplane cabin on dry eye disease', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.12-11361.

Thomas, G. W. *et al.* (2009) 'Mechanisms of delayed wound healing by commonly used antiseptics', *Journal of Trauma - Injury, Infection and Critical Care.* doi: 10.1097/TA.0b013e31818b146d.

Tobaldini, E. *et al.* (2017) 'Sleep, sleep deprivation, autonomic nervous system and cardiovascular diseases', *Neuroscience and Biobehavioral Reviews*. doi: 10.1016/j.neubiorev.2016.07.004.

Tomlinson, A. *et al.* (2006) 'Tear film osmolarity: Determination of a referent for dry eye diagnosis', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.05-1504.

Tomlinson, A., Doane, M. G. and McFadyen, A. (2009) 'Inputs and outputs of the lacrimal system: Review of production and evaporative loss', *Ocular Surface*. doi: 10.1016/S1542-0124(12)70186-6.

Tomlinson, A., McCann, L. C. and Pearce, E. I. (2010) 'Comparison of human tear film osmolarity measured by electrical impedance and freezing point depression techniques', *Cornea*. doi: 10.1097/ICO.0b013e3181cd9a1d.

Tong, L. *et al.* (2010) 'Impact of symptomatic dry eye on vision-related daily activities: The Singapore malay eye study', *Eye*. doi: 10.1038/eye.2010.67.

Tongg, L. *et al.* (2009) 'A questionnaire-based assessment of symptoms associated with tear film dysfunction and lid margin disease in an Asian population', *Ophthalmic Epidemiology*. doi: 10.1080/09286580802521317.

Truong, S. *et al.* (2014) 'Sex hormones and the dry eye', *Clinical and Experimental Optometry*. doi: 10.1111/cxo.12147.

Tuisku, I. S. *et al.* (2007) 'Dry eye and corneal sensitivity after high myopic LASIK', *Journal of Refractive Surgery*.

Uchida, A. *et al.* (2007) 'Noninvasive Interference Tear Meniscometry in Dry Eye Patients With Sjögren Syndrome', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2007.04.006.

Uchino, M. *et al.* (2008) 'Japan Ministry of Health Study on Prevalence of Dry Eye Disease Among Japanese High School Students', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2008.06.030.

Uchino, M. *et al.* (2011) 'Prevalence and risk factors of dry eye disease in Japan: Koumi study', *Ophthalmology*. doi: 10.1016/j.ophtha.2011.05.029.

Uchino, M. and Schaumberg, D. A. (2013) 'Dry Eye Disease: Impact on Quality of Life and Vision', *Current Ophthalmology Reports*. doi: 10.1007/s40135-013-0009-1.

Um, S. B. *et al.* (2014) 'Spatial epidemiology of dry eye disease: Findings from South Korea', *International Journal of Health Geographics*. doi: 10.1186/1476-072X-13-31.

Varikooty, J. *et al.* (2015) 'Variations in observable lid wiper epitheliopathy (LWE) staining patterns in wearers of silicone hydrogel lenses', *Contact Lens and Anterior*

Eye. doi: 10.1016/j.clae.2015.05.004.

Varikooty, J. and Simpson, T. L. (2009) 'The interblink interval I: The relationship between sensation intensity and tear film disruption', *Investigative Ophthalmology and Visual Science*. doi: 10.1167/iovs.08-1843.

Vehof, J. *et al.* (2014) 'Prevalence and risk factors of dry eye disease in a british female cohort', *British Journal of Ophthalmology*. doi: 10.1136/bjophthalmol-2014-305201.

Viso, E., Rodriguez-Ares, M. T. and Gude, F. (2009) 'Prevalence of and associated factors for dry eye in a Spanish adult population (The Salnes Eye Study)', *Ophthalmic Epidemiology*. doi: 10.1080/09286580802228509.

Ward, S. K. *et al.* (2010) 'Passive cigarette smoke exposure and soft contact lens wear', *Optometry and Vision Science*. doi: 10.1097/OPX.0b013e3181d95188.

Whitcher, J. P. *et al.* (2010) 'A Simplified Quantitative Method for Assessing Keratoconjunctivitis Sicca From the Sjögren's Syndrome International Registry', *American Journal of Ophthalmology*. doi: 10.1016/j.ajo.2009.09.013.

Willcox, M. D. P. *et al.* (2017) 'TFOS DEWS II Tear Film Report', *Ocular Surface*. doi: 10.1016/j.jtos.2017.03.006.

Wojtowicz, J. C. and McCulley, J. P. (2009) 'Assessment and impact of the time of day on aqueous tear evaporation in normal subjects', *Eye and Contact Lens*. doi: 10.1097/ICL.0b013e31819c2963.

Wolff, E. (1946) 'The muco-cutaneous junction of the lid margin and the distribution of the tear fluid', *Transactions of the Ophthalmological Societies of the United Kingdom*, 66, pp. 291–308.

Wolffsohn, J. S. *et al.* (2017) 'TFOS DEWS II Diagnostic Methodology report', *The Ocular Surface*. doi: 10.1016/j.jtos.2017.05.001.

Wolffsohn, J. S. *et al.* (2018) 'Blink Test enhances ability to screen for dry eye disease', *Contact Lens and Anterior Eye*. doi: 10.1016/j.clae.2018.06.003.

Wolkoff, P. *et al.* (2005) 'Eye complaints in the office environment: Precorneal tear film integrity influenced by eye blinking efficiency', *Occupational and Environmental Medicine*. doi: 10.1136/oem.2004.016030.

Yeniad, B., Beginoglu, M. and Bilgin, L. K. (2010) 'Lid-wiper epitheliopathy in contact lens users and patients with dry eye', *Eye and Contact Lens*. doi: 10.1097/ICL.0b013e3181d94e82.

Zhang, J. *et al.* (2017) 'A link between tear breakup and symptoms of ocular irritation', *Ocular Surface*. doi: 10.1016/j.jtos.2017.03.001.

Zhang, Y., Chen, H. and Wu, X. (2012) 'Prevalence and risk factors associated with dry eye syndrome among senior high school students in a county of shandong province, China', *Ophthalmic Epidemiology*. doi: 10.3109/09286586.2012.670742.